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Abstract
The ubiquitin-proteasome system (UPS) plays a critical role in the maintenance of cellular homeostasis
as it mediates the precise and temporal degradation of intracellular proteins and affects a variety of
cellular processes. The misregulation of the ubiquitin-proteasome system (UPS) can result in the
pathogenesis of human diseases including cancer. A proteasome inhibitor has been proven an effective
treatment for lymphoid malignancies, rendering the UPS appealing as a new therapeutic target for cancer.
Despite the significant progress, much more remains to be explored in the field of ubiquitin and molecular
mechanisms of tumorigenesis. KLHL6 is a frequently mutated in mature B-cell cancers, but the relevance
of these mutations and molecular function of KLHL6 are currently not known. Here, we show that KLHL6
is a novel E3 ubiquitin ligase and cancer-associated somatic mutations disrupt its catalytic activity. Via
proteomic analysis and mutagenesis screening approaches, we have further identified and validated
Roquin2, a mRNA decay factor, as a substrate of KLHL6. The interaction between KLHL6 and Roquin2
requires a tyrosine in position 691 of Roquin2 and can be inhibited when tyrosine 691 is phosphorylated.
Furthermore, using in vitro cell proliferation assays and xenograft mouse models, we show that KLHL6
has tumor suppressive effects that are dependent on Roquin2 stabilization in diffuse large B-cell
lymphoma (DLBCL). RNA sequencing analysis has revealed that Roquin2 regulated genes are implicated
in the NF-κB pathway and as lymphoid tumor suppressors, correlating with B-cell lymphoma proliferation
and survival. Taken together, the work described here highlights a previously uncharacterized molecular
mechanism whereby the novel E3 ligase modulates mRNA decay through its substrate degradation and
plays role in the pathogenesis of mature B-cell cancers.
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ABSTRACT

CROSS-TALK BETWEEN PROTEIN DEGRADATION AND MRNA DECAY IN
DIFFUSE LARGE B-CELL LYMPHOMA
Jaewoo Choi
Luca Busino

The ubiquitin-proteasome system (UPS) plays a critical role in the maintenance of
cellular homeostasis as it mediates the precise and temporal degradation of intracellular
proteins and affects a variety of cellular processes. The misregulation of the ubiquitinproteasome system (UPS) can result in the pathogenesis of human diseases including
cancer. A proteasome inhibitor has been proven an effective treatment for lymphoid
malignancies, rendering the UPS appealing as a new therapeutic target for cancer.
Despite the significant progress, much more remains to be explored in the field of
ubiquitin and molecular mechanisms of tumorigenesis. KLHL6 is a frequently mutated in
mature B-cell cancers, but the relevance of these mutations and molecular function of
KLHL6 are currently not known. Here, we show that KLHL6 is a novel E3 ubiquitin
ligase and cancer-associated somatic mutations disrupt its catalytic activity. Via
proteomic analysis and mutagenesis screening approaches, we have further identified and
validated Roquin2, a mRNA decay factor, as a substrate of KLHL6. The interaction
between KLHL6 and Roquin2 requires a tyrosine in position 691 of Roquin2 and can be
inhibited when tyrosine 691 is phosphorylated. Furthermore, using in vitro cell
proliferation assays and xenograft mouse models, we show that KLHL6 has tumor
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suppressive effects that are dependent on Roquin2 stabilization in diffuse large B-cell
lymphoma (DLBCL). RNA sequencing analysis has revealed that Roquin2 regulated
genes are implicated in the NF-κB pathway and as lymphoid tumor suppressors,
correlating with B-cell lymphoma proliferation and survival. Taken together, the work
described here highlights a previously uncharacterized molecular mechanism whereby
the novel E3 ligase modulates mRNA decay through its substrate degradation and plays
role in the pathogenesis of mature B-cell cancers.
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PREFACE

This thesis consist of a series of chapters based on the manuscript that is recently
accepted in Nature Cell Biology, as well as unpublished data that I am planning to submit
for publication in a small journal and some of ongoing studies in our laboratory. Chapter
1 contains general background and introduction for all, and each chapter contains an
introduction, result, and discussion. Chapter 2 contains experimental methods and
Chapter 6 contains conclusions and future directions for chapter 3, 4, and 5.
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CHAPTER 1 : INTRODUCTION

The ubiquitin proteasome system (UPS) plays a critical role in the regulation of
cell growth and survival and in maintaining cellular homeostasis. UPS mediates the
precise and temporal degradation of 80% of intracellular proteins, and the failure to
terminate such signals effectively results in numerous diseases, including hematological
malignancies and cancer (Silverman et al., 2012; Skaar et al., 2013). The ubiquitin–
proteasome system is catalyzed in a stepwise manner through an enzymatic cascade in
which ubiquitin is activated by an E1 enzyme, transferred to an E2 ubiquitin-conjugating
enzyme, and finally transferred to a substrate selected by an E3 ubiquitin ligase. The E3
ubiquitin ligase determines the substrate specificity for the ubiquitination of critical
regulators. These enzymes act together in a precise and specific manner to target and
regulate the degradation of the proteins in the proteasome complex. The proteasome
consists of regulatory 19S cap complexes that unfold the substrates in an ATP-dependent
manner and catalytic 20S core complexes that have proteolytic activities. (Hershko and
Ciechanover, 1998) Proteins that are tagged by the ubiquitin chains are recognized,
deubiquitylated, and unfolded by the 19S complex and then fed through inner
components of the 20S proteasome chamber (Braun et al., 1999). The success of a
proteasome inhibitor (bortezomib) in multiple myeloma and mantle cell lymphoma has
inspired to develop novel therapeutic approaches in investigating the biological
significance of protein ubiquitylation and degradation in B-cell cancers (Yang and Staudt,
2015). However, bortezomib affects thousands of intra-cellular proteins and results in
toxic side effects, which require substrate specificity. Thus, understanding how
1

ubiquitylation of protein is achieved and the downstream consequences of molecular and
signaling events becomes essential in developing therapeutic targets and studying their
efficacy.

CULLIN-RING ubiquitin ligases
Among more than 800 E3 ubiquitin ligases in the human genome, the CULLINRING ligases (CRLs) are the largest family of E3 ubiquitin ligases. They consist of a
CULLIN scaffold protein (CULLIN 1, 2, 3, 4A, 4B, 5, 7), a substrate receptor protein, an
adaptor protein, and a RING protein for recruitment of the E2 enzyme (Cardozo and
Pagano, 2004; Petroski and Deshaies, 2005c). The properties and biological function of
CULLINs are very different and they are involved in variety of cellular processes such as
cell growth, signal transduction, DNA replication, cell cycle, cell redox homeostasis, and
others (Petroski and Deshaies, 2005a). In terms of a structural module, a large body of
evidence suggests that CRLs share a similar architecture as substrates are recruited to the
N-terminal regions of CULLINs that comprises a substrate receptor and adaptor. For the
well-characterized example of CULLIN1, an adaptor protein SKP1 recruits numerous
substrate receptors, F-box proteins. SKP1 can interact with both CULLIN1 and
CULLIN7 (Dias et al., 2002). CULLIN2 and CULLIN5 utilize an elongin B/C adaptor
protein and recruits substrates through suppressor of cytokine signaling/elongin BC
(SOCS/BC)-box-protein, a substrate receptor. CULLIN3 utilizes BTB-domain-containing
proteins where it can function both as an adaptor and substrate receptor. CULLIN4A uses
an adaptor protein, DNA-damage-binding protein-1 (DDB1) (Petroski and Deshaies,
2

2005a). The activity of these CULLIN ligases is regulated by reversible conjugation of a
small-ubiquitin like protein; Neural precursor cell expressed developmentally downregulated protein 8 (Nedd8) (Wu et al., 2005). Nedd8 can be covalently attached to
CULLINs at a conserved lysine residue and follows a similar enzymatic cascade like
ubiquitination: E1 activating enzyme (Uba/APP-BP1) and E2 (Ubc12) conjugating
enzyme (Osaka et al., 2000; Read et al., 2000). Neddylation is critical for the function of
CULLINs and it can also increase CULLIN1-dependent ligase activity, which can
support the recruitment of E2s loaded with ubiquitin (Kawakami et al., 2001; Read et al.,
2000). In addition, Defective in CULLIN neddylation 1 (DCN1) works together with
RBX1 RING finger subunit within CULLINs to stimulate NEDD8 conjugation,
suggesting an E3-like activity for neddylation reaction (Scott et al., 2011). The Cop9
Signalosome (CSN) with a metalloprotease JAMM motif in CSN5 subunit deneddylates
NEDD8-CULLINs (Ambroggio et al., 2004; Cope et al., 2002). The cycling of
neddylation and deneddylation stimulates conformational changes and allows to
CULLINs and RING to be in a dynamic form that facilitates the transfer of ubiquitin to
the substrates.

CULLIN3-RING ubiquitin ligases
CULLIN3 is a highly conserved in the genomes of eukaryotes and the function of
CULLIN3 has been characterized in many different species. For example, loss of
CULLIN3 in C. elegans leads to defects in chromosome segregation and cytokinesis
3

defects during the embryogenesis probably due to katanin Mei1 accumulation (Kurz et
al., 2002). The genetic knockout of CULLIN3 in mice causes an embryonic lethal
phenotype with disorganization of embryonic tissues. The CULLIN3 knockout embryos
accumulate excess of cyclin E leading to misregulation of S phase in cell cycle (Singer et
al., 1999). Depletion of CULLIN3 homolog in fission yeast shows a retarded growth and
elongation phenotype with increased sensitivity for hydroxyurea although no obvious
phenotype is observed in budding yeast (Kominami and Toda, 1997; Michel et al., 2003).
The CULLIN3 family of ubiquitin ligases is different from other CULLIN-based
complexes in that it only requires a protein that contains a-brac/tramtrack/broad-complex
(BTB) that can function both as an adapter and substrate recognizer. The human genome
encodes about 200 BTB domain proteins and the structural analysis has shown that BTB
domain forms a five a-helical fold that resembles other adaptors similar to SKP1 and
ElonginC (Stogios et al., 2005). Furthermore, sequence analyses of the BTB-domain
proteins have identified some of associated domains that can be sub-classified such as
Meprin and TRAF homology (MATH), Kelch, BTB-non-phototropic hypocotyl 3
(NPH3), Zinc Finger, and PAM domain. Notably, these analyses also show that not all
BTB domain proteins can serve as a adaptor for CULLIN3 (Stogios et al., 2005) as
BTBD12 and KLHL39 that lack the 3-box motif critical for CULLIN3 binding fail to
interact with CULLIN3 (Chen et al., 2015; Zhuang et al., 2009). In fact, many of these
identified BTB protein family function is related to cell cycle regulation as shown by
regulation of cyclin E degradation by CULLIN3. The maternal lethal effect-26 protein
(MEL26), a MATH-BTB family member, degrades the complex meiosis inhibitor protein
4

(MEI-1) after meiosis to assemble a functional spindle and activate cytokinesis in the
right time and place (Luke-Glaser et al., 2005). In addition, KLHL18-CULLIN3 complex
promotes ubiquitylation and proteasomal degradation of Aurora-A kinase, an essential
protein for mitotic entry. Depletion of KLHL18 results in a delay in both centrosomal
activation of Aurora-A and timely entry into mitotic process (Moghe et al., 2012).
Similarly, KLHL21 directly binds and ubiquitylates Aurora-B kinase, a member of the
chromosomal passenger complex (CPC) that regulates chromosome alignment and
separation, in the middle region of microtubules during anaphase process (Maerki et al.,
2009). KLHL22-CULLIN3 complex regulates kinetochore localization of polo-like
kinase 1 (PLK1) that regulates mitotic division by controlling spindle assembly and
chromosome alignment (Beck et al., 2013; Elowe et al., 2007). Although KLHL22 does
not regulate PLK1 stability, loss of KLHL22 results in accumulation of PLK1 on
kinetochores and sustained activation of the spindle assembly checkpoint, leading to
unstable kinetochore-microtubule interaction.
The other unique property of BTB-domain containing protein is that they can
dimerize and form two CULLIN3 complexes within one E3 ligase complex, a feature that
can increase the affinity for substrates (Zhuang et al., 2009). The best example for
dimerization in substrate recognition is human Keap1 dimer that binds single Nrf2
molecule with two distinct binding sites (McMahon et al., 2006) important for optimal
orientation of ubiquitylation. The CULLIN3-SPOP complex and CULLIN3-HIB
complex also are shown to assemble dimers to recognize a single substrate (Zhang et al.,
2009). Furthermore, SPOP-mediated CULLIN3 dimerization can enhance a rate of
5

polyubiquitylation by increasing associated E2 enzymes. Furthermore, there are cases
where CULLIN3 complexes such as KCTD11 and SPOP form high orders of
oligomerization that increase E3 ligase activity similar to dimerization (Correale et al.,
2011; Errington et al., 2012).

CULLIN3-RING ubiquitin ligases in cancer
Following, I will provide descriptions for some of CULLIN3-based E3 ligases
implicated in cancer biology.
KEAP1: One of the well-characterized CULLIN3 adaptor proteins is the BTBKelch-like ECH-associated protein (Keap1 or KLHL19) (Motohashi and Yamamoto,
2004). Keap1 was first identified as a critical inhibitor of the transcription factor Nf-E2related factor 2 (Nrf2) by targeting it for proteasomal degradation at a steady state
(Cullinan et al., 2004; Itoh et al., 1999; Kobayashi et al., 2004). Upon the oxidative or
electrophilic stress, cysteine residues in Keap1 can be modified and this leads to a
conformational change inhibiting activity of CULLIN3-Keap1 ubiquitin ligase complex.
Accordingly, Nrf2 is stabilized and is now free to translocate into the nucleus to bind
anti-oxidant responsive elements (ARE) of its target genes encoding many cytoprotective
enzymes (Cullinan et al., 2004). Thus, the Keap1-Nrf2 pathway is a critical factor in the
stress response and cell protective mechanism. As the oxidative stress is implicated in
cancer, it is conceivable that cancer cells might hijack this pathway for their growth and
survival under the stress conditions. For instance, increased Nrf2 expression provides
6

chemo-resistant phenotype in cancer cells while knocking down Nrf2 increases their
sensitivity to chemotherapy. Moreover, overexpression of Nrf2 is shown to inhibit p53dependent apoptosis, suppress reactive oxygen species (ROS) production in response to
oncoproteins and promote proliferation of tumor cells (DeNicola et al., 2011; Faraonio et
al., 2006).
Accumulating evidence suggests that the components of the Keap1-Nrf2 pathway
are mutated in a variety of cancer types including ovarian, liver, lung and gallbladder
cancers (Konstantinopoulos et al., 2011; Shibata et al., 2008; Yoo et al., 2012). The
somatic mutations of the substrate-binding domain of Keap1 have been first found in
lung cancer leading to its loss of function (Ohta et al., 2008; Singh et al., 2006). In
addition, the BACK domain of Keap1 has been also altered and mutated, resulting into
disruption of CULLIN3 binding and subsequent repression of ligase activity. In some
cases, the mutations of Keap1 have a dominant negative effect that can disrupt the
function of wild-type Keap1 and consequently activation of Nrf2. The gain of function
mutation of Nrf2 has also been observed in several cancers and these mutations directly
disrupt the DLG or ETGE motif where Keap1 binds (Ohta et al., 2008; Shibata et al.,
2011). Nrf2 can also indirectly activate the transcription of the multidrug resistanceassociated protein-1 (MRP1). MRP1 has been considered as a critical regulator of chemoresistance and is constitutively expressed in the presence of Nrf2 (Ji et al., 2013). Other
additional mechanisms such as hyper-methylation or mi-RNA silencing also deregulate
the Keap1-Nrf2 pathway to repress Keap1 promoter or target Nrf2 levels, respectively
(Eades et al., 2011; Guo et al., 2012; Wang et al., 2008).
7

SPOP: Emerging evidences have shown that Speckle-type POZ (pox virus and
zinc finger protein) protein (SPOP) is involved in prostate and endometrial cancers (Kan
et al., 2010). SPOP contains a MATH domain, BTB/POZ domain, and nuclear
localization sequence in the C-terminus (Mani, 2014). The MATH domain is utilized for
substrate binding while the BTB/POZ domain binds CULLIN3 to form an active E3
ligase complex. To date, all SPOP mutations identified in prostate and endometrial
cancers are clustered in the MATH domain, supposedly disrupting the substrate binding.
Interestingly, SPOP has a tumor suppressor role in these cancers while it has oncogenic
role in kidney cancers where no mutations have been reported (Li et al., 2014). In fact,
SPOP is another transcriptional target of HIFs and SPOP accumulation promotes
tumorigenesis under the hypoxia condition. In clear cell renal cell carcinoma, SPOP is
shown to degrade tumor suppressors such as PTEN, ERK phosphatases (DUSP6 and
DUSP7) and pro-apoptotic DAXX protein, suggesting that it acts as a key modulator of
proliferation pathway. On the other hand, SPOP directly targets oncoproteins such as
androgen receptor (AR) and steroid receptor co-activator (SRC)-3 in the context of
prostate cancers. AR signaling is essential for tumor initiation and progression.
Importantly, SPOP cancer-associated mutations fail to bind AR, inhibiting AR
proteolysis by the proteasome. Moreover, AR splicing mutations have been observed
where it loses SPOP-binding hinge domain and are insensitive to SPOP-dependent
degradation (An et al., 2014). Similar mechanisms apply for SRC-3 mutations to enhance
AR functions and AR signaling pathways and promote prostate cancer development. This
dual tumor-promoting or tumor-suppressing function of SPOP is partially explained by
8

its different substrates in different cancer types, suggesting that SPOP function is cellcontext and substrate-dependent.
KLHL25: Recently, KLHL25-CULLIN3 complex has been shown to target ATPcitrate lyase (ACLY), a key regulator of de novo lipid synthesis (Zhang et al., 2016).
ACLY is an enzyme that converts citrate to acetyl-CoA in the cytosol, and this acetylCoA is utilized to create fatty acids, cholesterol, and isoprenoids (Menendez and Lupu,
2007). ACLY is frequently elevated in several cancers including lung cancer and
suppression of ACLY by a small molecular inhibitor has shown an efficacy in slowing
down the tumor proliferation (Hatzivassiliou et al., 2005; Milgraum et al., 1997). In lung
cancers, CULLIN3 expression is often down-regulated and subsequently ACLY is
overexpressed, which is critical for lipid synthesis and proliferation of cancer cells. This
novel tumor suppressing mechanism of CULLIN3 could be a potential therapeutic target
with lung cancer with lower CULLIN3 expression.
KLHL20: Kelch-like family member 20 (KLHL20) is another adaptor protein that
can bind to CULLIN3 and acts as CULLIN3-RING ubiquitin ligase complex. This
protein has also been implicated in cancers, as it is first uncovered as a binding partner of
death-associated protein kinase (DAPK), a tumor suppressor promoting cell death (Lee et
al., 2010). By directly ubiquitylating and degrading DAPK, KLHL20-CULLIN3 complex
can antagonize the cellular apoptosis, autophagic death, and necrosis. In addition to
cellular death mechanisms, DAPK can also suppress cell migration and motility by
regulating cytoskeletal proteins, thereby promoting anti-metastatic effects (Chen et al.,
2014). Interferon (IFN) signaling regulates the KLHL20-DAPK pathway as IFN-α and
9

IFN-γ can can sequester KLHL20 into the PML-nuclear body. Induction of PML by
interferon promotes INF-induced cell death since PML competes with DAPK for
KLHL20 binding, resulting in stabilization of DAPK. This establishes the basis for IFNbased cancer treatment. The fact that PML interacts with KLHL20 suggests that PML
serves as a substrate of KLHL20. Previous studies have shown that PML, similar to
DAPK, also exerts tumor suppressive effects as it can induce apoptosis and inhibit
proliferation, metastasis and neo-angiogenesis (Bernardi et al., 2006; Reineke et al.,
2010). Consistent with antitumor effects of PML, this gene is frequently mutated or
deleted in a variety of cancer types. One of the main mechanisms to down-regulate PML
protein levels in tumors is through hypoxia-inducible factor-1 (HIF-1) (Yuan et al.,
2011). HIF-1 and HIF-2 can mediate the transcriptional programs of genes that contain
hypoxia responsive element (HRE) and influence many different aspects including
metastasis, metabolic reprogramming, tumor initiation and maintenance, angiogenesis,
chemotherapy resistance, and others (Semenza, 2012). Since KLHL20 contains HREs in
its promoter, its expression is induced under hypoxia condition and potentiates PML
ubiquitylationa and degradation by proteasome. Accordingly, KLHL20 expression is upregulated and PML is down-regulated in tumors as HIF-1a is frequently elevated through
hypoxia-regulated mechanism. Specifically, the KLHL20-PML pathway is dysregulated
in prostate cancers and KLHL20, HIF-1α , and PML expression pattern nicely correlates
with survival and disease progression. Interestingly, KLHL20 interacts with KLHL39,
which adds an additional layer of regulation to this pathway, as it can block KLHL20mediated degradation of PML and DAPK by binding to KLHL20 and disrupting
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interaction of these substrates from KLHL20 (Chen et al., 2015). Although KLHL39 is a
BTB-Kelch protein, it does not bind to CULLIN3 and is not able to form a functional E3
ligase. Rather, it can regulate PML and DAPK stability as an inhibitor of KLHL20CULLIN3 complex.
A significant number of studies, as shown above, highlight the biological function
of CULLIN3-RING ubiquitin ligases in cancer. More comprehensive understanding with
systematic characterization of other CULLIN3 adaptors will be helpful to develop new
therapeutic targets for cancer prevention. Further, it would be interesting to identify other
BTB-proteins that are involved in development of other human pathologies and
investigate novel insights into molecular basis of CULLIN3 E3 ligases and substrates.

Protein ubiquitylation and de-ubiquitylation in lymphoid malignancies
Emerging evidences suggest that human lymphoid cancers are derived from
various stages of B-cell differentiation and where the cancers are originated dictate their
biology. Mantle cell lymphoma and chronic lymphocytic leukemia are from pre-germinal
center mature B-cells whereas the most of non-Hodkin’s lymphomas and multiple
myeloma are from germinal center B-cells or B-cells that have passed though germinal
center. Gene expression profile studies have provided instructive recognition of different
subtypes by specific transcriptional signatures (Staudt and Dave, 2005). Based on these
signatures, the germinal center B cell-like (GCB) subtype of diffuse large B-cell
lymphoma (DLBCL), follicular lymphoma, and Burkitt lymphoma appear to be from
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germinal center B cells while the activated B cell-like (ABC) subtype of DLBCL appear
to be from a post-germinal center B cells. A third subgroup of DLBCL, primary
mediastinal B-cell lymphoma (PMBL) shares a significant similarity with Hodgkin
lymphoma and is believed to arise from thymic post- germinal center B cells (Staudt and
Dave, 2005).
It is conceivable that each of these lymphoid malignancies might activate
oncogenic signaling pathways through different genomic alterations such as mutations,
deletions, amplifications and translocations to promote their growth and survival. In some
cases, the constitutive signaling comes from chromosomal rearrangements of
transcription regulators such as Bcl6 and Irf4 (Pasqualucci and Dalla-Favera, 2015).
Perhaps, the most common ways for lymphoid malignancies to prevent cell apoptosis is
the constitutive activation of NF-κB pathway. Various upstream of NF-κB signaling
molecules are aberrantly mutated from oncogenic events leading to more translocation of
NF-κB into the nucleus and activation of pro-survival transcription programs. These
oncogenic pathways are the hallmarks of ABC-DLBCL subtype and are regulated at
numerous levels by ubiquitination and deubiquitination enzymes (Staudt, 2010).

Protein ubiquitination in the oncogenic signaling pathway of ABC-DLBCLs
ABC-DLBCL cell lines are addicted to NF-κB activation for their survival, and
this subtype has gene expression profiling similar to normal B-cells that are activated by
antigen recognition of the B-cell receptor (BCR). The BCR signaling triggers numerous
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downstream signaling molecules to regulate proliferation and survival during B-cell
development and is turned off in a tight fashion for cellular homeostasis. There are other
receptors including CD40, BAFF, TNF receptor family, and various Toll-like receptors
(TLRs) that can eventually converge into the NF-κB pathway (Young et al., 2015). ABCDLBCLs display a high activity of IKKβ and knockdown of this kinase in a loss of
function RNA interference (RNAi) screening showed toxicity effects specifically to
ABC-DLBCL subtype. Further, previous RNAi study revealed a critical role CARD11BCL10-MALT1 (CBM) complex, which is an upstream signalosome of IKK activation
and mediator of NF-κB activation, as knockdown of each component was also toxic to
ABC-DLBCL cell lines (Ngo et al., 2006). In normal B-cells, BCR signaling activates
protein kinase C β (PKCβ), which in turn phosphorylates CARD11, releasing the
inhibitory linker domain and changing into an active conformation. The active CARD11
translocates to the inner part of plasma membrane, recruits and associates with BCL10
and MALT1 to form an active complex. About 10% of ABC-DLBCLs carry activating
mutations in the coiled-coil domain of CARD11, which causes freeing of the linker
domain without PKCβ phosphorylation and allows formation of CARD11 clusters that
co-localize with MALT1 and IKKβ (Lenz et al., 2008a). The levels of NF-κB activity
correlate with those of CARD11 clusters in the cancer cells with mutations of CARD11,
supporting the relevance of the complex in pathology of ABC-DLBCLs.
Once the CBM complex is assembled, it promotes K63-linked ubiquitination
chains by TRAF6 E3 ligase family. TRAF6 family contains a RING domain in the Nterminus, zinc finger domain, and TRAF domain. MALT1, a protease that is
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constitutively activated in ABC-DLBCLs, brings TRAF6 to the CBM complex through
TRAF6 binding domain and triggers auto-ubiquitination of TRAF6 with K63-linked
chains. TRAF6 also functions as an E3 ligase for K63-polyubiquitination of MALT1
(Oeckinghaus et al., 2007). The importance of MALT1 K63-ubiquitin chains are
supported by the MALT1 mutants that are not able to rescue NF-κB signaling in
MALT1-lacking cells. MALT1, acting as a scaffold protein, in the CBM complex is
recently shown to be mono-ubiquitinated on lysine 644 residue, which is necessary and
sufficient for activation of its protease activity (Pelzer et al., 2013). This allows MALT1
dimerization, which is critical for its enzymatic function. In ABC-DLBCLs, MALT1 is
mono-ubiquitinated constitutively, and MALT1 mutant that cannot be monoubiquitinated is toxic to ABC-DLBCLs. Although CARD11 mutations contribute to
oncogenic transformation in ABC-DLBCLs, the majority of ABC tumors do not contain
mutations of the CBM complex, suggesting that upstream signaling pathways such as
BCR signaling.
Another pathway relevant in ABC-DLBCLs is the Toll-like receptors (TLRs) and
MYD88. About 30% of oncogenic active MYD88 mutations are found in ABCLDLBCLs, and the mutation targets the L265 residue in Toll/IL1 receptor (TIR) domain to
Proline, which is essential for homo- and hetero-dimerization with TLRs (Ngo et al.,
2011). This mutation induces activation of IRAK4, which in turn promotes the formation
of a protein complex with IRAK4 and IRAK1 and activates NF-kB pathway. The ectopic
expression of L256P mutant form of MYD88 is shown to induce NF-κB activation and
this mutant cannot be substituted with the wild-type MYD88 in ABC-DLBCLs for their
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survival. In Toll-like receptor (TLR) signaling pathway, interaction of MYD88 with
IRAK4 and IRAK1 leads to recruitment of TRAF6. TRAF6 undergoes autoubiquitination with K63-linked ubiquitin chains that create interaction sites for other
proteins such as TAK1. The recruitment of TAK1 to TRAF6 leads to activation of TAK1
itself that can phosphorylate IKKβ (Bhoj and Chen, 2009). IRAK1 can also be polyubiquitinated by K63-linked chains in TLR signaling and mutations that impair this
ubiquitination are shown to inhibit NF-κB activation. Although mutation of MYD88 can
promote ABC-DLBCL through activation of NF-κB pathway, the evidence of MYD88IRAK1-IRAK4 ubiquitination status is lacking. Moreover, whether TRAF6 is modified
with K63-ubiquitin chains and how this might contribute to oncogenic MYD88 signaling
pathway still remains open questions and will be important to understand the biology of
ABC-DLBCLs.
The linear ubiquitin chain assembly complex (LUBAC) also plays an oncogenic
role in activating NF-kB signaling pathway. LUBAC consists of RNF31 (HOIP), RBCK1
(HOIL-1L), and SHARPIN, and RNF31 belongs to the RBR family of E3 ligases that
promotes the formation of linear polyubiquination (Kirisako et al., 2006). In a classical
NF-κB pathway, it targets NEMO/IKKγ to promote linear ubiquitination, which is
necessary for IKK activation. LUBAC is recruited to receptor complexes including
TRAFs and other ubiquitin ligases with K63-linked chains and provides binding domains
for additional IKK complexes to be recruited. The auto-phosphorylation of IKK
complexes due to the close proximity of each component increases NF-κB activation.
LUBAC can also associate with the CBM complex through interaction with other
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ubiquitin chains attached to the complex. LUBAC induces MALT1 activity and plays a
crucial role in chronic active BCR signaling in ABC-DLBCL cell lines as depletion of
components of LUBAC impaired NF-κB activity and is toxic to the cells (Yang et al.,
2014). The cancer-associated mutations of LUBAC have been shown to increase
ubiquitin ligase activity of LUBAC by enhancing the interaction between RBCK1 and
RNF31, which in turn increases NF-κB pathway. Given that mutations increase the
binding of LUBAC components, it is conceivable that a small molecule inhibitor of
RFN31-RBCK1 interaction could be a potential therapeutic target in ABC-DLBCLs.

TNFAIP3/A20 in ABC-DLBCLs
As mentioned previously, protein ubiquitination play an essential role in
regulating NF-κB activity. Ubiquitination process can be reversed by the deubiquitinating
enzymes (DUBs), and there are about 100 DUBs in the human genome (Nijman et al.,
2005). One of the most essential DUBs in lymphoid biology is the gene encoding A20
(also known as TNFAIP3). A20 is first identified as the primary gene induced by TNF
treatment in endothelial cells and characterized as a protector from TNF-induced cell
death (Dixit et al., 1990). Further studies have demonstrated the role of A20 as a negative
regulator of NF-κB activation in response to TNF, CD40, interleukin (IL-1), and B- and
T-cell receptor activation (Beyaert et al., 2000). As mentioned above, NF-κB signaling
pathway is heavily dependent on protein ubiquitination and A20 is a central modulator of
this ubiquitin-dependent signaling pathways. A20 is a dual function protein containing an
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amino-terminal ovarian tumor (OTU) domain for deubiquitinating activity and zinc finger
domain for ubiquitin ligase activity. The first substrate identified for A20 is receptor
interacting protein-1 (RIP-1) (Wertz et al., 2004). The K63-ubiquitin chains of RIP-1 are
modified by cellular inhibitor of apoptosis proteins (cIAP 1/2) during TNF receptor
stimulation and deubiquitinated by A20. In immune cells, other identified substrates for
A20 include MALT1, TRAF6, and IKKγ through poly-ubiquitination with K63-linked
ubiquitin chains (Hymowitz and Wertz, 2010). A20 is recruited to CBM complex by
binding to K63-linked poly-ubiquitin chains from the signalosomes upon the recognition
of antigen in normal lymphocytes. CBM complex formation can activate TAK1 kinase to
phosphorylate IKKβ, leading to NF-κB activation. MALT1 cleavage of A20 is also
increased upon recruitment of A20 to CBM complex (Coornaert et al., 2008).
One of the critical roles of A20 is to establish a negative feedback that terminates
the NF-κB signaling. One model suggests that A20 removes K63-linked chains by its
DUB activity and replacing with K48-linked chains that lead to degradation of its
substrates (Wertz et al., 2004). However, other study provides an evidence that the ability
of A20 to bind ubiquitin chains through its zinc finger domain is sufficient to block NFκB activation, suggesting its ligase activity is dispensable for IKK activation (Bosanac et
al., 2010; Skaug et al., 2011). Specifically, its zinc finger #4 domain has an ability to bind
K63-ubiquitin chains and this binding contributes to repression of TNF-α medicated NFκB activation. Therefore, it is conceivable that A20 acts in a variety of different ways
such as interacting with and promoting ubiquitination and de-ubiquitination proteins
involved in NF-κB pathway. In normal mouse B-cells, deletion of A20 enhances their
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response to variety of stimuli including BCR signaling activation. Consequently, mice are
prone to develop autoimmunity due to increase in germinal center B-cells and plasma
cells and die from the lethal inflammatory phenotypes (Turer et al., 2008).
A20 is frequently inactivated or lost by mutation, deletion, translocation and
epigenetically silencing in lymphoid malignancies. ABC-DLBCL, MALT lymphomas,
and classical Hodkin’s lymphoma carry inactivating mutations of A20 about 25%, 20%,
and 45%, respectively (Compagno et al., 2009; Kato et al., 2009; Novak et al., 2009).
A20 is well characterized as a tumor suppressor in ABC-DLBCLs as re-introduction of
wild-type A20 in ABC-DLBCLs with biallelic deletion of A20 is shown to cause cellular
apoptosis and growth arrest. A20 inactivation co-occurs with MYD88 and CD79B
mutations, suggesting that it might contribute to oncogenic MYD88 and BCR signaling
pathways (Ngo et al., 2011). In ABC-DLBCLs, it is likely that A20 mutations can
enhance constitutive NF-κB signaling with other genetic alteration events and its
mutation alone may not be sufficient to activate NF-κB signaling activity. Of note, A20 is
recruited to the CBM complex when IKKγ is modified with linear ubiquitin chains via
LUBAC and gain of function mutations of LUBAC increases A20 recruitment (Yang et
al., 2014). Given that virtually almost all lymphoid malignancies activate NF-κB
signaling for their growth and survival, pharmacological interference with this pathway
provides a strong rationale for therapeutics.

Pharmacological inhibitions in lymphoid malignancies
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Given that UPS plays an important role in a variety of biological processes, it is
conceivable that deregulation in this system would contribute to human diseases
including lymphoid malignancies. The proteasome degradation is the final step in the
UPS pathway and proteasome is investigated as the first potential target for therapeutic
approaches. Proteasome inhibitors were initially synthesized to determine the function
and proteolytic specificity of the proteasome (Vinitsky et al., 1994; Vinitsky et al., 1992).
The possibility of proteasome inhibitors as therapeutic agents derives from the early work
where the inhibitors induced apoptotic cell death in leukemic cell lines (Imajoh-Ohmi et
al., 1995; Shinohara et al., 1996). This tumor inhibition effect was supported further by
efficacy of the proteasome inhibitor against an in vivo Burkitt’s lymphoma tumor model
(Orlowski et al., 1998). Later on, proteasome inhibitors showed a wide spectrum of proapoptotic effects against hematologic malignancies and solid tumors including non-small
cell lung and prostate cancer as well as follicular non-Hodgkin’s lymphoma, multiple
myeloma and mantle cell lymphoma (Aghajanian et al., 2002; Cortes et al., 2004;
Papandreou et al., 2004; Richardson et al., 2003).
One of the mechanisms of proteasome inhibitors is to suppress nuclear factor-κB
(NF-κB) signaling by stabilizing the inhibitory molecule IκB that binds NF-κB factors.
This, in turn, prevents NF-κB factors from nuclear translocation and down-regulates their
target genes, resulting in anti-survival effects. Specifically, NF-κB can induce production
of growth and angiogenesis factor like interleukin-6 and increase expression of cell
adhesion
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cells,
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microenvironment. Given that NF-κB is involved in suppression of apoptosis,
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proliferation, angiogenesis, and oncogenic transformation, it is considered that the NF-κB
pathway is central to pathogenesis of cancer and a strong rationale therapeutic target. In
addition, the pro-survival effects of NF-κB functions are activated by the chemotherapies
and inhibition of this pathway enhances sensitivity to the treatment (Wang et al., 1999;
Wang et al., 1996). In addition to NF-κB inhibition, there are number of other
mechanisms of proteasome inhibitors that contribute to anti-tumor effects. For instance,
the inhibitors can interfere with timely degradation of cell cycle regulators such as p27
and p21, causing cell cycle arrest in cancer cells while they can also accumulate c-myc
and cylin-D1 for the proliferative effect (Adams et al., 1999; Almond and Cohen, 2002;
Chauhan et al., 2005). The proteasome inhibitor can also stabilize pro-apoptotic proteins
such as p53 and Bax proteins and anti-apoptotic Bcl-2, promoting a pro-survival state
(Hideshima et al., 2003). It is recognized that proteasome activity is generally elevated in
lymphoid malignancies, and this led to development of more potent and selective
proteasome inhibitor with improved pharmacological properties, a bortezomib, which is
entered into the clinic trials (Jagannath et al., 2004; Richardson et al., 2003; Richardson
et al., 2006).
Bortezomib, a boronic acid dipeptide, binds with high specificity and affinity to
the 20S proteasome reversibly and blocks its hydrolyzing activity. In the animal models,
bortezomib did not enter the tissues such as brain, eyes and spinal cord, suggesting that
these tissues are protected from toxic effects of proteasome inhibition (Adams et al.,
1999). Strikingly, bortezomib potently inhibited proliferation of multiple myeloma cells
and binding of these tumor cells to bone marrow stromal cells in preclinical models, thus
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inhibiting tumor microenvironment. Bortezomib-induced cell death is accompanied by
release of a pro-apoptoic mitochondrial protein such as cytochrome c, up-regulation of
endoplasmic reticulum (ER) stress, and induction of c-Jun N-terminal kinase (JNK)
(Mitsiades et al., 2002). Activation of JNK leads to Fas up-regulation and induction of
caspase-8-mediated apoptotic pathway with caspase-3 activation. Caspase-3 induction
results in cell apoptosis by increase of p53 activity by MDM2 degradation. Several
evidences have suggested that myeloma cells are highly sensitive to bortezomib because
of high level of immunoglobulin synthesis that correlates with the high level of ER stress
(Nawrocki et al., 2005a; Nawrocki et al., 2005b; Obeng et al., 2006). This characteristic
of myeloma cells make them more dependent on unfolded-protein response and
susceptible to bortezomib compared to other B-cell malignancies. The efficacy and safety
of this drug were proven through Phase 1-3 clinical trials and the impressive results led to
an approval by the FDA in 2003 to use bortezomib as the third-line treatment for relapsed
or refractory plasma cell myeloma (PCM) patients (Kane et al., 2003; Kane et al., 2006).
Subsequently, it became the first line treatment in 2008 (Islam and Ambrus, 2008; San
Miguel et al., 2008). There are extensive ongoing studies to examine the combination of
bortezomib and other chemotherapy or active agents in clinical trials for blood cancers.
Given that ABC-DLBCLs harbor constitutive NF-κB activation, combination of
bortezomib treatment and cytotoxic chemotherapy (Etoposide, Prednisolone, Oncovin,
Cyclophosphamide, and Hydroxydaunorubicin called EPOCH) in a clinical trial was
initiated for the relapsed and refractory DLBCL patients (Dunleavy et al., 2009).
Although bortezomib as a single agent did not show any efficacies, the combination
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therapy yielded high responses and greatly improved overall survival rates specifically in
ABC-DLBCL patients. This was remarkable achievement in that previous clinical trials
with chemotherapy alone had very poorer cure rates. Another way of targeting NF-κB is
to interfere with β-TrCP ligase that recognizes the phosphorylated IkBα and degrades in
a proteasome-dependent manner. The NEDD8 modification is required for CULLINRING-ubiquitin ligases and small molecule (MLN4924) that inhibits NEDD8 activating
enzyme (NAE) has been regarded as an attractive therapeutic approach in clinical trials
(Soucy et al., 2009). Treatment with MLN4924 can inhibit neddylation and the ligase
activity of β-TrCP to promote IκBα stabilization, leading to suppression of NF-κB
transcriptional program. Additionally, inhibition of MALT1 proteolytic activity with
peptide mimetics showed efficacy in decreasing NF-κB activation and IL-2 secretion in
antigen-stimulated T-cells (Rebeaud et al., 2008). Since MALT1 also cleaves and
inactivate A20, the peptide inhibitors of MALT1 have also been utilized and shown some
toxicity in ABC-DLBCL cell lines even in those with CARD11 mutations, providing a
great rationale for development of MALT1 therapy (Ferch et al., 2009; Hailfinger et al.,
2009). More recently, the most prominent therapeutic targets are upstream kinases of
IKK complexes including BTK kinase that couples chronic active BCR signaling with
NF-κB activation. The BTK inhibitor, ibrutinib, is an irreversible and covalent inhibitor
and shown to potently target BCR signaling and inhibit lymphocytes adhesion and tumorpromoting microenvironment (Davis et al., 2010; Yang et al., 2012). Specifically, it can
prevent bone-marrow homing mechanisms of lymphoma cells and lead the cells from the
tissue to the peripheral blood causing lymphocytosis. Almost all BCR signaling inhibitors
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utilize this similar mechanism to attack lymphoid malignancies. Given that ABCDLBCLs depends on BCR and NF-κB signaling for its growth and survival, it is
expected that the patients with this subtype would be more responsive to ibrutinib
treatment. The phase II trials have confirmed that ibrutinib produced complete and partial
response about 40% in ABC-DLBCL patients, but only 5% in GCB-DLBCL patients
(Wilson et al., 2015). The interesting point of this study was that ABC tumors with
concomitant MYD88 mutations with BCR mutations display greater response rates, a
result confirming cooperation between BCR and MYD88 pathways. Both SYK and
PKCβ kinases are therapeutic targets because PKCβ phosphorylates and activates the
wild-type CARD11 and SYK phosphorylates many downstream effectors of BCR
signaling pathway. Although SYK inhibitor, fostamatinib, showed some efficacy (22%)
in phase I/II study for DLBCL patients, the follow-up phase II trial only showed 3% for
refractory and relapsed DLBCL patients and no response rate for ABC-DLBCL (Flinn et
al., 2016). However, BCR pathway inhibitors are very effective treating CLL and MCL
and considered a major breakthrough for treating B-cell malignancies although the
reasons why these particular B-cell cancers are more sensitive are not much known
(Jerkeman et al., 2017). Nevertheless, BCR inhibition will be the basis for therapeutic
combination therapy and understanding molecular mechanism for drug sensitivity and
resistance will help to design more rational treatment for the lymphoid malignancies. In
addition, going forward, evaluation of risks such as unexpected side effects along with
benefits of combination therapy will be critical for the effective targeted treatment.
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CHAPTER 2 : EXPERIMENTAL METHODS

Cell lines, antibodies, drugs, and other reagents
HEK293T cells were cultured using Dulbecco’s modified Eagle’s medium containing
10% fetal bovine serum (FBS). The following cell lines were cultured in RPMI 1640
medium containing 10% FBS: BJAB, Pfeiffer, OCI-LY8, Karpas422, ARP1, SUDHL4,
SUDHL6, SUDHL10, VAL RAMOS, U2932, TMD8, HBL1, RCK8, and HLY-1. The
following cell lines were cultured in Iscove’s modified Dulbecco’s Medium containing
10% FBS: OCI-LY1, OCI-LY7, OCI-LY10, and OCI-LY19. All antibodies were diluted
with 1:1000 ratio unless otherwise specified. The following antibodies were used: antiRoquin1/2 (MABF288), anti-Roquin2 (sc-165026) anti-Roquin2 (Bethyl Laboratories,
A305-150A), anti-KLHL6 (ab182163), anti-KLHL6 (NBP1-46128), anti-Tubulin (sc8035), anti-GAPDH (MAB374,1:5000), anti-CDK1 (sc-954), anti-CDK2 (sc-163), antip-AKT S473 (CST, #4051), anti-FLAG (Sigma F7425, 1:3000), anti-HA (Biolegend,
#901513), anti-Cullin1 (Invitrogen, #71-8700), anti-Cullin3 (Bethyl Laboratories, A301109A), anti-ubiquitin K48 (EMD Millipore, 05-1307), anti-p-ERK T202/Y204 (CST,
#9101), anti-ERK1/2 (CST, #9102), anti-AKT (CST, #4691), anti-TNFAIP3 (CST,
#5630), anti-p-IkB S32 (CST, #2859,1:500), anti-p100/p52 (CST, #4882), anti-p105/p50
(sc-7178), anti-RelA (sc-372), anti-RelB (sc-226), anti-histone H2A(EMD Millipore, 07146) and anti-histone H3 (ab1791, 1:5000), ECL Rabbit IgG HRP-linked whole antibody
(NA934-1ML, 1:5000), ECL Mouse IgG, HRP-linked whole antibody (NA931-1ML,
1:5000), Anti-Rat IgG (H+L) polyclonal antibody (Jackson Immunoresearch, 112-03524

003, 1:5000), Anti-Goat IgG (H+L) polyclonal antibody (Jackson Immunoresearch, 705035-003,1:5000). The following agarose beads were used: anti-FLAG-M2 affinity gel
(Sigma, A2220) and Strep-Tactin Superflow 50% suspension (Neuromics). Goat-F(ab’)2
anti-human IgM (SouthernBiotech, #2022-01) was used for BCR stimulation experiment.
150µl of Corning Matrigel Basement Membrane Matrix was used in mix of 100µl of
DMEM/F12 containing 10% Knockout Serum Replacement (SR) and plated in Millicell
EZ slide (Millipore) for 3D culture assays. Cell colonies were grown for 14 days and
300µl of Corning Dispase (#354235) was used to count the cell numbers according to
manufacturers’ protocols. The following drugs were used: ActinomycinD (Sigma
Aldrich; 2µg/ml final concentration), proteasome inhibitor MG132 (Peptide Institute Inc.;
10

µM

final

concentration),

Cycloheximide

(Sigma

Aldrich;

50µg/ml

final

concentration), Doxycycline hyclate (Sigma Aldrich; 1 µg/ml final concentration), IKK16 (Selleckchem; 10µM final concentration), MLN4924 (Active Biochem; 5µM final
concentration),

Bortezomib

(Selleckchem),

Ibrutinib

(Selleckchem;

5µM

final

concentration). Cells were also selected with puromycin (Sigma Aldrich; 0.5µg/ml1µg/ml final concentration) and hygromycin (ThermoFisher; 100µg/ml) for generation of
stable cell lines. MTS assays (Promega, G5421), AnnexinV staining (Thermo fisher
Annexin V, Alexa Fluor® 680 conjugate; A35109) was carried out according to
manufacturers’ protocols. FITC mouse anti-human IgM (BD, #562029) and APC mouse
anti-human IgG (BD, #562025) were used according to manufacturing instruction to
detect expression of B-cell receptors.
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Immunoblotting and immunoprecipitation
For immunoblotting, cell lysis was carried out with RIPA-lysis buffer (50 mM Tris pH
8.0, 150 mM NaCl, 0.1% SDS, 0.5% Na deoxycholate, 1% NP-40) supplemented with
protease and phosphatase inhibitors and N-ethylmaleimide (Sigma Aldrich; 10mM).
Equal amount of proteins (~15µg) were used to a 6% polyacrylamide gel for
electrophoresis. Bands quantification was performed using ImageJ software and plotted
using nonlinear-fit curve in Prism. For immunoprecipitation, cell lysis was carried out
with NP40 buffer (15 mM Tris pH 7.4, 1 mM EDTA, 150 mM NaCl, 1 mM MgCl2, 10%
glycerol, 0.1% NP-40) containing protease inhibitors and DTT. After 5 min of lysis, the
whole cell lysates were spun at 15,000 rpm for 5 min at 4 ºC. The supernatants were
incubated with 15 µL of anti-FLAG-M2 affinity gel agarose beads per each sample for 2
hrs at 4 ºC. After 4 washes with NP-40 lysis buffer, the immunoprecipitates were eluted
with 2X Laemmeli buffer (240 mM Tris pH 6.8, 8% SDS, 0.04% bromophenol blue, 5%
β-mercaptoethanol, 40% glycerol) and boiled for electrophoresis.

Nuclear extraction
Cell lysis was carried out in hypotonic buffer (50 mM Tris pH 8.0, 1 mM EDTA, 0.02%
NP-40, 10% glycerol) containing protease inhibitors. Trypan blue was used to check
nuclear isolation efficiency. Once 90% cell lysis efficiency was achieved, the whole
lysates were spun at 2,400 rpm for 3 min at 4 ºC. The supernatants were removed and
used as a hypotonic cytoplasm fraction. The intact nuclear pellets were washed one time
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with hypotonic buffer. The nuclei were lysed with RIPA buffer (50 mM Tris pH 8.0, 150
mM NaCl, 0.1% SDS, 0.5% Na deoxycholate, 1% NP-40) with protease and phopshotase
inhibitors. After 5 min of nuclear lysis, the samples were spun at 15,000 rpm for 5 min at
4 ºC. The supernatants were separated and used as a detergent-soluble nuclear fraction.

λ-Phosphatase treatment
After the fours washes of the immunoprecipitation protocol, the beads were washed two
times with the Tris-NaCl buffer (25 mM Tris pH 7.4, 50mM NaCl) and divided equally
for each condition indicated. The beads were than incubated with the reaction mix (25
mM Tris pH 7.4, 50mM NaCl, 0.1 mM MnCl2, 1X NEB buffer PMP) with or without 1
µl of λ-phosphatase (New England Biolabs, P0753, 400 U) for 30 min at 30 ºC. The
immunoprecipitates were eluted with 2X Laemmeli buffer were eluted with 2X
Laemmeli buffer.

Chromatin immunoprecipitation
Cells were collected, washed with PBS two times and cross-linked with 1%
formaldehyde for 5min. Next, cross-linked cells were treated with 125 mM glycine for 5
min, washed with PBS once and lysed with the lysis buffer (0.2% NP-40, 100 mM TrisHCl pH8, 10 mM NaCl) on ice for 10 min. The cells were centrifuged at 2500 rpm for
5min at 4 °C, and the cell pellets were re-suspended with nucleus lysis buffer (0.1% SDS,
50 mM Tris-HCl pH8, 10 mM EDTA) followed by sonication using the Covaris S220
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system (Thermo Fisher Scientific, #4465653) according to the manufacturer’s protocol.
After the sonication, the nucleus lysates were centrifuged at 13,000 rpm for 5 min at 4 °C
and the supernatants were collected. Next, 10 µl of Dynabeads Protein A (Life
Technology, #10001D) were incubated with 1 mg/ml of BSA for 1 hour at 4 °C and 30 µl
of Dynabeads were incubated with 5 µg of antibodies at 4 °C for 4 hours. The sonicated
nuclear lysates (300µl) were incubated with 10 µl of BSA-blocked Dynabeads for 3 hours
at 4 °C. These pre-cleared nuclear lysates (300µl) was incubated with 30 µl of antibodyconjugated Dynabeads overnight with addition of 700 µl of IP buffer (0.01% SDS, 1%
TritonX-100, 20 mM Tris-HCl pH8, 2 mM EDTA, 150 mM NaCl). The Dynabeads were
washed two times each with low salt IP wash buffer (0.01% SDS, 1% TritonX-100, 20
mM Tris-HCl pH8, 2 mM EDTA, 50 mM NaCl), with medium salt IP wash buffer
(0.01% SDS, 1% TritonX-100, 20 mM Tris-HCl pH8, 2 mM EDTA, 300 mM NaCl), and
with high salt IP wash buffer (0.01% SDS, 1% TritonX-100, 20 mM Tris-HCl pH8, 2
mM EDTA, 500 mM NaCl). Then, the Dynabeads were washed with LiCl buffer (1%
NP-40, 1% deoxycholic acid, 10 mM Tris-HCl pH8, 1 mM EDTA, 0.25 M LiCl) and
with TE buffer (10 mM Tris-HCl pH8, 1 mM EDTA) one time each. The chromatin
reverse cross-linking and DNA elution were performed using IPure kit (diagenode,
C03010015) according to the manufacturer’s protocol.

Xenograft experiments
NOD/SCID/IL2Rγ−/− (NSG) mice were purchased from the Jackson Laboratory. For
KLHL6 experiment, NSG mice (6-8 weeks old) were injected sub-cutaneously with
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1x107 U2932 KLHL6-/- (clone-derived) cells re-expressing either with KLHL6 (WT),
KLHL6 (S94I) or empty vector (EV). For Roquin2 experiment, NSG mice were injected
sub-cutaneously with 1x107 U2932 cells infected with retroviruses encoding HARoquin2 (WT) or HA-Roquin2 (Y691F). Tumor volume and weight was monitored
weekly by palpation and eye inspection and measured with caliper and analytical scale.
All animal work was performed following the ethical guidelines and protocols approved
by the Institutional Animal Care and Use Committee of the University of Pennsylvania.

KLHL6 complexes purification for mass spectrometry
HEK293T and ARP-1 cells stably expressing FLAG-tagged KLHL6 (WT) or FLAGtagged KLHL6 (L65P) were collected and lysed in lysis buffer (50 mM Tris-HCl pH 7.5,
150 mM NaCl, 1 mM EDTA, 50 mM NaF, 0.5% NP40) with protease and phosphatase
inhibitors. Flag-KLHL6 (WT) or Flag-KLHL6 (L65P) was immunoprecipitated with antiFLAG agarose beads and washed five times with lysis buffer and proteins were eluted
with FLAG peptides. 1% of protein eluates were separated by SDS-PAGE and stained by
Silver Staining (Life Technology). The final eluates were precipitated with trichloroacetic
acid (TCA) for mass spectrometry analysis.

In vitro binding assays
In vitro-translated FLAG-tagged KLHL6 was incubated with indicated amounts of
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Roquin2 peptides in lysis buffer (50 mM Tris-HCl pH 7.5, 250 mM NaCl 0.1% Triton X100, 1 mM EGTA). Anti-streptavidin resin was added to the samples and incubated at
4°C for 2hrs with rotation. Samples were washed three times with the lysis buffer, and
protein complexes were eluted in Laemmli buffer. For another binding experiment,
HEK293T cells stably expressing KLHL6 (WT) were lysed with the lysis buffer and the
whole cell lysates were incubated with anti-streptavidin resin and the peptides. The
protein complexes were eluted in Laemmli buffer.

In vitro and in vivo ubiquitylation assay
For in vitro ubiquitylation assay, FLAG-KLHL6 or FLAG-KLHL6/HA-Roquin2
complex were immunoprecipitated from HEK293T cells with anti-FLAG agarose beads.
The purified proteins on the beads were incubated with 10 µl of ubiquitylation mix (50
mM Tris pH 7.6, 5 mM MgCl2, 2 mM ATP, 1.5 ng/µl E1 (Boston Biochem), 10 ng/µl
Ubc3, 10 ng/µl Ubc5, 2.5 µg/µl ubiquitin (Sigma), 1 µM ubiquitin aldehyde). The
ubiquitylation reactions were incubated at 37°C for the indicated time points and
subjected to SDS-PAGE analysis. When indicated, upon ubiquitylation reaction, beads
were re-suspended in 1% SDS, boiled, and diluted to 0.1% SDS. The eluted proteins were
immunoprecipitated with anti-FLAG agarose beads, washed, and eluted in Laemmli
buffer. For in vivo ubiquitylation assay, U2932 KLHL6+/+ and KLHL6-/- (clone-derived)
cells were pre-treated with or without MG132 for 6hrs before cell lysis with 1% SDS and
incubated in 95°C for 5 min. Then, the cell lysates were diluted to 0.1% SDS in NP-40
buffer and immunoprecipated using a polyclonal antibody against Roquin2. The
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immunocomplexes were subjected to SDS-PAGE analysis.

Transient transfections, generation of viruses for infection, and electroporation
Polyethylenimine (PEI) was used for transient transfection in HEK293T cells. For
retrovirus and lenvirius production, GP-293 packaging cells (Clontech) or pCMVDeltaR8.2 were used respectively. After 48 hours of transfection, the virus-containing
medium was collected, filtered, and used to spin-infect the cells at 1800 rpm for 30
minutes. 10 µg/ml of polybrene was added to the cells with virus supernatant and
incubated with six hours to overnight. RCK8 cells were electroporated using Neon
transfection system according to manufacture’s protocol with LentiCRISPRv2 vector
carrying a GFP marker. Transfected cells were sorted by GFP positive cells. siRNA
oligos transfection was also performed with Neon transfection system according to
manufacture’s protocol.

Generation clonal KLHL6-/- cell lines
U2932 or OCI-LY10 Cas9-expressing cells were infected with lentiviruses encoding
gRNAs targeting KLHL6 gene. After puromycin selection, cells were plated at a
concentration of 0.5 cells/well in a 96 well plate and a single cell was grown and
screened for KLHL6 knockout.

Plasmids, cloning, shRNA, gRNA, and siRNA sequences
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Dr. Carola Vinuesa kindly provided human Roquin1 and Roquin2 cDNA and we subcloned Roquins into different vectors: pcDNA3.1-FLAG, pcDNA3.1-HA or pcDNA3.1FLAG-Streptavidin. Human KLHL6 cDNA was purchased from Dharmacon and we subcloned into different vectors: pcDNA3.1-FLAG, pcDNA3.1-FLAG-Streptavidin, and
pREV-TRE. QuikChange Site-directed Mutagenesis kit (Stratagene) was used to generate
C-terminal deletion mutants and point mutants of Roquin2. Standard PCR methods were
used to generate N-terminal deletion mutants. The pcDNA3.1 V5-PTPN14 (#61003)
vector was purchased from Addgene. Dr. Elizabeth White kindly provided all MSCV-Nterm V5-tagged PTPN14 deletion mutants. cDNAs encoding FLAG-tagged or HA-tagged
KLHL6 and KLHL6 mutants were sub-cloned into MIGR1 retroviral vector and pREVTRE vector. cDNAs encoding FLAG-HA-tagged or untagged Roquin2 and Roquin2
mutants were sub-cloned into pBabe Puro or pMSCV retroviral vector. shRNAs targeting
human KLHL6 were sub-cloned into pSicoR-Puro lentiviral vector. shRNAs targeting
human Roquin2 were sub-cloned into pSicoR-GFP lentiviral vector. KLHL6 cDNA and
HA-tagged PTPN14 cDNA were sub-cloned into pTRIPZ vector.

The target sequences to knock-down human KLHL6:
hKLHL6_shRNA#1:
For:TGCAGCCAGCAACTATTTCATTCAAGAGATGAAATAGTTGCTGGCTGCTT
TTTTC
Rev:TCGAGAAAAAAGCAGCCAGCAACTATTTCATCTCTTGAATGAAATAGTT
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GCTGGCTGCA
hKLHL6_shRNA#2:
For:TGAAGCCTTGAACCCAGAAATTCAAGAGATTTCTGGGTTCAAGGCTTCTT
TTTTC
Rev:TCGAGAAAAAAGAAGCCTTGAACCCAGAAATCTCTTGAATTTCTGGGTTC
AAGGCTTCA
hKLHL6_shRNA#3:
For:TGCATGATGTTTGGAAATATTTCAAGAGAATATTTCCAAACATCATGCTTT
TTTC
Rev:TCGAGAAAAAAGCATGATGTTTGGAAATATTCTCTTGAAATATTTCCAAA
CATCATGCA
hKLHL6_shRNA#4:
For:TGGATTCAGATTGAGTATTTTTCAAGAGAAAATACTCAATCTGAATCCTTT
TTTC
Rev:TCGAGAAAAAAGGATTCAGATTGAGTATTTTCTCTTGAAAAATACTCAAT
CTGAATCCA

The target sequences to knock-down human Roquin2:
hRoquin2 shRNA#1:
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For:TGCAGTTGTCTGCCAATCTATTCAAGAGATAGATTGGCAGACAACTGCTT
TTTTC
Rev:TCGAGAAAAAAGCAGTTGTCTGCCAATCTATCTCTTGAATAGATTGGCAG
ACAACTGCA

hRoquin2 shRNA#2:
For:TGGACTCAGATACCCTTTGATTCAAGAGATCAAAGGGTATCTGAGTCCTT
TTTTC
Rev:TCGAGAAAAAAGGACTCAGATACCCTTTGATCTCTTGAATCAAAGGGTA
TCTGAGTCCA
gRNAs targeting human KLHL6 were sub-cloned into Lenti-Guide-Puro vector, LentiGuide-GFP and LentiCRISPRv2 vector. The target sequences to knockout human
KLHL6:

hKLHL6_gRNA#2

For: CAGAGCGTTTTCCATTCGCA
Rev: TGCGAATGGAAAACGCTCTG

hKLHL6_gRNA#3

For: TCAGAGCGTTTTCCATTCGC
Rev: GCGAATGGAAAACGCTCTGA

hKLHL6_gRNA#4

For: AAAGGTCAAATTTGACGACG
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Rev: CGTCGTCAAATTTGACCTTT
hKLHL6_gRNA#5

For: GACTTGGTCGAGATCTTAAA
Rev: TTTAAGATCTCGACCAAGTC

hKLHL6_gRNA#6

For: ACTTGGTCGAGATCTTAAAT
Rev: ATTTAAGATCTCGACCAAGT

siRNA duplexes were ordered from Dharmacon.
The target sequence for human KLHL6 siRNA: GCACGAAGGAUGAACGGUU
The target sequence for human Roquin2 siRNA: GCUUGAAAAGUAUCGAUUA
Non-targeting siRNA control sequence: UGGUUUACAUGUCGACUAA

mRNA Analysis and q-PCR primers
RNeasy Kit (Qiagen) and trizol (Invitrogen) were used for extracting RNA. Maxima first
strand cDNA synthesis kit (Thermo Fisher) and RNA to cDNA Ecodry Premix kit
(Clontech) were used for cDNA synthesis. Quantitative PCR analysis with SYBR Green
PCR Master Mix (Applied Biosystems) was carried out according to standard procedures.
Primer sequences used for q-PCR analysis:
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hGAPDH

FOR: 5’ GGAGCGAGATCCCTCCAAAAT 3’
REV: 5’ GGCTGTTGTCATACTTCTCATGG 3’

hTNFAIP3

FOR: 5’ TCCTCAGGCTTTGTATTTGAGC 3’
REV: 5’ TGTGTATCGGTGCATGGTTTTA 3’

hTNFRSF14 FOR: 5’ CCACTGGGTATGGTGGTTTC 3’
REV: 5’ TCACCTTCTGCCTCCTGTCT 3’
hTNF

FOR: 5’ CTGCACTTTGGAGTGATCGGC3’
REV: 5’ CACCAGCTGGTTATCTCTCAGCTCC 3’

hNFKBIE

FOR: 5’ TCTGGCATTGAGTCTCTGCG 3’
REV: 5’ AGGAGCCATAGGTGGAATCAG 3’

hLTA

FOR: 5’ GCTGCTGGTTCTGCTGCC 3’
REV: 5’ CAAGGAGAAACCATCCTGGAGGAAG 3’

hNEDD4L

FOR: 5’ ACTTCCTCCTCCTCCTCTGC 3’
REV: 5’ TCCAAGTCTTCGCTGATGTG 3’

hABLIM1

FOR: 5’ ACTGCATCTCTCCCTGGCTA 3’
REV: 5’ TGTTGGTCACCATGAGCATT 3’

hSYNGAP1

FOR: 5’ TCTGAGGAAAACTGCGAGGT 3’
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REV: 5’ GCAAACACCTCCTTCAGCTC 3’
hNEIL2

FOR: 5’ GCCTCCACAAAAAGAAGTGC 3’
REV: 5’ TTGTTGGCTTTCTTGGCTCT 3’

hLGALS8

FOR: 5’ CTGGGCATTTATGGCAAAGT 3’
REV: 5’ GACAGTTCTGGGTGCGATTT 3’

hCD274

FOR: 5’ TATGGTGGTGCCGACTACAA 3’
REV: 5’ TGCTTGTCCAGATGACTTCG 3’

hKLHL6

FOR: 5’ GCAGCCAGCAACTATTTCAGG 3’
REV: 5’ ACGTGTAGTCCAACAGAGTGT 3’

hNFKBIA

FOR: 5’ TATAAACGCTGGCTGGG 3’
REV: 5’ CCCTAGTGGCTCATCGC 3’

Normalization and quantification of protein levels
Protein concentrations of whole cell lysates were quantified using a Bio-Rad DC protein
assay (Lowry assay) according to the manufacturer’s protocol. Equal amounts of protein
(~15µg) were loaded for SDS-PAGE analyses. Additionally, equal amount of protein
levels was confirmed by staining the membraine with Ponceau S and by immunoblotting
for a normalization control.
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Cell proliferation assay
For MTS cell proliferation assay, 2 x 103 cells were used according to manufacturers’
protocols. For the long-term cell proliferation assay, ~ 5x104-2x105 cells were plated,
counted and re-plated every 3-5 days and cumulative cell numbers were graphed.

Flow cytometry
Flow cytometry was performed using Attune NxT Flow Cytometer and following
channels were used: FITC for GFP-expressing cells, Alexa-680 AnnexinV to detect
apoptosis, FITC to detect IgM or APC to detect IgG staining. All stainings were
performed according to manufacturers’ protocols. To measure shRNA or gRNA effects
on cell proliferation and survival, 5x105 cells were spin-infected with 1000 µl lentivirus
supernatant with the addition polybrene (8µg/ml) in a 24-well plate. After the spininfection, the supernatant was removed and replaced with regular medium and the
percentage of infected cells was measured from day 2 when GFP was visible in the
infected cells. The number of alive GFP-positive cells on day 2 was set to 100% to
normalize for transduction efficiency and every consecutive assessment was calculated
based on day 2. When indicated, AnnexinV positive cells were gated on GFP positive
cells.
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MudPIT analysis
TCA-precipitated proteins were urea-denatured, reduced, alkylated and digested with
endoproteinase Lys-C (Roche) and modified trypsin (Roche), as previously described
(Florens and Washburn, 2006; Washburn et al., 2001). Peptide mixtures were loaded onto
100-µm fused silica microcapillary columns packed with 5-µm C18 reverse phase (Aqua,
Phenomenex), strong cation exchange particles (Luna, Phenomenex), and reverse phase
(McDonald et al., 2002). Loaded microcapillary columns were placed in-line with a
Quaternary Agilent 1100 series HPLC pump and a LTQ linear ion trap mass spectrometer
equipped with a nano-LC electrospray ionization source (Thermo Scientific). Fully
automated 10-step MudPIT runs were performed on the electrosprayed peptides, as
previously described (Florens and Washburn, 2006). Tandem mass (MS/MS) spectra
were analyzed using SEQUEST (Eng et al., 1994) against a database of 61,318
sequences, consisting of 30,449 non-redundant human proteins (downloaded from NCBI
on 2012-08-27, 160 usual contaminants (such as human keratins, IgGs and proteolytic
enzymes), and, to estimate false discovery rates, 30,659 randomized amino-acid
sequences derived from each non-redundant protein entry. Peptide/spectrum matches
were sorted and selected using DTASelect with the following criteria set: spectra/peptide
matches were only retained if they had a DeltCn of at least 0.08 and a minimum XCorr of
1.8 for singly-, 2.0 for doubly-, and 3.0 for triply-charged spectra. Additionally, peptides
had to be fully tryptic and at least seven amino acids long. Combining all runs, proteins
had to be detected by at least two such peptides, or one peptide with two independent
spectra. Under these criteria the final FDRs at the protein and spectral levels were
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2.1%±0.3 and 0.94%  ±  0.03, respectively. Peptide hits from multiple runs were compared
via CONTRAST (Tabb et al., 2002). Normalized Spectral Abundance Factors (NSAFs)
were calculated for each detected protein, as previously described (Florens et al., 2006;
Paoletti et al., 2006; Zybailov et al., 2006).

Analysis of KLHL6 expression in DLBCL patients
Raw DNA copy number data from high-resolution single nucleotide polymorphism
(SNP) microarray analysis of 609 primary DLBCL tumors were used from a previously
published study (Green et al., 2014). The data were visualized via the integrative
genomics viewer (IGV) (Robinson et al., 2011). Cases were sorted by their KLHL6 copy
number status, and those with copy number <1.8 were classified as a deletion, as
previously described criteria (Monti et al., 2012). Gene expression microarray from 249
tumors with matched DNA copy number data were from a previously published study
(Green et al., 2014). Their cell of origin subtype was determined via the Wright algorithm
(Wright et al., 2003), as previously reported (Monti et al., 2012). Row normalized
heatmaps for 4 probe sets corresponding to KLHL6 were sorted according to their
average expression, and significant reduction in KLHL6 expression defined as being 1
standard deviation below the mean. Raw cel files for publicly available Affymetrix U133
plus 2.0 gene expression microarray data for diffuse large B-cell lymphoma tumors
(GSE10846, GSE34171, GSE31312) were obtained from the gene expression omnibus.
Data were RMA normalized using the ExpressionFileCreator module of GenePattern
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(Reich et al., 2006). Scores to categorize diffuse large B-cell lymphoma tumors by cell of
origin subtype were calculated according to the Wright algorithm (Wright et al., 2003).
Intensities from the 4 probes for KLHL6 (1555275_a_at, 1560396_at, 1560397_s_at,
228167_at) were averaged for use in the survival analysis. Cases were dichotomized into
being above or below the median expression level of KLHL6 expression within each
dataset to avoid confounding batch effects. For NF-κB signatures, Affymetrix U133 plus
2 gene expression microarrays were performed on 84 matched DLBCL tumors (Green et
al., 2014; Lenz et al., 2008f). Raw cel files were RMA normalized with median scaling
using the ExpressionFileCreator module of GenePattern (Reich et al., 2006). Samplelevel enrichment of NF-κB target genes was calculated using the single sample gene set
enrichment analysis (Barbie et al., 2009) and the c3 TFT gene set database of mSigDB
(Liberzon et al., 2011).

RNA sequencing
Total RNA was extracted using RNeasy Mini Kit (QIAGEN, #74104) and polyA+
transcripts were obtained with oligo (dT)25-conjugated magnetic Dynabeads (Thermo
Fisher). Preparation of strand specific RNA-seq libraries were carried out according to a
published protocol (Parkhomchuk et al., 2009). In short, RNA was fragmented
chemically in first strand buffer, converted to cDNA utilizing SuperScript® III reverse
transcriptase (Invitrogen), end-repaired, A-tailed and ligated to custom-designed
universal adapters utilizing an end-repair mix, klenow fragment, and T4 DNA ligase (all
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from Enzymatics). After the ligation step, adapters were removed by SPRI purification
utilizing SPRIselect beads (Beckman coulter) and amplified with Q5 Hot Start DNA
polymerase (New England Biolabs) while introducing custom dual indexes. Three
biological replicates were used to sequence on a NextSeq 500 (Illumina) at a depth of at
least 2x107 reads each. Reads were mapped and analyzed via a custom bioinformatic
pipeline based on STAR (Dobin et al., 2013), SAMTOOLS (Li et al., 2009), and the R
packages DEGseq (Wang et al., 2010) and DEseq2 (Love et al., 2014). We used human
genome version GRCh38 and gene annotations from the ENSEMBL release 83. GO
analyses were performed using version 6.8 of the DAVID web server (Huang et al.,
2009a, c).

CHIP sequencing
The previously published data were obtained from the NCBI's Gene Expression Omnibus
(Zhao et al., 2014) and they are accessible through GEO at Series accession numbers
GSE55105. FASTQs were downloaded and mapped to hg19 with bowtie2 (v2.1.0).
Genome browser tracks were generated using custom scripts. When available, biological
replicates were merged by taking the mean of the reads density at each position. The data
were visualized via the integrative genomics viewer (IGV) (Robinson et al., 2011).

Statistics and reproducibility
Mean values with error bars indicating standard deviation (s.d.) were shown in the
graphs. Unless otherwise noted, all the experiments were successfully repeated at least
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three times. One-tailed t-test, two-tailed t-test, one-way or two-way ANOVA was
performed as indicated in the figure legends. DEseq2 was performed for RNA-seq
analysis in Fig. 4.3b and Table 4.1. Weighted Exclusivity Test (WExT) was performed
for Table 4.3. Mantel-Cox was performed for survival analysis in Fig. 4.1l. Pearson
Correlation Coefficient was used in Fig. 3.5b.
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CHAPTER 3 : BIOCHEMICAL ANALYSIS OF KLHL6 AND ROQUIN2 AS AN
E3 LIGASE-SUBSTRATE PAIR

Chapter Summary
Research described in this chapter was performed in collaboration with the
laboratories of Dr. Michael Washburn and Dr. Michael Green. Mass Spectrometry (MS)
sample preparations were carried out in our laboratory, and MS analysis was performed
by Anita Saraf and Laurance Florens in Dr. Michael Washburn lab (Stowers Institute).
Re-analysis of published SNP array data and KLHL6 transcript expression in DLBCL
tumors were performed in collaboration with Saber Tadros, a graduate student in Dr.
Michael Green lab (MD Anderson Cancer Center).
The work described here forms the body of a manuscript that is currently accepted
at Nature Cell Biology. This chapter is heavily focused on biochemical approaches to
understand KLHL6 as a CULLIN3-RING-ubiquitin Ligase for Roquin2 protein and is
written and arranged differently from the original manuscript.

Jaewoo Choi, Kyutae Lee, Kristin Ingvarsdottir, Roberto Bonasio, Anita Saraf, Laurence
Florens, Michael P. Washburn, Saber Tadros, Michael R. Green, and Luca Busino. Loss
of KLHL6 promotes diffuse large B-cell lymphoma growth and survival by stabilizing
the mRNA decay factor Roquin2
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Introduction
Kelch-like protein 6 (KLHL6) is a highly conserved and uncharacterized BTBKelch protein with a lymphoid tissue-restricted expression pattern (Gupta-Rossi et al.,
2003). Although expressed at all stages of B-cell development, Klhl6 levels are highly
up-regulated in sheep Peyer’s patch, human tonsil B cells and germinal center (GC) Bcells, suggesting a functional relevance in GC reaction (Kroll et al., 2005). In line with
this expression profile, Klhl6-/- mice fail to mount a full GC formation in vivo (Kroll et
al., 2005). Recently, whole-genome and exome sequencing have revealed cancerassociated mutations of the KLHL6 gene in mature B-cell malignancies, including diffuse
large B-cell lymphoma (DLBCL) (Lohr et al., 2012; Morin et al., 2011). The somatic
mutations tend to localize to the N-terminus of the protein, namely the BTB domain and
the relevance of these mutations or the molecular function of KLHL6 is currently not
known. The BTB protein family can be sub-divided into BTB-BACK-Kelch (BBK),
MATH-BTB, BTB-NPH3, Kelch repeat and BTB-domain containing proteins (KBTBD),
BTB-zinc finger (BTB-ZF), and Kelch family (KLHL)(Pintard et al., 2004). Many of
these BTB proteins interact with CULLIN3, but not with other CULLIN scaffold
proteins, to induce ubiquitination of target proteins involved in a variety of biological
processes such as cell cycle regulation, oxidative stress, and others (Anderica-Romero et
al., 2013). Although approximately 500 BTB-domain proteins have been identified, little
is known about the physiological and molecular functions of these proteins.
The Roquin family of proteins consists of Roquin1 (Rc3h1) and Roquin2
(Rc3h2). The N-terminal region of Roquin proteins comprises a RING finger, a
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conserved ROQ domain, and a CCCH-type zinc finger (Vinuesa et al., 2005).
Specifically, mRNAs that display a 3’ UTR sequence conserved a stem-loop motif, called
a constitutive-decay element (CDE), which are recognized by the ROQ domain of
Roquin1 and 2 (Leppek et al., 2013; Schlundt et al., 2014; Tan et al., 2014). Upon
recognition, Roquin proteins recruit the mRNA decapping and deadenylation complexes
through their C-terminal effector domains leading to the destabilization of their target
mRNAs. CDEs are reported to be highly conserved in the 3’ UTRs of more than 50
vertebrate genes, suggesting that CDE is a ubiquitous regulatory element (Leppek et al.,
2013).

Genome-wide

identification

of

Roquin

targets

by

crosslinked-

immunoprecipitation (CLIP)-Seq revealed that many mRNAs associated with the roquin
encode for proteins are important for immunity, inflammation, and development (Leppek
et al., 2013). Accordingly, in the context of lymphocyte biology, tissue-specific ablation
of Roquin1 in T cells causes expansion of CD8 effector-like T cells with up-regulation of
essential T-cell co-stimulatory receptor, ICOS, which is a well-known target for Roquin
proteins (Bertossi et al., 2011; Glasmacher et al., 2010; Yu et al., 2007). Mice with a Tcell-specific combined deficiency of Roquin1 and Roquin2 exhibit lymphadenopathy and
splenomegaly with spontaneous development of follicular T-helper cells (Tfh) and GC Bcells, suggesting the function of these cells in the control of T-cell activation and Tfh
differentiation. This autoimmunity phenotype is partially caused by elevated levels of
ICOS.
Many studies defining the role of Roquin proteins have focused on T-cell biology
and T-cell differentiation. Recent studies on the regulation of Roquin protein stability
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have suggested that it is regulated by the paracaspase MALT1 (Jeltsch et al., 2014).
Stimulation of wild-type CD4+ T cells by the pharmacological agents PMA and
ionomycin mimic for activation of T-cell receptor and co-stimulation causes the cleavage
of Roquin proteins by MALT1 and this phenomenon is blocked by the specific peptide
inhibitor z-VPR-fmk. Both Roquin1 and Roquin2 are cleaved and inactivated to control
post-transcriptional targets for promoting TH17 differentiation. However, the regulation
of Roquin protein abundance in B-cell biology has not been investigated.
Based on a proteomic analysis of the purified KLHL6 complex, we show that
KLHL6 assembles a functional multi-subunit E3 ligase based on CULLIN3. We have
found that binding CULLIN3 to KLHL6 requires an intact BTB-domain and the cancerassociated mutations of KLHL6 inhibit its ubiquitin ligase activity by disrupting this
interaction. Furthermore, we have identified Roquin2 as a novel substrate and found that
the integrity of a specific tyrosine residue (Y691) in Roquin2 is crucial for KLHL6
binding. In addition, degradation of Roquin2 is dependent on B-cell receptor activation.
These findings identify KLHL6 as the E3 ligase for Roquin2 and can provide critical
evidence and implements to uncover the connection between the ubiquitin proteasome
system and mRNA decay in B-cell cancers.

Results
Cancer-associated mutations of KLHL6 in B-cell malignancies
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KLHL6 is a lymphoid-tissue expressed gene (Gupta-Rossi et al., 2003; Kroll et al.,
2005) with uncharacterized function. Mutations of the KLHL6 gene were observed in
DLBCL (http://cancergenome.nih.gov/ and (Idoia et al., 2016; Lohr et al., 2012; Morin et
al., 2011; Reddy et al., 2017), chronic lymphocytic leukemia (CLL) (Puente et al., 2015)
and multiple myeloma (MM) (Lohr et al., 2014) (Fig. 3.1A) via analysis of genomic
databases of B-cell cancer patients. DLBCL cohorts from UNMC, TCGA and CMSGSC
revealed the highest rate of genetic mutations with 10%, 14.5%, and 12.5%, respectively
(Fig. 3.1A), which are stratified in a similar rate amongst GCB-DLBCL, ABC-DLBCL
and uncharacterized DLBCL (Fig. 3.1B). Majority of the cancer-associated mutations are
missense and monoallelic mutations as non-sense and frameshift mutations exhibit a very
low frequency (Fig. 3.1C, Table 3.1) (Idoia et al., 2016; Lohr et al., 2012; Morin et al.,
2011; Reddy et al., 2017). Most of mutations occur near and inside the BTB-domain of
KLHL6, and the residues Leucines 65 and 90 of KLHL6 are mutational hotspots as
shown (Fig. 3.1C). Additionally, infrequent deletion of the KLHL6 locus was observed
upon re-analysis of previously published SNP array data (Green et al., 2014) (Fig. 3.1D).
Gene expression microarray analysis showed that ~6% of DLBCL tumors have lower
expression of KLHL6 transcript (Fig. 3.1E), suggesting that there might be possible role
of transcriptional silencing as a way to inactivate KLHL6 function.

KLHL6 assembles a CULLIN3-based E3 ligase
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To gain insight into the molecular function of KLHL6 and to understand the
impact of the cancer associated mutations, we first compared the protein interactome
change between KLHL6 (WT) and the cancer mutant KLHL6 (L65P). FLAG-KLHL6
(WT) or FLAG-KLHL6 (L65P) complexes were immunopurified from two different cell
lines (HEK293T and ARP-1) and the tryptic digestion of each protein eluate was
measured by mass spectrometry (Table 3.2). In the two cell lines, high unique spectral
counts corresponding to CULLIN3 were identified in KLHL6 (WT) immunoprecipitates
as opposed to none in the KLHL6 (L65P) purifications (Fig. 3.2A and Table 3.2),
indicating that CULLIN3 is a novel KLHL6 binding partner and that a hotspot BTBdomain mutation of KLHL6 (L65P) abolishes this interaction.
To

validate

the

mass

spectrometric

analyses,

we

expressed

and

immunoprecipitated FLAG-tagged KLHL6 from HEK293T cells and confirmed
interaction with endogenous CULLIN3 (Fig. 3.2B), similarly to the established
CULLIN3 interactor IBTK (Bennett et al., 2010) (Fig. 3.2B). KLHL14 was used as a
negative control of a BTB-containing protein that did not interact with CULLIN3. In
contrast, CULLIN1 was detected in FBXW7 and FBXL15 immunoprecipitations (Fig.
3.2B), as previously shown (Busino et al., 2012; Cui et al., 2011), but not in association
with KLHL6, suggesting that KLHL6 specifically assembles a CULLIN3-based ubiquitin
ligase complex.
To determine whether KLHL6 is capable of catalyzing polyubiquitylation, we
carried out an in vitro ubiquitylation assay where we incubated purified KLHL6 (WT) or
KLHL6 (ΔKelch), a deletion mutant that contains only the BTB-domain, with a
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ubiquitylation mix consisting of E1 enzyme, Ubch5a (E2) enzyme, ATP and ubiquitin.
As expected, KLHL6 promoted self-ubiquitylation, and, notably, its BTB-domain alone
was sufficient in catalyzing self-polyubiquitylation to a higher degree as recognized by an
antibody specific to K-48 linked ubiquitin chains (Fig. 3.2C). These data revealed that the
KLHL6 complex catalyzes ubiquitin transfer in vitro, further supporting the notion of
assembling a functional CULLIN3-RING ubiquitin Ligase (CRL3) (Lydeard et al.,
2013).

BTB-domain mutations of KLHL6 abolishes its ligase activity
Having established above that KLHL6 is a CRL3 ligase, we tested the effect of
BTB-domain mutations on ligase assembly and activity. First, we confirmed our initial
proteomic data by showing that the KLHL6 (L65P) mutant did not co-immunoprecipitate
endogenous CULLIN3 (Fig. 3.3A). We also found that two other cancer mutants
(KLHL6 (S94I) and KLHL6 (F97L)) did not interact with CULLIN3 (Fig. 3.3A).
Secondly, we showed that mutations in the BTB-domain were sufficient in inhibiting
self-polyubiquitylation in vitro (Fig. 3.3B), as a result of a loss of catalytic activity due to
endogenous CULLIN3 dissociation.
The latter findings prompted us to determine whether loss of KLHL6 selfubiquitylation would affect its turnover in cells. To this end, we expressed KLHL6 (WT)
or BTB-domain KLHL6 mutants (L65P, S94I and F97L) in OCI-LY10 KLHL6-/- and
assessed protein half-life in cycloheximide (CHX) chase experiments (Fig. 3.3C).
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Consistent with our in vitro findings, the protein levels of BTB-domain KLHL6 mutants
were remarkably high at steady state and displayed extended half-lives as compared to
that of KLHL6 (WT) (Fig. 3.3C). These results suggested that KLHL6 promotes autoubiquitylation and degradation via CULLIN3 interaction (Fig. 3.3D).
Together, our data show that (i) KLHL6 is a CRL3 that promotes selfubiquitylation and degradation, and (ii) cancer-associated mutations within the BTBdomain abrogate the interaction with CULLIN3, resulting in the loss of ubiquitin ligase
activity (Fig.3.3D)

KLHL6 specifically interacts with Roquin2
Based on our previous findings, we hypothesized that the molecular function of
KLHL6 is to ubiquitylate and degrade one or more substrates. Since KLHL6 (L65P)
mutant is unable to promote ubiquitylation, we reasoned that it might trap (i.e. interact
with, but not ubiquitylate or degrade) natural KLHL6 substrates offering an opportunity
to identify them. Thus, we ranked the identified proteins by the number of unique spectral
counts associated to KLHL6 (L65P) and compared them to KLHL6 (WT) (Fig. 3.4A and
Table 3.2). Roquin2 was enriched in the KLHL6 (L65P) complex in both HEK293T cells
and ARP-1 cells. Notably, Roquin1 was not detected, suggesting that KLHL6 interacts
preferentially with Roquin2 (Fig 3.4A).
To investigate whether the binding between Roquin2 and KLHL6 is specific, we
screened a panel of human F-box proteins, as well as BTB-domain containing proteins
(Fig. 3.4B). We found that only KLHL6 co-immunoprecipitated endogenous Roquin2
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(but not Roquin1 despite its higher expression), in agreement with our mass spectrometry
results (Fig. 3.4B). To further confirm this finding, we expressed FLAG-tagged Roquin1
or Roquin2 in HEK293T cells stably expressing exogenous KLHL6 (HEK293T cells do
not express KLHL6 at the endogenous level). Analysis of FLAG immunoprecipitates
confirmed that Roquin2, but not Roquin1, interacted with KLHL6 (Fig. 3.4C). We also
confirmed the endogenous KLHL6 and Roquin2 interaction in DLBCL cells (Fig. 3.4D).
KLHL6 required an intact Kelch domain to interact with Roquin2 (Fig. 3.4E), further
supporting substrate-like interaction between KLHL6 and Roquin2 (Lo et al., 2006).
Consistent with the proteomic data, mutations in the BTB-domain did not affect binding
of KLHL6 to Roquin2 (Fig. 3.4E).

KLHL6 promotes ubiquitylation and degradation of Roquin2.
To investigate whether KLHL6 regulates Roquin2 protein levels, we first
analyzed Roquin2 abundance in a panel of DLBCL cell lines. Interestingly, higher levels
of KLHL6 protein in OCI-LY1, SUDHL4, SUDHL6 and U2932 cell lines correlated with
lower levels of Roquin2 protein (Fig. 3.5A and 3.5B). Inversely, lower levels of KLHL6
protein in OCI-LY7, OCI-LY10, OCI-LY19, TMD8, HLB1, Pfeiffer, and Karpas422 cell
lines correlated with higher levels of Roquin2 protein (Fig. 3.5A and 3.5B). We further
assessed Roquin2 protein turnover by analysis of its half-life in two ABC-DLBCL cell
lines (OCI-LY10 and U2932) (Fig. 3.5C and Fig. 3.5D respectively). In both cell lines,
down-regulation of KLHL6 via siRNAs or ablation via gRNAs significantly extended
Roquin2 half-life. Roquin1 half-life was not significantly changed upon KLHL6 down52

regulation or ablation, further confirming that KLHL6 specifically promotes Roquin2 but
not Roquin1 degradation (Fig. 3.5C and Fig. 3.5D).
Gain of function experiments also confirmed that Roquin2 protein levels were
negatively regulated by expression of KLHL6 using a doxycycline-dependent promoter
in cell lines with low KLHL6 expression (i.e.; HEK293T and HBL1) (Fig. 3.5E).
Moreover, overexpression of KLHL6 (WT), but not BTB-domain KLHL6 mutants, in
OCI-LY8 (a DLBCL cell line with undetectable KLHL6 levels), induced Roquin2 downregulation (Fig. 3.5F), indicating that loss of function cancer-associated mutations of
KLHL6 is incapable of promoting Roquin2 degradation.
To explore whether KLHL6 directly controls Roquin2 ubiquitylation in vitro, we
purified KLHL6-Roquin2 complex from HEK293T cells by immunoprecipitations and
incubated with a ubiquitylation mix. High-molecular species of Roquin2 were detected
only upon incubation with the KLHL6 (WT) complex, but not with the KLHL6 (L65P)
complex, suggesting that Roquin2 is conjugated with polyubiquitin chains in a
CULLIN3-dependent manner (Fig. 3.5G). Furthermore, we investigated whether Roquin2
ubiquitylation is regulated by KLHL6 in vivo. The K48-linked polyubiquitin chains of
Roquin2 were only detected in KLHL+/+ cell lines, but not in KLHL6-/- cell lines (Fig.
3.5H).
Hence, we have shown that Roquin2 is the first identified bona fide substrate of
the CRL3KLHL6 E3 ubiquitin ligase complex.
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BTB-mutations of KLHL6 are not dominant-negative
First, we utilized HEK293T cells stably expressing BTB-mutants of KLHL6. We
infected these cells with lentiviruses encoding a doxycline (DOX) inducible expression of
KLHL6 (WT) and found that the expression KLHL6 (WT) still promoted Roquin2
degradation, suggesting these BTB-domain mutations of KLHL6 are not dominant
negative (Fig. 3.6A).
Next, we utilized B-cell lymphoma cell lines harboring endogenous KLHL6
mutations. VAL cells harbor two endogenous BTB-mutations: N60T and T72R (Fig.
3.6B). We found that only the KLHL6 (T72R) mutant lost interaction with CULLIN3
(Fig. 3.6B) while KLHL6 (N60T) mutant was still able to interact. Interestingly,
knockdown of KLHL6 in VAL cells did not have any effects on Roquin2 protein levels
(Fig. 3.6C), suggesting that KLHL6 is not functional in VAL cells. Additionally,
retroviral expression of KLHL6 (WT) in VAL cells still promoted degradation of
Roquin2 (Fig. 3.6D), suggesting this mutation as non-dominant. In VAL cells, expression
of KLHL6 at the mRNA level was comparatively low (Fig. 3.6E). Overall, this suggests
that VAL cells display one KLHL6 allele inactivated by a mutation in the BTB-domain
and an additional down-regulation of KLHL6 mRNA, a scenario suggestive of a loss of
function.
We have also analyzed the effect of KLHL6 mutations in SUDHL10 cells with
two mutations (L24R and A25E). Both the KLHL6 (L24R) and KLHL6 (A25E) mutants
retained interaction with CULLIN3, suggesting an intact KLHL6 function (Fig. 3.6B).
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Indeed, knockdown of KLHL6 in SUDHL10 cells induced stabilization of Roquin2 (Fig.
3.6C) and over-expression of KLHL6 WT had a minor effect on Roquin2 degradation,
likely because endogenous KLHL6 is already functional (Fig. 3.6D).
Taken together, our biochemical analyses on mutations suggest that the BTBdomain mutations of KLHL6 do not have dominant-negative effects on KLHL6 (WT).

Interaction between KLHL6 and Roquin2 requires a functional tyrosine residue Y691 in
Roquin2
Next, we investigated the KLHL6 binding region in Roquin2 by performing an
unbiased mutagenesis screening. To this end, we generated a set of C-terminal deletion
mutants in Roquin2 and identified that a region between amino acids 640 and 700 is
required for interaction with KLHL6 (Fig. 3.7A). Consistently, deletion of N-terminal
residues up to amino acids 439 did not alter KLHL6-Roquin2 interaction (Fig. 3.7B). We
performed more refined deletions and further narrowed down the interaction motif
between amino acids 690 and 695 (Fig. 3.7C). By carrying out alanine scanning
mutagenesis of the individual residues of Roquin2 from 691 to 704 region, we identified
a specific and conserved tyrosine residue, in position 691. The single alanine mutation at
this specific tyrosine completely abrogated the interaction between Roquin2 and KLHL6
(Fig. 3.7D). In-vitro binding assays confirmed that a Roquin2 peptide containing the
region from 686 to 700 directly interacts with KLHL6 (Fig. 3.7E-H). Further, mutations
of tyrosine 691 into alanine (Y691A) or phenylalanine (Y691F) disrupts the ability of
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Roquin2 to co-immunoprecipitate with KLHL6 both in vitro and in vivo. This suggests
that the intact tyrosine hydroxyl group is required for the KLHL6-Roquin2 interaction
(Fig 3.7G and I).
To determine whether tyrosine 691 controls Roquin2 stability in DLBCL cells, we
retrovirally-transduced a DLBCL cell line, BJAB, with Roquin2 (WT) or Roquin2
(Y691F). Strikingly, Roquin2 (Y691F) displayed increased protein levels at steady state
as well as an extended half-life when compared to that of Roquin2 (WT) (Fig. 3.7J),
suggesting that the integrity of tyrosine 691 controls Roquin2 protein turnover. To further
validate this finding, we expressed KLHL6 (WT) or KLHL6 (L65P) in HEK293T cells
and assessed the effect on Roquin2 protein levels. While Roquin2 (WT) was effectively
down-regulated by the expression of KLHL6 (WT), Roquin2 (Y691F) was not (Fig.
3.7K). Expression of KLHL6 (L65P) had no effects on protein levels of Roquin2 (WT) or
Roquin2 (Y691F) (Fig. 3.7K).
Collectively, these data show that tyrosine 691 in Roquin2 is required for
KLHL6-mediated degradation of Roquin2 in DLBCL.

KLHL6 promotes Roquin2 degradation upon BCR stimulation
KLHL6 was shown to be involved in the B-cell Receptor (BCR) signaling and a
part of BCR signalosome (Satpathy et al., 2015). Also, KLHL6 was induced upon antigen
stimulation in the germinal center (Kroll et al., 2005), so we first investigated whether
mRNA and protein levels of KLHL6 and Roquin2 were affected by BCR stimulation in
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DLBCL cell lines. We first screened DLBCL cell lines for IgM or IgG surface expression
(Fig. 3.8A). Consistent with previous findings, ABC-DLBCL cells predominantly
express an IgM-BCR as opposed to GCB-DLBCL cells, which are positive for IgG-BCR
(Lenz et al., 2007). Amongst the DLBCL cell lines screened, we analyzed levels of
KLHL6 and Roquin2 in IgM-positive ABC- DLBCL cell lines (U2932, OCI-LY10 and
HBL1) (Fig 3.8B). BCR activation using the fragment affinity-purified antibody F(ab’)2IgM induced up-regulation of KLHL6 and down-regulation of Roquin2 protein levels in
OCI-LY10 and U2932, but not in HBL1, lacking KLHL6 mRNA and protein (Fig.3.8B).
Thus, Roquin2 down-regulation upon BCR stimulation correlated with KLHL6
expression in DLBCLs.
To further prove that BCR-dependent down-regulation of Roquin2 protein in
ABC-DLBCLs is controlled by CRLs, we pre-treated U2932 cells with MLN4924, a
NEDD8-activating enzyme (NAE) inhibitor blocking neddylation of CULLINs
(Milhollen et al., 2010). MLN4924 treatment rescued Roquin2 down-regulation induced
by BCR-crosslinking, suggesting that a functional CRL-complex is necessary to promote
degradation of Roquin2 (Fig. 3.8C). As a positive control, phosphorylation of ERK is
shown to assess the efficacy of BCR-crosslinking. Notably, BCR stimulation induced
KLHL6 up-regulation at transcriptional levels (Fig. 3.8D), revealing KLHL6 as a BCRsignaling dependent gene. Consistently, BCR-crosslinking in both U2932 and OCI-LY10
induced KLHL6 expression in a time and dose-dependent manner, which inversely
correlated with Roquin2 protein levels (Fig. 3.8E and 3.8F). Furthermore, silencing the
expression of KLHL6 via siRNA ablated F(ab’)2-IgM-induced Roquin2 degradation
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(Fig. 3.8E and 3.8F), indicating that BCR-signaling promotes Roquin2 degradation in a
KLHL6-dependent manner. BCR-induced Roquin2 degradation was also impaired in
KLHL6-/- cells (Fig. 3.8G)
Consistent with degradation of endogenous Roquin2, we found that exogenous
Roquin2 (WT) was also degraded in a dose-dependent manner upon BCR stimulation
(Fig 3.8H). In contrast, levels of Roquin2 (Y691F) mutant were higher already at steady
state and unaffected by BCR stimulation, confirming that BCR-signaling induces
KLHL6-mediated degradation of Roquin2.

Discussion
Our work uncovers, for the first time, uncovers a functional link between KLHL6
and Roquin2 protein as an E3 ligase-substrate pair. KLHL6 is a BTB-Kelch domain
protein mutated in human DLBCLs. BTB domain-containing zinc finger proteins and
Kelch domain are evolutionarily conserved from Drosophila melanogaster to Homo
sapiens (Adams et al., 2000; Siggs and Beutler, 2012). The common function of the
BTB/Kelch domain is to facilitate protein binding and associated proteins control various
biological processes such as transcription repression, protein degradation, and
organization and binding of actin filaments, and cellular morphology (Albagli et al.,
1995; Kang et al., 2004; Melnick et al., 2000; Perez-Torrado et al., 2006). Somatic
mutations localize to the BTB-domain with relevant hotspots at amino acid residue 65
and 90 (Idoia et al., 2016; Lohr et al., 2012; Morin et al., 2011; Reddy et al., 2017). Most
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KLHL6 genetic alterations in DLBCL contain monoallelic missense mutations and
infrequent copy loss (Idoia et al., 2016; Lohr et al., 2012; Morin et al., 2011; Reddy et al.,
2017). It is likely that most of cancer-associated mutations KLHL6 are the consequence
of aberrant hypersomatic mutation (Puente et al., 2011), similarly to those of BCL6 and
MYC (Pasqualucci et al., 2001). More importantly, we have shown that the hotspot
mutations and other deleterious BTB-domain mutations cause a dissociation of CULLIN3
and loss of E3 ligase activity. Although cancer-associated mutations in the Kelchdomain, which can serve as a substrate-binding domain, are observed in DLBCLs,
mutation such as T440A is not able to disrupt binding of Roquin2 with KLHL6
completely (Fig 3.4E). This observation suggests that somatic mutations in the BTBdomain are more potent than the ones in the Kelch-domain in terms of disrupting the
ligase activity and leading to substrate accumulation. This might be the reason that
KLHL6 alterations in DLBCLs happen more frequently in the BTB-domain.
Furthermore, we identified Roquin2 as the bona fide substrate of KLHL6.
KLHL6 interacts specifically with Roquin2, ubiquitylates and triggers its degradation
upon BCR stimulation. It is noticeable that Roquin1, which is a Roquin2 paralog and has
highly similar amino acid sequence across RING, ROQ, and CCCH (C3H) domains
(Pratama et al., 2013), is not a target of KLHL6. Indeed, the binding domain of KLHL6
in Roquin2 is in the proline rich region, which has only about ~40% sequence similarity
with Roquin1. Therefore, it is conceivable that this sequence difference only allows
KLHL6 to recognize Roquin2 via tyrosine 691 residue. The Roquin-1 and Roquin-2
proteins in T-cell activation and Tfh differentiation have been reported to be functionally
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redundant as both can regulate and act together to degrade key mRNAs and control
inflammation and autoimmunity such as ICOS and Ox40 costimulatory receptors and
TNF (Vogel et al., 2013). These redundant functions serve as a critical safety mechanism
for preventing cancer development and autoimmune diseases. However, systemic
Roquin1 knockout mice are born with a caudal spine defect and impaired lung
development, resulting in a poor perinatal survival (Bertossi et al., 2011), implying a role
of Roquin1 in embryonic development that extends beyond the immune system.
Moreover, systemic Roquin2 deficient mice are born at a Mendelian ratio, but very few
individual mice reach adulthood. Notably, a large proportion of Roquin2 deficient mice
died within the first few days after birth (Vogel et al., 2013). This suggests that Roquin1
and Roquin2 redundancy varies in a cell-context dependent manner. Therefore, it is
possible that, in B-cell biology where Roquin2 is specifically degraded by KLHL6,
Roquin1 and Roquin2 might have a functional difference, adding new aspects of the
regulation of Roquin proteins.
Notably, cancer-associated mutations of KLHL6 in the BTB-domain are not
dominant negative as KLHL6 (WT) is still able to degrade Roquin2 in the presence of
these BTB-domain mutants. Moreover, N-terminal mutations outside of the BTB-domain
do not disrupt the function of KLHL6, suggesting that it is mainly BTB-domain
mutations that lead to loss of function. We have not investigated whether these BTBdomain mutations affect the dimerization of KLHL6 and whether KLHL6 is functional in
the dimer form. Indeed, SPOP, a MATH-BTB protein, generates a dimeric ubiquitin
ligase to recognize a single substrate, and a dimerization defective SPOP mutant is not
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able to promote ubiquitination of the substrate (Zhuang et al., 2009). Dimerization and
conformational variability is an important factor to facilitate elongation of ubiquitin chain
on the substrate and to provide a variety of orientation flexibility as previously shown by
the SCF ligase, Cdc4 (Tang et al., 2007). The dimerization of Cdc4 affects the
positioning of the substrate for the formation of the ligase complex rather than the affinity
with its substrate. It is possible that KLHL6 works as a homodimer and mutations in the
BTB-domain disrupt interaction between the wild-type KLHL6s in addition to disrupting
the CULLIN3 association. Furthermore, we have not characterized the function of the
BACK domain as no somatic mutations for this domain are found in KLHL6. It has been
shown that single mutation in the BACK domain results in decreased efficiency of
CULLIN3-KLHL7 ligase complex in autoimmune diseases (Kigoshi et al., 2011). How
KLHL6 protein exists in cells in terms of its complex formation and whether the cancerassociated mutations have any impacts on dimerization or other regulation part of
KLHL6 remain to be elucidated.
KLHL6 has been shown to be a novel component of BCR signalosomes (Satpathy
et al., 2015). Our study demonstrates that KLHL6 transcription is up-regulated upon BCR
stimulation leading to corresponding degradation of Roquin2 protein. Furthermore, the
protein levels of non-degradable Roquin2 mutant are insensitive to BCR stimulation.
Although we have not investigated whether this regulation exists similarly in primary Bcells, we have, for the first time, identified the physiological condition where Roquin2
protein abundance is controlled by proteasomal degradation in B-cell cancers. The
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mechanism of how KLHL6 expression is up-regulated by BCR signaling will be explored
further in chapter 4.
Taken together, our findings indicate that KLHL6 is an E3 ligase for Roquin2.
Cancer-associated mutations of KLHL6 inhibit its ubiquitin ligase activity, leading to
CULLIN3 dissociation. The integrity of the tyrosine 691 in Roquin2 is critical for the
KLHL6-Roquin2 interaction, and B-cell receptor activation induces degradation of
Roquin2. How the KLHL6-Roquin2 axis functions in DLBCL biology and how alteration
of this pathway affects cancel cell proliferation and survival will be discussed in chapter
4.

62

A

B

Missense
Nonsense
Frameshift

MM (Broad)
CLL (IUOPA)

GCB-DLBCL

DLBCL (Broad)

ABC-DLBCL

DLBCL (CMSGSC)

0

5
10
15
% of KLHL6 Mutations

15

% of KLHL6 Mutations

20

missense
nonsense
in frame deletion

C

0

10

0

DLBCL (UNMC)

5

Uncharacterized

DLBCL (TCGA)

BTB

BACK

1

2

3

4

5

6 621

Kelch Domain
D

E
1 SD below mean (15 / 249 tumors)

Copy Loss
COO
1555275_a_at
1560396_at
1560397_s_at
228167_at

Cell of Origin (COO) Subtype
ABC-like
Unclassified GCB-like

Copy Loss
CN < 1.8

Expression
Row Min.

Row Max.

Figure 3.1 Analyses of KLHL6 cancer mutations in B-cell malignancies
(A) KLHL6 mutations occur most frequently in DLBCL. The graph shows the percentage
of KLHL6 mutations found in different B-cell cancer patients. Diffuse Large B-cell
Lymphoma DLBCL [University of Nebraska Medical Center (UNMC), n=140, The
Cancer Genome Atlas (TCGA), n=48, Canada’s Michael Smith Genome Sciences Centre
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(CMSGSC), n=96, and Broad Institute (Broad), n=58], Chronic Lymphocytic Leukemia
(CLL) [Departamento de Bioquímica y Biología Molecular, Instituto Universitario de
Oncología (IUOPA), n=586] and Multiple Myeloma (MM) [Broad Institute (Broad),
n=205]. In blue, missense mutations; in red, nonsense mutations; in green, frameshift
mutations. (B) KLHL6 mutations occur in a similar rate among different DLBCL subtypes. UNMC and CMSGSC cohorts were pooled and sub-classified as Activated B-celllike (ABC), Germinal Center B-cell-like (GC) and Unclassified DLBCL. (C) Schematic
representation of KLHL6 protein (BTB, Broad-Complex, Tramtrack and Bric-a-brac;
BACK, BTB and C-terminal Kelch plant homeodomain; Kelch domain, Kelch motif). In
blue, missense mutations; in red, nonsense mutations; in green, frameshift mutations. (D)
DNA copy number (chromosome 3) data were used from previously published highresolution single nucleotide polymorphism (SNP) microarray analysis of 609 primary
DLBCL tumors (Green et al., 2014). The position of KLHL6 is annotated for 21 DLBCL
tumors with copy number <1.8. About 3.4% of patients show KLHL6 loss. (E) A rownormalized heat map is shown for probe sets of KLHL6. 249 tumors with matched DNA
copy number data from a previously published study (Green et al., 2014) were analyzed
for gene expression microarray and annotated for the cell of origin subtype and DNA
copy loss of KLHL6 as shown in (D). 6% of DLBCL patient cases have a lower
expression of KLHL6 transcripts defined as expression ≤1 standard deviation below the
mean.
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Figure 3.2 KLHL6 assembles a CULLIN3-based E3 ligase
(A) CULLIN3 interacts with KLHL6 (WT) and not with KLHL6 BTB-mutant (L65P).
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counts numbers for CULLIN3 protein are shown. EV, empty vector control. (B) KLHL6
is a CULLIN3-Ring-Ligase (CRL3). HEK293T cells were transfected with FLAG-tagged
E3 ligases. Proteins were immunoprecipitated (IP) from cell extracts with an anti-FLAG
resin, and immunocomplexes were probed with antibodies to the indicated proteins.
Bottom panels show whole cell lysates (WCL). EV, empty vector control. (C) KLHL6
promotes self-ubiquitylation. FLAG-KLHL6 (WT) or FLAG-KLHL6 (ΔKelch) was
immunopurified (IP) from transfected HEK293T cells. The IP was incubated with E1,
Ubch5c (E2), Ubiquitin and ATP as indicated. After 30 minutes, reactions were
denatured with SDS-lysis buffer and further immunopurified using an anti-FLAG resin
and stopped by addition of Laemmli buffer. IPs were subjected to immunoblotting for the
indicated proteins.
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Figure 3.3 BTB-domain mutations of KLHL6 abolishes its ligase activity
(A) Cancer-associated mutations in the BTB-domain inhibit interaction with CULLIN3.
HEK293T cells were transfected with FLAG-tagged KLHL6 wild-type (WT), BTBmutants (L65P, S94I and F97L), or empty vector control (EV). Proteins were
immunoprecipitated

(IP)

from

cell

extracts

with

an

anti-FLAG

resin,

and

immunocomplexes were probed with antibodies to the indicated proteins. Bottom panels
show whole cell lysates (WCL). (B) Mutations in the BTB-domain impair KLHL6 selfubiquitylation. FLAG-KLHL6 (WT and BTB-mutants) was immunopurified (IP) from
transfected HEK293T. The IP was incubated with E1, Ubch5c (E2), Ubiquitin and ATP
as indicated. After 30 minutes, reactions were denatured with SDS-lysis buffer and
further immunopurified using an anti-FLAG resin and stopped by addition of Laemmli
buffer. IPs were subjected to immunoblotting for the indicated proteins. (C) Mutations in
the BTB-domain extend KLHL6 half-life. A DLBCL cell line, OCI-LY10, was
engineered by CRISPR to generate a OCI-LY10 KLHL6-/- cell line. Cells were
retrovirally transduced with cDNAs encoding an empty vector (EV), KLHL6 (WT) or
BTB-mutants (L65P, S94I and F97L). Cells were treated with cycloheximide (CHX) for
the indicated times, and whole cell lysates were analyzed by immunoblotting for the
indicated proteins. Bottom panel shows quantification of KLHL6 protein levels using
ImageJ and their relative intensities were plotted over time. (D) Schematic model of
CULLIN3-Ring-Ligase (CRL3)-KLHL6. KLHL6 assembles a functional CRL via
interaction with CULLIN3 and promotes ubiquitylation of itself and a substrate. Cancerassociated mutations in the BTB-domain displace CULLIN3 interaction.
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Figure 3.4 KLHL6 specifically interacts with Roquin2.
(A) Roquin2, but not Roquin1, is highly enriched in catalytic inactive KLHL6 (L65P)
mutant complex. The graphs show mass spectrometry analysis of KLHL6
immunoprecipitations in two different cell lines (HEK293T and ARP-1). Unique spectral
counts for Roquin2 proteins are shown. EV, empty vector control. (B) Roquin2 interacts
with KLHL6 specifically. HEK293T cells were transfected with cDNAs encoding the
indicated FLAG-tagged F-box proteins (FBPs) or BTB proteins (BTBPs). Exogenous
proteins were immunoprecipitated (IP) from cell extracts with an anti-FLAG resin, and
immunocomplexes were probed with antibodies to the indicated endogenous proteins.
Lane 1 shows a whole cell lysates (WCL) from cells transfected with an empty vector
(EV). (C) Roquin2, but not Roquin1, interacts with KLHL6. HEK293T cells stably
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expressing KLHL6 were transfected with cDNAs encoding the FLAG-Roquin1 or
FLAG-Roquin2. Exogenous proteins were immunoprecipitated (IP) from cell extracts
with an anti-FLAG resin, and immunocomplexes were probed with antibodies to the
indicated proteins. Bottom panels show whole cell lysates (WCL). (D) Endogenous
Roquin2 and KLHL6 complex is detectable in DLBCL cells. Endogenous KLHL6 was
immunoprecipitated from U2932 cells and immunocomplexes were probed with
antibodies to the indicated proteins. IgG antibody immunoprecipitates=negative control.
A representative blot from two independent experiments is shown. * indicates nonspecific band. (E) KLHL6 binds Roquin2 through the Kelch domain. HEK293T cells
were transfected with constructs encoding FLAG-tagged KLHL6 (WT) or mutants as
indicated and empty vector (EV). KLHL6 was immunoprecipitated (IP) from cell extracts
with an anti-FLAG resin, and immunocomplexes were probed with antibodies to the
indicated proteins.
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FLAG

Figure 3.5 KLHL6 promotes ubiquitylation and degradation of Roquin2.
(A) Protein levels of Roquin2 and KLHL6 are inversely correlated in human DLBCL
cells. Indicated human DLBCL cell lysates were analyzed by immunoblotting for the
indicated proteins. (B) Quantification of Roquin2 (x-axis) and KLHL6 (y-axis) protein
levels in each DLBCL cell line. n=11 DLBCL cell lines. r, Pearson correlation coefficient
(95% confidence interval). (C) Knockdown of KLHL6 extends Roquin2 half-life in OCILY10 cells. OCI-LY10 cells were electroporated with siRNA scramble (siCTRL) or
targeting KLHL6 (siKLHL6). Cells were treated with cycloheximide (CHX) for the
indicated times. Whole cell lysates were analyzed by immunoblotting for the indicated
proteins (top panel). Bottom panel shows quantification of Roquin1 and Roquin2 protein
levels using ImageJ and their relative intensities were plotted over time. (D) Loss of
KLHL6 extends Roquin2 half-life in U2932 cells. U2932 KLHL6+/+ and KLHL6-/- cells
were treated with cycloheximide (CHX) for the indicated times. Whole cell lysates were
analyzed by immunoblotting for the indicated proteins (top panel). Bottom panel shows
quantification of Roquin1 and Roquin2 protein levels using ImageJ and their relative
intensities were plotted over time. (E) Roquin2 protein levels were negatively regulated
by expression of KLHL6. HEK293T (TET)-OFF cells were transduced with retroviruses
encoding a doxycycline (DOX) inducible expression of FLAG-tagged KLHL6 carrying a
hygromycin cassette (left panel). DOX was added and/or washed at the indicated times.
Whole cell lysates were analyzed by immunoblotting for the indicated proteins (left
panel). HBL1 cells were transduced with lentiviruses encoding a doxycycline (DOX)
inducible expression of KLHL6 wild-type (WT) carrying a puromycin cassette. The cells
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were treated with DOX for 12 hours. Whole cell lysates were analyzed by
immunoblotting for the indicated proteins (right panel). (F) Cancer-associated mutations
of KLHL6 are incapable of promoting Roquin2 degradation. OCI-LY8 cells were
transduced with retroviruses encoding empty vector (EV), KLHL6 wild type (WT) or
BTB-mutants (L65P, S94I and F97L). Whole cell extracts were subjected to
immunoblotting for the indicated proteins. (G) Roquin2 is ubiquitylated in vitro in a
KLHL6 and CULLIN3-dependent manner. FLAG-KLHL6 and Roquin2 were
immunopurified from HEK293T cells and incubated at 30°C with a ubiquitylation mix
containing E1, UbcH5c, ubiquitin, and ATP. Reactions were stopped by addition of
Laemmli buffer at the indicated times, and analyzed by immunoblotting for the indicated
proteins. (H) Roquin2 ubiquitylation is regulated by KLHL6 in vivo. Endogenous
Roquin2 was immunoprecipitated from U2932 KLHL6+/+ or KLHL6-/- (clone-derived) cell
extracts pre-treated with or without MG132 for 6 hours, and immunocomplexes were
probed with antibodies to the indicated proteins. A representative blot from two
independent experiments is shown.
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Figure 3.6 BTB-mutations of KLHL6 are not dominant-negative
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0

(A) Expression KLHL6 (WT) promotes Roquin2 degradation even in the presence of
BTB-mutations of KLHL6. HEK293T cells were transduced with lentiviruses encoding a
doxycline (DOX) inducible expression of KLHL6 carrying a puromycin cassette and then
infected with lentiviruses encoding empty vector (EV) or KLHL6 BTB-mutants (L65P
and S94I) carrying a GFP marker. The cells were treated with DOX for 12 hours, and
whole cell extracts were subjected to immunoblotting for the indicated proteins. (B)
BTB-mutations of KLHL6 are not dominant-negative. Top panel shows the schematic
representation of KLHL6 protein displaying endogenous mutations in two different cell
lines (VAL and SUDHL10). HEK293T cells were transfected with constructs encoding
FLAG-tagged KLHL6 wild-type (WT), KLHL6 mutants (L24R, A25E, N60T, and
T72R), or empty vector (EV). Exogenous proteins were immunoprecipitated (IP) from
cell extracts with an anti-FLAG resin, and immunocomplexes were probed with
antibodies to the indicated proteins. (C) KLHL6 is not functional in VAL cells. VAL and
SUDHL10 cells were electroporated with siRNA scramble (siCTRL) or targeting KLHL6
(siKLHL6) and whole cell extracts were subjected to immunoblotting for the indicated
proteins. (D) KLHL6 is not functional in VAL cells. VAL and SUDHL10 cells stably
expressing KLHL6 under a doxycycline (DOX) inducible promoter with a puryomycin
cassette were treated with DOX for 12hrs and whole cell extracts were subjected to
immunoblotting for the indicated proteins. (E) KLHL6 mRNA levels were comparably
low in VAL cells. Analysis of KLHL6 expression by quantitative PCR (qPCR) in
different cell lines is shown, and the value for the PCR product from U2932 cells was set
as 1. A representative graph from two independent experiments is shown.
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Figure 3.7 Interaction between KLHL6 and Roquin2 requires a functional tyrosine
residue Y691 in Roquin2
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(A) Mapping strategy for KLHL6 binding motif in Roquin2. HEK293T cells stably
expressing KLHL6 were transfected with constructs encoding an empty vector (EV),
FLAG-tagged Roquin2 wild type (WT) or mutants as indicated. Left panel shows a
schematic representation of Roquin2 mutants. Roquin2 mutants that interact (+) or do not
interact (-) with KLHL6 are shown. Right panel shows immunoblot analysis of FLAGRoquin2 immunoprecipitation (IP). Immunocomplexes were probed with antibodies to
the indicated proteins. Asterisk indicates non-specific bands. (B) Same as in (A). (C)
Same as in (A). (D) Roquin2 binds KLHL6 through tyrosine 691. Left panel shows
conservation of tyrosine 691 in lower species. HEK293T cells stably expressing KLHL6
were transfected with constructs encoding an empty vector (EV), FLAG-tagged Roquin2
wild type (WT) and mutants as indicated. Roquin2 was immunoprecipitated (IP) from
cell extracts with an anti-FLAG resin, and immunocomplexes were probed with
antibodies to the indicated proteins (right panel). (E) Schematic representation of the
biotinylated Roquin2 peptide sequences. (F) KLHL6 directly interacts with Roquin2 in in
vitro pull-down assay. The indicated amount of biotinylated Roquin2 peptides were
incubated with whole cell extracts from HEK293T cells stably expressing KLHL6.
Affinity Purification, AP. (G) and (H) KLHL6 directly interacts with Roquin2 in in vitro
pull-down assay. Same as in (F) except that FLAG-tagged in-vitro translated proteins
were utilized instead of whole cell extracts as indicated. Immunocomplexes were probed
with anti-FLAG antibody to the indicated proteins as all in-vitro translated proteins were
FLAG-tagged. (I) Mutation of tyrosine 691 into alanine or phenylalanine inhibits
interaction with KLHL6. HEK293T cells stably expressing KLHL6 were transfected with
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constructs encoding an empty vector (EV), FLAG-tagged Roquin2 wild type (WT) or
mutants as indicated. Roquin2 was immunoprecipitated (IP) from cell extracts with an
anti-FLAG resin, and immunocomplexes were probed with antibodies to the indicated
proteins. (J) A mutant of Roquin2 incapable of interacting with KLHL6 displays a
prolonged half-life in DLBCL cells. A DLBCL cell line, BJAB, was retrovirally
transduced with cDNAs encoding Roquin2 (WT) or Roquin2 (Y691F). Cells were treated
with cycloheximide (CHX) for the indicated times, and whole cell lysates were analyzed
by immunoblotting for the indicated proteins (top panel). Roquin2 protein levels were
quantified using Image J and their relative intensities were plotted over time (bottom
panel). (K) KLHL6 (WT) induces degradation of Roquin2 (WT), but not Roquin2
(Y691F), while KLHL6 (L65P) has no effect. HEK2932T cells stably expressing KLHL6
(WT) or KLHL6 (L65P) were further infected with retroviruses encoding an empty
vector (EV), Roquin2 (WT) or Roquin2 (Y691F). Whole cell lysates were analyzed by
immunoblotting for the indicated proteins. A low exposure (l.e) and high exposure (h.e)
are shown for HA-tagged Roquin2.
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Figure 3.8 KLHL6 promotes Roquin2 degradation upon BCR stimulation
(A) ABC-DLBCLs and GCB-DLBCLs express IgM and IgG on their cell surfaces,
respectively. A panel of human DLBCLs were stained either with anti-IgM or anti-IgG
antibody to detect surface expression. A darker curve indicates a positive signal. A
representative image from two independent experiments is shown. (B) B-cell receptor
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activation induces Roquin2 down-regulation in DLBCL cells. KLHL6-expressing ABCDLBCL cell lines, OCI-LY10 and U2932, and a non-expressing cell line, HBL1, were
stimulated with 10 µg/ml of F(ab’)2-IgM for 3 and 6 hours. Whole cell lysates were
analyzed by immunoblotting for the indicated proteins. A low exposure (l.e.) and high
exposure (h.e.) are shown for Roquin2 (Left Panel). Right panel shows levels of KLHL6
mRNA analyzed by qPCR. The value for the PCR product from U2932 was set as 1. A
representative graph from two independent experiments is shown. (C) Degradation of
Roquin2 is blocked upon chemical inhibition of CULLIN neddylation. U2932 cells were
treated with 10 µg/ml of F(ab’)2-IgM for the indicated times. Where indicated, cells were
pre-treated with 5µM MLN4932 for 1 hour. Whole cell lysates were analyzed by
immunoblotting for the indicated proteins. (D) BCR stimulation up-regulates KLHL6
transcriptionally. U2932 cells were treated with 10 µg/ml of F(ab’)2-IgM for the
indicated times. Levels of KLHL6 mRNA were analyzed by real time PCR. The value for
PCR product present without treatment was set as 1. A representative graph from two
independent experiments is shown. (E) Roquin2 is degraded in a dose-dependent BCR
signaling- and KLHL6-dependent manner. U2932 cells were electroporated with a
siRNA scramble (siCTRL) or targeting KLHL6 (siKLHL6) and treated with increasing
concentrations of F(ab’)2-IgM for 6 hours. Whole cell lysates were analyzed by
immunoblotting for the indicated proteins. (F) Degradation kinetics of Roquin2 are
dependent on BCR signaling and KLHL6 expression. OCI-LY10 cells were treated with
10µg/ml F(ab’)2-IgM for the indicated times. Where indicated, cells were electroporated
with a siRNA scramble (siCTRL) or targeting KLHL6 (siKLHL6). Whole cell lysates
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were analyzed by immunoblotting for the indicated proteins. (G) Roquin2 is degraded in
a KLHL6-depenent manner. U2932 KLHL6+/+ and KLHL6-/- (clone-derived) cells were
treated with increasing concentrations of F(ab’)2-IgM for 6 hours. Whole cell lysates
were analyzed by immunoblotting for the indicated proteins. (H) Roquin2 (Y691F)
mutant is insensitive to BCR-induced degradation. U2932 cells were stably transduced
with retroviruses encoding HA-Roquin2 (WT) or HA-Roquin2 (Y691F). Cells were
treated with increasing concentrations of F(ab’)2-IgM for 6 hours, and whole cell lysates
were analyzed by immunoblotting for the indicated proteins.
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University of Nebraska Medical Center(UNMC)
Type
Chromosome
Sample ID
DLBCL
3 DLBCL-36539
DLBCL
3 DLBCL-43092
DLBCL
3 S02-2857
DLBCL
3 S02-312
DLBCL
3 S08-4728
DLBCL
3 S08-4728
DLBCL
3 S08-4728
DLBCL
3 SC06-1631
DLBCL
3 SC06-1631
DLBCL
3 SC06-1631
DLBCL
3 SC06-3802
DLBCL
3 SC07-2866
DLBCL
3 SC08-2147
DLBCL
3 SP01-10756

Variant Classification
missense
missense
missense
missense
missense
missense
missense
missense
missense
stop-gained
missense
missense
missense
missense

Amino Acid Change
C85W
M67I
A135V
V78E
N69D
D73H
I80M
M3R
E17A
L42*
D29N
G475E
L90F
E568K

Canada's Michael Smith Genome Sciences Centre(CMSGSC)
Type
Chromosome
Sample ID
Variant Classification Amino Acid Change
DLBCL(GCB)
3
98-22532/DLBCLmissense
S83T, S94T
DLBCL(GCB)
3
95-32814
not-classified
2
DLBCL(GCB)
3
05-24561
not-classified
1
DLBCL(GCB)
3
96-20883
missense
L54V, L65V
DLBCL(ABC)
3
02-22991
missense, stop
L45*, L56*, T53I, T64I
DLBCL(ABC)
3
07-37968
not-classified
1
DLBCL(GCB_Line)
3
OCI-Ly1
not-classified
1
DLBCL(GCB)
3
05-24904
not-classified
1
DLBCL(ABC)
3
06-16716
missense
T53S, T64S
DLBCL(U)
3
82-57570
not-classified
1
DLBCL(U)
3
04-20644
not-classified
1
For CMSGSC data, the total numbers of cSNV detected are reported (the exact change of cSNV is not reported)

Broad Institute(Broad)
Type
Chromosome
DLBCL
DLBCL
DLBCL
DLBCL
DLBCL

3
3
3
3
3

The Cancer Genome Atlas(TCGA)
Type
Chromosome
DLBCL
DLBCL
DLBCL
DLBCL
DLBCL
DLBCL
DLBCL

3
3
3
3
3
3
3

Sample ID
4
5
47
49
49

Sample ID
TCGA-GR-A4D6-01
TCGA-FM-8000-01
TCGA-FF-8047-01
TCGA-G8-6914-01
TCGA-GR-A4D9-01
TCGA-FF-A7CW-01
TCGA-FF-8062-01

86

Variant Classification
missense
missense
missense
missense
missense

Amino Acid Change
R566W
C578S
C508R
F83L
D14N

Variant Classification
missense
missense
missense
missense
missense
missense
missense

Amino Acid Change
T387A
L90P
A91V
L65P
E547K
L90F
E547Q

Duke Cancer Institute
Type
Chromosome
DLBCL
3
DLBCL
3
DLBCL
3
DLBCL
3
DLBCL
3
DLBCL
3
DLBCL
3
DLBCL
3
DLBCL
3
DLBCL
3
DLBCL
3
DLBCL
3
DLBCL
3

Sample ID
Variant Classification
Amino Acid Change
3620*
frameshift substitution
exon1:c.268_280CA
3582*
nonframeshift substitution exon1:c.60_75A
2613
nonsynonymous SNV
exon1:c.A126C:p.L42F
3593
nonsynonymous SNV
exon1:c.A152G:p.D51G
3593*
nonsynonymous SNV
exon1:c.A168C:p.L56F
3401
nonsynonymous SNV
exon1:c.A179T:p.N60I
2217, 3439
nonsynonymous SNV
exon1:c.A236T:p.D79V
2290, 3703
nonsynonymous SNV
exon1:c.A246T:p.E82D
705*
nonsynonymous SNV
exon1:c.A287C:p.Y96S
3506*
stopgain
exon1:c.C175T:p.Q59X
3625
nonsynonymous SNV
exon1:c.C209G:p.A70G
2158, 2213
nonsynonymous SNV
exon1:c.C211G:p.L71V
2809*
stopgain
exon1:c.C241T:p.Q81X
2243, 2559, 2901,
DLBCL
3 2945, 3634*
nonsynonymous SNV
exon1:c.C268T:p.L90F
DLBCL
3 2649*
nonsynonymous SNV
exon1:c.G217A:p.D73N
DLBCL
3 2901
nonsynonymous SNV
exon1:c.G232C:p.V78L
DLBCL
3 3681*
nonsynonymous SNV
exon1:c.G254A:p.C85Y
DLBCL
3 2827, 3627*
nonsynonymous SNV
exon1:c.G281A:p.S94N
DLBCL
3 2073*
nonsynonymous SNV
exon1:c.T161C:p.L54P
705, 2158, 2302,
2522, 2544, 2613,
DLBCL
3 3548, 3601, 3614, 3819*
nonsynonymous SNV
exon1:c.T194C:p.L65P
DLBCL
3 2048*
nonsynonymous SNV
exon1:c.T200A:p.M67K
DLBCL
3 3739*
nonsynonymous SNV
exon1:c.T247A:p.F83I
DLBCL
3 2556, 3739*
nonsynonymous SNV
exon1:c.T286G:p.Y96D
DLBCL
3 2613*
stopgain
exon1:c.T288A:p.Y96X
DLBCL
3 2654*
nonsynonymous SNV
exon2:c.A320G:p.E107G
DLBCL
3 2286
nonsynonymous SNV
exon3:c.C743T:p.S248L
DLBCL
3 2952, 3542
nonsynonymous SNV
exon4:c.G1040A:p.R347H
DLBCL
3 3609
nonsynonymous SNV
exon4:c.G1105A:p.E369K
DLBCL
3 3741
nonsynonymous SNV
exon5:c.A1184G:p.N395S
DLBCL
3 2826, 2840
nonsynonymous SNV
exon5:c.C1231T:p.R411C
DLBCL
3 2676, 3468, 3495
nonsynonymous SNV
exon5:c.G1324A:p.D442N
DLBCL
3 2543
nonsynonymous SNV
exon5:c.T1313A:p.V438E
DLBCL
3 3903
nonsynonymous SNV
exon6:c.G1427A:p.G476E
DLBCL
3 3718, 3832
nonsynonymous SNV
exon7:c.A1640G:p.E547G
DLBCL
3 3944
nonsynonymous SNV
exon7:c.C1675T:p.R559W
DLBCL
3 2455
nonsynonymous SNV
exon7:c.C1724T:p.T575M
DLBCL
3 3883
nonsynonymous SNV
exon7:c.G1639A:p.E547K
705, 2083, 2120,
2153, 2269, 2709,
2785, 2912, 2944,
DLBCL
3 3401, 3484
nonsynonymous SNV
exon7:c.G1702A:p.E568K
DLBCL
3 2867, 3595
nonsynonymous SNV
exon7:c.G1781A:p.R594Q
DLBCL
3 3542, 3585, 3627
nonsynonymous SNV
exon7:c.G1804A:p.V602I
DLBCL
3 2654
nonsynonymous SNV
exon7:c.T1685C:p.I562T
DLBCL
3 2827
nonsynonymous SNV
exon7:c.T1735G:p.W579G
DLBCL
3 2816
nonsynonymous SNV
:exon7:c.T1819G:p.S607A
* BTB mutations experimentally verified to abolish CULLIN3 interaction.
These mutations where utilized to calculate statistical association with TNFAIP3 mutations
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Instituto Universitario de Oncologia(IUOPA)
Type
Chromosome Sample ID
CLL
3
CLL
3
CLL
3
CLL
3
CLL
3
CLL
3
CLL
3
CLL
3
CLL
3
CLL
3
CLL
3
CLL
3
CLL
3
CLL
3
CLL
3
CLL
3
CLL
3
CLL
3
CLL
3
CLL
3

Broad Institute(Broad)
Type
Chromosome
MM
3
MM
3
MM
3
MM
3
MM
3
MM
3
MM
3
MM
3
MM
3
MM
3
MM
3

3
3
287
287
338
338
338
381
535
535
594
669
770
884
1237
1353
1462
1465
1465
1471

Sample ID
MM-0308-Tumor
MM-0335-Tumor
MM-0338-Tumor
MM-0389-Tumor
MM-0389-Tumor
MM-0408-Tumor
MM-0447-Tumor
MM-0456-Tumor
MM-0456-Tumor
MM-0633-Tumor
MM-0510-Tumor

Variant Classification
missense
missense
missense
missense(synonymous)
missense
missense
missense
missense
missense
missense
missense
missense
missense
missense
missense
missense
stop
missense
missense
missense

Amino Acid Change
L65P
F49L
V47G
D14D
T6S4
F49I
L38S
L65P
I75F
M67V
L90F
L6P5
S94I
L65P
L90R
L90V
Q81*
Y96F
Q81K
A93G

Variant Classification
missense
Intron
Intron
Intron
Intron
Intron
Intron
Intron
Intron
3'UTR
In frame deletion

Amino Acid Change
F97L
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
V89

Table 3.1 KLHL6 mutations in DLBCLs
List of KLHL6 mutations in B-cell cancer patients [University of Nebraska Medical
Center (UNMC), The Cancer Genome Atlas (TCGA), Canada’s Michael Smith Genome
Sciences Centre (CMSGSC), Broad Institute (Broad), Duke Cancer Institute (DCI) and
Instituto Universitario de Oncología (IUOPA)].
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Data set

Cell Type

Condition

# Replicates

Mass
Spectrometry

HEK293T cells

1

Mass
Spectrometry

ARP-1 cells

Empty Vector,
KLHL6 (WT),
KLHL6 (L65P)
Empty Vector,
KLHL6 (WT),
KLHL6 (L65P)

Accession
Code
PXD008963

1

PXD008963

Table 3.2 Proteomic analyses of KLHL6 complexes generated in this dissertation
List of KLHL6 interacting proteins identified by proteomic analyses of KLHL6
complexes purified from ARP-1 and HEK293T cells.

89

CHAPTER 4 : THE BIOLOGICAL FUNCTION OF KLHL6-ROQUIN2 AXIS IN
ABC-DLBCLS

Chapter summary
Research described in this chapter was performed in collaboration with the
laboratories of Dr. Roberto Bonasio and Dr. Michael Green. RNA-seq sample
preparations and analyses were carried out in collaboration with Kristin Ingvarsdottir, a
postdoctoral fellow in Dr. Roberto Bonasio’s laboratory (Upenn). The mutual exclusivity
analysis for DLBCL patients was carried out in collaboration with Dr. Roberto Bonasio
laboratory (Upenn) and Dr. Michael Green laboratory (MD Anderson Cancer Center)
Some of works presented here forms the body of a manuscript that is currently
accepted at Nature Cell Biology. Experiments on GCB-DLBCL cell growth and survival
are unpulished and establish the basis for the ongoing projects in our laboratory to
investigate whether KLHL6 has a function beyond cell autonomous regulation. This
chapter is focused on elucidating the role of the KLHL6-Roquin2 axis on ABC-DLBCL
biology and is written and arranged differently from the original manuscript.

Jaewoo Choi, Kyutae Lee, Kristin Ingvarsdottir, Roberto Bonasio, Anita Saraf, Laurence
Florens, Michael P. Washburn, Saber Tadros, Michael R. Green, and Luca Busino. Loss
of KLHL6 promotes diffuse large B-cell lymphoma growth and survival by stabilizing
the mRNA decay factor Roquin2
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Introduction
DLBCL is the most common lymphoid malignancy accounting for ~30% of
lymphoma cases and can be sub-divided into three distinct molecular subtypes: activated
B cell-like (ABC) DLBCL, germinal center B cell-like (GCB) DLBCL, and primary
mediastinal B cell lymphoma (PMBL) (Alizadeh et al., 2000; Rosenwald et al., 2003).
These subtypes arise from different stages of B-cell differentiation and are characterized
by reliance on completely distinctive oncogenic signaling pathways. GCB-DLBCLs are
arising from centroblasts within the germinal center and generally expresses lower NFκB target genes than ABC-DLBCL (Staudt, 2010). One of the key features of GCBDLBCLs is the amplification of chromosome 2 encoding c-rel with 27% of occurrence
and translocation involving bcl2 gene (Lenz et al., 2008f). Furthermore, GCB-DLBCLs
are characterized by deletion of PTEN, a tumor suppressor gene, and amplification of
mir-17-92, an oncogenic micro-RNAs with deregulated expression of Bcl-6 (Parekh et
al., 2007; Shaffer et al., 2002). BCL6 gene plays an important role in germinal center
(GC) formation and suppresses genes involved in cell cycle arrest, apoptosis, and DNA
checkpoint genes (Cerchietti et al., 2010; Phan and Dalla-Favera, 2004). This suggests
that Bcl-6 is a potential target gene in GCB-DLBCL. In fact, inhibitors of Bcl-6 BTB
domain, histone deacetylase, and topoisomerase II have shown some efficacies in downregulating Bcl6 expression and improved survival of younger DLBCL patients (Cerchietti
et al., 2010; Kurosu et al., 2003; Parekh et al., 2007).
On the other hand, key features of human ABC-DLBCLs are hyper-activation of
the inhibitor of IkB kinase (IKK) and the NF-κB transcription factor program (Staudt,
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2010). ABC-DLBCL cell lines depend on chronic active B-cell receptor (BCR) signaling
that mediates NF-κB activation for their proliferation and survival (Staudt, 2010; Young
et al., 2015). This is evidenced by frequent mutations occurrence in the BCR pathway,
including activating mutations of positive (CD79A/B and CARD11 (Davis et al., 2010;
Lenz et al., 2008a)) and inactivating mutations of negative (TNFAIP3 (Compagno et al.,
2009; Davis et al., 2010; Kato et al., 2009; Lenz et al., 2008a)) NF-κB regulators. This
suggests that ABC-DLBCLs might have increased BCR antigenic response and targeting
the components of the BCR pathway such as Bruton’s tyrosine kinase (Btk) would be a
great therapeutic approach. In fact, ibrutinib, which is a covalent inhibitor of Btk, is
selectively toxic to ABC-DLBCL cell lines with an anti-proliferative activity (Davis et
al., 2010). More importantly, in a phase 1/2 clinical trial, ibrutinib has shown to produce
complete or partial responses with relapsed or refractory ABC-DLBCL patients with
more frequent response rate for the patients with BCR mutations and concomitant
myeloid differentiation primary response 88 (MYD88) mutations (Wilson et al., 2015).
ABC-DLBCLs are also dependent on MYD88, which is an adaptor protein that
mediates NF-κB pathway after activation of toll-like receptors and IL-1 and IL-8
receptors (Iwasaki and Medzhitov, 2010). RNA interference screening has shown that
MYD88 and the IRAK1 and IRAK4 (IL-1 receptor-associated kinases) are critical for
ABC DLBCL survival (Ngo et al., 2011). About 29% of ABC DLBCL tumors harbors
L265P mutation in MYD88, which is a gain of function mutation that activates NF-κB
signaling, JAK-STAT3 and cytokine signaling such as IL-6, IL-10, and interferon-β,
promoting survival of ABC-DLBCLs. More recently, integrative analysis of whole92

exome and transcriptome seqeuencing have identified novel genetic drivers and defined
oncogenes that promote DLBCL growth and survival, including well-known genes
described above such as MYD88 and CARD11 (Reddy et al., 2017) along with unknown
gene like KLHL6 with 10-15% of cases in DLBCLs. We have analyzed the biochemical
aspects of cancer-associated mutations in KLHL6 and found that mutations completely
disrupt its ligase activity and interaction with CULLIN3 in chapter 3. However, exact
mechanisms of how KLHL6 contributes to the pathology of human DLBCL and whether
the stabilization of KLHL6 substrate, Roquin2, influences NF-κB activation or BCR
signaling pathways is currently unknown.
One another common target of genetic alteration in ABC-DLBCLs is tumor
necrosis factor-a-inducible gene 3 (TNFAIP3 or A20), a negative regulator of NF-κB
signaling pathway. Roughly 30% of ABC-DLBCL patients show nonsense mutations and
biallelic inactivation of this gene, and re-introduction of wild-type A20 in A20-null ABCDBLCL cell lines induces cellular apoptosis and growth arrest. This suggests that A20 is
a relevant tumor suppressor in ABC-DLBCLs (Compagno et al., 2009). A20 belongs to
deubiquitinating enzymes with ovarian tumour (OTU) domain and serves as a terminator
of NF-κB responses by deubiquitinating TRAF2/6, IKKγ subunit, and MALT1 proteins
(Boone et al., 2004; Lin et al., 2008; Wertz et al., 2004). The fact that A20-deficient mice
die from spontaneous inflammation suggests that A20 mutations alone might not be
sufficient to induce constitutive NF-κB signaling pathway (Boone et al., 2004). Instead,
they might rather cooperate with other genetic alteration events such as CARD11 or
CD79A/B mutations to enhance NF-κB programs. Although there are many cases
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reported for genetic mutation and inactivation of A20, whether there are additional
mechanisms to inhibit its function in B-cell malignancies remain to be determined.
In chapter 4, we have identified a novel role for KLHL6-Roquin2 axis in ABCDLBCLs. We found that KLHL6 is a tumor suppressor gene where loss of KLHL6 favors
cancer cell growth and survival both in vitro and in xenograft models. Correspondingly,
ABC-DLBCL cell lines expressing non-degradable Roquin2 (Y691F) mutant exhibit a
similar growth advantage compared to cells expressing Roquin2 (WT). These
proliferative and growth effects were dependent on RNA binding ability of Roquin2.
Mechanistically, stabilization of Roquin2 promotes mRNA decay of the tumor suppressor
and NF-κB pathway inhibitor, tumor necrosis factor-a-inducible gene 3 (TNFAIP3),
thereby enhancing NF-κB programs in ABC-DLBCLs. All together, our study shows a
previously uncharacterized molecular mechanism whereby the KLHL6-Roquin2 axis
affects B-cell cancer cell proliferation through modulation of the NF-κB activity via
mRNA decay.

Results
KLHL6 is a tumor suppressor in ABC-DLBCL subtype
Given that cancer-associated mutations of KLHL6 result in loss of E3 ubiquitin
ligase activity, we hypothesized that KLHL6 acts as a tumor suppressor by promoting
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Roquin2 degradation. KLHL6 mutations are equally distributed among the two molecular
subtypes of DLBCL, even though KLHL6 mutations are predictive of poor patient
survival mainly in the ABC-DLBCL cohorts (Meriranta et al., 2016). First, we
investigated the dependency of GCB-DLBCL cells on Roquin2. We utilized shRNAmediated knockdown of Roquin2 in SUDHL10, which display a functional KLHL6. Loss
of Roquin2 had no significant effects on cell proliferation (Fig 4.1A). Similar data were
obtained in VAL cells (Fig 4.1B), which harbor a KLHL6 loss of function mutation.
Furthermore, we edited the KLHL6 locus in the GCB-DLBCL cell line BJAB, which
carries wild-type KLHL6 alleles, and showed that concomitant knockdown of Roquin2
had no significant effects on cell proliferation in both KLHL6+/+ and KLHL6-/- cells (Fig
4.1C). To analyze the impact of Roquin2 stabilization in GCB-DLBCL cells, we
generated BJAB cells stably expressing Roquin2 (WT) or Roquin2 (Y691F) and
measured differential gene expression in these cells via RNA sequencing. GO enrichment
analysis revealed minor pathway alteration (Fig 4.1D). Thus, although the mutational
pattern in GCB-DLBCL patients suggests KLHL6 as a tumor suppressor in this subtype,
the survival data (Meriranta et al., 2016) together with our functional characterization
indicate that the KLHL6-Roquin2 axis does not play a role in cellular proliferation and
survival in the GCB-DLBCL subtype.
Since somatic mutations of KLHL6 are clinically relevant in the ABC-DLBCL
subtype (Leo Meriranta, 2016), we assessed the biological effect of KLHL6 loss by
infecting Cas9-expressing U2932, OCI-LY10 and TMD8 cells with lentiviruses encoding
three different gRNAs targeting the KLHL6 gene locus. Loss of KLHL6 in all three ABC95

DLBCL cell lines resulted in an increase in cellular proliferation with a corresponding
decrease in apoptosis (Fig. 4.1E and 4.1F). This effect was confirmed in 3D cultures as
measured by a larger number and size of colonies (Fig. 4.1G). To rule out the possible
off-target effects of gRNAs, we utilized shRNA-mediated knockdown of KLHL6 in
U2932 and OCI-LY10 and observed similar results (Fig. 4.1H and 4.1I).
Having established that KLHL6 loss promotes ABC-DLBCL growth and survival,
we next investigated whether cancer mutations in the BTB-domain of KLHL6 would
affect cell growth. To this aim, we re-introduced KLHL6 (WT) or KLHL6 BTB-domain
mutants (L65P, S94I and F97L) along with an empty vector (EV) in U2932 KLHL6-/cells (Fig. 4.1J). Re-expression of KLHL6 (WT) in KLHL6-/- cells decreased the rate of
cancer cell proliferation, confirming KLHL6 as a tumor suppressor in DLBCLs.
However, KLHL6 BTB-domain mutants displayed similar proliferative effects compared
to KLHL6 (EV), phenocopying the loss of KLHL6 (Fig. 4.1J). This confirms the fact that
mutations in the BTB-domain of KLHL6 are loss of function mutation in ABC-DLBCLs.
Furthermore, we injected these U2932 KLHL6-/- cells re-expressing either EV, KLHL6
(WT) or KLHL6 (S94I) subcutaneously into NOD/SCID/IL2Rγ-/- (NSG) mice. In
agreement with the cell proliferation data, expression of KLHL6 (WT) decreased tumor
burden, measured by tumor volume and tumor weight (Fig. 4.1K). In contrast, DLBCL
cells expressing KLHL6 (S94I) displayed a similar tumor burden compared to KLHL6-/cells (EV).
Lastly, to examine whether KLHL6 expression correlates with better survival of
ABC-DLBCL patients, we combined gene expression data sets from three different
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studies (Lenz et al., 2008f; Monti et al., 2012; Visco et al., 2012) and found that low
KLHL6 expression correlated with significantly poorer survival in ABC-DLBCL patients
(Fig. 4.1L). This analysis further supports the notion that KLHL6 is a tumor suppressor in
ABC-DLBCL cells.

Roquin2 stabilization promotes ABC-DLBCL growth and survival
Since loss of KLHL6 induces stabilization of Roquin2, we investigated the
significance of the KLHL6-Roquin2 axis by analyzing the effect of Roquin2 stabilization
on ABC-DLBCL growth. We generated U2932 cells stably expressing Roquin2 (WT) or
Roquin2 (Y691F) for use in xenograft experiments. Consistent with the hypothesis that
loss of KLHL6 promotes cell proliferation and survival via stabilization of Roquin2,
expression of the non-degradable Roquin2 (Y691F) mutant increased tumor burden when
inoculated sub-cutaneously in NSG mice as monitored by tumor volume and weight at the
experimental endpoint (Fig. 4.2A). This effect was not due to an overexpression artifact
because the levels of Roquin2 (Y691F) were similar (actually even lower) to those of
endogenous Roquin2 in KLHL6-/- cells (Fig. 4.2B).
Furthermore, we utilized shRNA-mediated knockdown of Roquin2 in KLHL6-/U2932 and OCI-LY10 cells and found that ablation of Roquin2 impaired the cell growth
advantage of both KLHL6-/- cells (Fig. 4.2C, and 4.2D). Importantly, loss of Roquin2
increased cell toxicity preferentially in KLHL6-/- cells (Fig. 4.2E), supporting the notion
that loss of KLHL6 promotes cell proliferation in a Roquin2-dependent manner.
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Stabilization of Roquin2 down-regulate BCR responsive genes
Roquin proteins act broadly as regulators of mRNA deadenylation and
degradation by recognizing stem-loop RNA degradation motifs through a ROQ domain
(Leppek et al., 2013). We generated a double mutant Roquin2 (Y691FΔROQ) lacking the
ROQ domain (Fig. 4.3A) to examine whether the pro-proliferative effect of Roquin2
(Y691F) mutant depends on its RNA binding ability. Remarkably, concomitant deletion
of the ROQ domain in non-degradable Roquin2 mutant (Y691F) completely abolished
the growth advantage induced by this mutant, implying that the effect of Roquin2
stabilization on cell growth requires an intact RNA binding domain.
BCR signaling is a major pathway driving ABC-DLBCL survival (Staudt, 2010).
Since stabilization of Roquin2 promotes DLBCL proliferation in a manner dependent on
the mRNA binding ability of Roquin2, we hypothesized that deregulation of Roquin2
proteolysis would result in aberrant BCR-dependent transcriptional program. Since
Roquin2 is targeted for protein degradation in a KLHL6-dependent manner upon
activation of BCR signaling, we reasoned that expression of the non-degradable Roquin2
(Y691F) mutant would result in constitutive mRNA decay of Roquin2 targets upon BCR
activation. We treated U2932 cells expressing Roquin2 (WT) or Roquin2 (Y691F) with
F(ab’)2-IgM and measured differential gene expression via RNA sequencing analysis
(Fig. 4.3B and Table 4.1). We performed a pairwise comparison of RNA reads and found
that 133 mRNAs were significantly down-regulated in Roquin2 (Y691F) expressing cells
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as compared to Roquin2 (WT). Since Roquin2 is degraded upon BCR stimulation, we
specifically searched for the BCR dependent transcripts whose expression was upregulated by at least two-fold upon BCR activation (Fig. 4.3C). Among 133 genes, we
identified 64 genes whose expression was BCR-responsive and down-regulated when
Roquin2 is not properly degraded in DLBCL cells.
Additionally, we performed gene ontology (GO) enrichment analysis (Fig. 4.3D
and Table 4.2) and found that Roquin2 putative mRNA targets are involved in immune
and inflammatory responses, including genes implicated in the NF-κB pathway and as
lymphoid tumor suppressors (e.g..TNF, NFKBIE, TNFAIP3, LTA, TNFRSF14) (Boice et
al., 2016; Compagno et al., 2009; Mansouri et al., 2016; Tian et al., 2005; Zhou et al.,
2003). Further, we ranked the final 64 genes by the genetic alteration frequencies in
human DLBCLs (TCGA, http://cancergenome.nih.gov/) and base mean expression in our
RNA-Seq analysis to identify relevant targets in DLBCL biology (Fig. 4.3E and Table
4.1). We identified 11 potential candidates that were additionally validated in a secondary
screen to evaluate dependency on a functional ROQ domain. We confirmed that all 11
transcripts were down-regulated by expression of non-degradable Roquin2 (Y691F), with
7 transcripts rescued upon expression of the double mutant Roquin2 (Y691FΔROQ) (Fig.
4.3F), suggesting their dependency on Roquin2 mRNA binding/decay activity. We
concluded that these 7 transcripts were likely direct mRNA targets of Roquin2.
Amongst the putative mRNA targets we identified, we decided to focus on tumor
necrosis factor-a-inducible gene 3 (TNFAIP3) with the consideration that human ABCDLBCLs frequently harbor inactivating mutations or deletions in the TNFAIP3 gene
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(Compagno et al., 2009; Davis et al., 2010; Kato et al., 2009; Lenz et al., 2008a). Kinetic
analysis of mRNA expression in response to BCR stimulation revealed a time-dependent
up-regulation of TNFAIP3 (Fig. 4.3G), consistent with its function as a negative feedback
regulator of the NF-κB program (Chu et al., 2011). This response was mitigated in cells
expressing the non-degradable Roquin2 (Y691F) mutant, suggesting that degradation of
Roquin2 contributes to a build up TNFAIP3 mRNA levels upon BCR signaling. Notably,
TNFAIP3 mRNA levels were partially rescued in cells expressing Roquin2 double
mutant (Y691FΔROQ), indicating that down-regulation of Roquin2 specific targets are
dependent on the ability of Roquin2 to bind RNA. These data are consistent with
previous findings that TNFAIP3 mRNA directly interacts with Roquin proteins
(Murakawa et al., 2015). Moreover, similar results were obtained with the NF-κB target
genes (NFKBIE and LTA) and the tumor suppressor gene TNFRSF14 (Fig. 4.3G).
Lastly, we investigated whether the KLHL6-Roquin2 axis can directly control
TNFAIP3 mRNA levels and its stability. The mRNA half-life of TNFAIP3 was shortened
upon knockdown of KLHL6 and was partially rescued by concomitant knockdown of
Roquin2 (Fig. 4.3H). When we re-expressed of KLHL6 (WT) in VAL cells carrying,
endogenous BTB-domain mutations of KLHL6, the mRNA half-life of TNFAIP3 (Fig.
4.3I) was greatly extended. Our findings suggest that TNFAIP3 is a target of Roquin2 and
reveal that loss of KLHL6 promotes down-regulation of TNFAIP3 mRNA in ABCDLBCLs.
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KLHL6-Roquin2 axis controls NF-κB activation via TNFAIP3
TNFAIP3 is a ubiquitin-editing enzyme that inhibits the NF-κB signaling
pathway via catalytic and non-catalytic inhibition of the IKK complex (Srinivasula and
Ashwell, 2011). Since we observed that KLHL6 loss promotes TNFAIP3 mRNA downregulation, we expected that loss of KLHL6 might result into a higher NF-κB activation
in ABC-DLBCLs. First, we investigated whether the TNFAIP3 protein levels are
regulated in a similar way as the TNFAIP3 transcriptional levels. BCR stimulation
induced degradation of Roquin2 (WT) with the corresponding up-regulation of TNFAIP3
protein levels (Fig. 4.4A). More importantly, TNFAIP3 up-regulation upon BCR
stimulation was abolished in cells stably expressing the non-degradable Roquin2 (Y691F)
mutant, reflecting its transcriptional changes.
Since KLHL6 levels are also dependent on BCR activation and the KLHL6Roquin2 axis regulates the NF-κB pathway through TNFAIP3 decay, we hypothesized
that KLHL6 itself is regulated by NF-κB. To explore this hypothesis, we analyzed
previously published CHIP-seq datasets for NF-κB factors (Zhao et al., 2014) and found
that p50, p52, RelA, RelB and cRel were indeed enriched at the KLHL6 gene locus. This
suggests that KLHL6 is a bona fide NF-κB target gene (Fig. 4.4B). Correspondingly,
IKK or a BTK inhibitor (ibrutinib) treatment (Davis et al., 2010) induced a downregulation of KLHL6 both at mRNA and protein levels (Fig. 4.4C). Interestingly, we
found that KLHL6-/- cells are less sensitive to ibrutinib treatment (Fig. 4.4D). These data
support a model in which BCR signaling induces KLHL6 up-regulation, Roquin2
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degradation and TNFAIP3 mRNA stabilization. In agreement with this model, TNFAIP3
protein levels were down-regulated in KLHL6-/- cells as compared to KLHL6+/+ cells,
both at steady state and in response to BCR stimulation (Fig. 4.4E), phenocopying the
effect of the non-degradable Roquin2 mutant on TNFAIP3 protein. Knockdown of
Roquin2 in U2932 KLHL6-/- cells increased TNFAIP3 levels similar to those of KLHL6+/+
cells (Fig. 4.4F), suggesting a direct regulation of TNFAIP3 protein levels by Roquin2.
Likewise, depletion of Roquin2 increased TNFAIP3 protein levels in HBL1 cells along
with more robust up-regulation upon BCR stimulation (Fig. 4.4G). Correspondingly, reintroduction of KLHL6 (WT) in KLHL6-/- cells increased TNFAIP3 levels (Fig. 4.4H).
Further, we investigated whether KLHL6-dependent down-regulation of
TNFAIP3 would result in increased IKK activation utilizing IκBα phosphorylation as
readout. Although IκBα was rapidly phosphorylated in both KLHL6+/+ and KLHL6-/cells following BCR activation, the amplitude of phosphorylation was higher in KLHL6-/cells, suggesting an increased activity of IKK (Fig. 4.4I). Importantly, the increase in
phosphorylation was mitigated after re-introduction of KLHL6 (WT) (Fig. 4.4J). More
importantly, the increase in phosphorylation correlated with more nuclear translocation of
the NF-κB transcriptional factors in KLHL6-/- cells (Fig. 4.4K). The increase in nuclear
translocation was partially mitigated by the concomitant knockdown of Roquin2 (Fig.
4.4L). Correspondingly, we also observed that loss of KLHL6 increased DNA-binding of
RelA to its target promoter, NFKBIA, and this effect was reversed upon concomitant
knockdown of Roquin2 (Fig. 4.4M).
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KLHL6 BTB-domain mutations and TNFAIP3 mutations are mutually exclusive in
DLBCL patients
If KLHL6-Roquin2 axis acts through TNFAIP3 as a main downstream effector, it
is likely that loss of function mutation of KLHL6 would be mutually exclusive with
TNFAIP3 inactivating mutation or deletion. Correspondingly, when we performed the
mutual exclusivity analysis on BTB-associated KLHL6 mutations with TNFAIP3
alterations in DLBCL patients, we observed no overlap with deleterious KLHL6 BTBmutations and TNFAIP3 biallelic deletion or mutation (Fig. 4.5A and 4.5B). Using a
weighted test (Leiserson et al., 2016), we found there was a trend toward significance for
KLHL6 and TNFAIP3 mutual exclusivity with the p-value of 0.085 (Table 4.3). Notably,
there were cases where deleterious BTB-domain mutations of KLHL6 did co-occur with
monoallelic deletion of TNFAIP3. This suggests that these mutations might cooperate to
increase NF-κB activation in the cases where only one TNFAIP3 allele is lost. This is in
line with the fact that patients with KLHL6 mutations tended to have a higher NF-κB
activity, although this signature was not only restricted to KLHL6 mutated cases (Fig.
4.5C).
Next, we investigated whether the tumor suppressing effects of KLHL6 would be
decreased in TNFAIP3-null ABC-DLBCLs (RCK8 and HLY1 cells). Loss of KLHL6 in
RCK8 cells (Compagno et al., 2009) did not show any noticeable effects on cellular
proliferation (Fig. 4.5D) and apoptosis (Fig. 4.5E). Correspondingly, knockdown of
Roquin2 in HLY1 cells (TNFAIP3-null (Fontan et al., 2012)) resulted into a greater
cellular apoptosis compared to HBL1 cells (TNFAIP3-WT) (Fig. 4.5F). All together, this
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indicates the functional relevance of Roquin2 in cells harboring a wild-type TNFAIP3
gene.

Discussion
Although KLHL6 mutations occur at a similar frequency in GCB-DLBCL, we
have shown that the KLHL6-Roquin2 axis does not play a significant role in cell
proliferation and survival in the GCB-DLBCL subtype. In contrast, ablation of KLHL6 in
ABC-DLBCL cell lines promotes cell growth both in vitro and in vivo, supporting a
tumor suppressor role of KLHL6. These findings are indeed consistent with low KLHL6
expression levels correlating with poorer survival in ABC-DLBCL patients (Kunder et
al., 2017; Leo Meriranta, 2016). Furthermore, expression of a non-degradable Roquin2
(Y691F) mutant phenocopies loss of KLHL6 in ABC-DLBCLs and concomitant ablation
of Roquin2 in KLHL6-/- cells results in an inhibition of cell proliferation. This proproliferative effect depends on the ability of Roquin2 to bind RNA (Glasmacher et al.,
2010; Leppek et al., 2013; Murakawa et al., 2015; Schlundt et al., 2014; Vogel et al.,
2013). Although Roquin1 and Roquin2 are reported to be functionally redundant in the Tcells (Vogel et al., 2013), no studies so far have examined the functional redundancy of
Roquin proteins in mature B-cell cancers. The fact that KLHL6 targets only Roquin2
suggests that, in the context of B-cell cancers, Roquin2 might play a non-redundant role
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from Roquin1. Consistent with this hypothesis, the expression of Roquin2 is higher in
germinal center B-cells, which is the origin of DLBCL (data not shown).
Genetic screens based on loss of function via CRISPR technology have identified
negative regulators of NF-κB (such as TNFAIP3, CD83 and CBLB) as tumor suppressors
in ABC-DLBCL cells (Reddy et al., 2017). This suggests that the degrees of NF-κB
activation in DLBCL cells can vary as a consequence of changes in the negative
regulators of NF-κB. Furthermore, ABC-DLBCL cell lines can respond to BCRstimulation and further activate the NF-κB pathway (Yang et al., 2016). We have used
U2932 cells, which harbors KLHL6 wild-type and a hemi-deletion of TNFAIP3 (Ferch et
al., 2009) along with a basal level of NF-κB activation (Ferch et al., 2009). Although
featured as a single wild–type allele, U2932 cells express detectable levels of TNFAIP3
both at mRNA and protein levels. This emphasizes that TNFAIP3 is a relevant target of
Roquin-mediated mRNA decay (Murakawa et al., 2015) in ABC-DLBCLs. BCRsignaling triggers up-regulation of KLHL6 transcripts, leading to down-regulation of
Roquin2 protein and de-repression of TNFAIP3 mRNA. We expect that KLHL6
suppresses TNFAIP3 mRNA decay via Roquin2 degradation to establish a negative
feedback loop and fine-tune the NF-κB signaling pathways (Fig 4.5G). Therefore, it is
conceivable that loss of KLHL6 promotes BCR-signaling dependent NF-κB activation by
down-regulation of TNFAIP3 mRNA and protein levels, disengaging this negative
feedback loop in ABC-DLBCLs. Correspondingly, we found that DLBCL patients with
BTB-domain mutations of KLHL6 are likely to have high NF-κB signatures. Therefore,
KLHL6 mutation spectrum could serve as a resistance marker to NF-κB pathway
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inhibitors such as ibrutinib (Davis et al., 2010), MLN4924 (Milhollen et al., 2010) or
bortezomib (Yang and Staudt, 2015). Interestingly, we have found that loss of KLHL6
predisposes ABC-DLBCL cells to ibrutinib desensitization. A complete characterization
of KLHL6 loss in the ibrutinib mechanism remains to be further elucidated.
TNFAIP3 genetic alterations including inactivation mutations and deletions are
frequently observed in ABC-DLBCLs (Compagno et al., 2009; Davis et al., 2010; Kato et
al., 2009; Lenz et al., 2008a). Several studies have shown that TNFAIP3 is a tumor
suppressor by re-introduction of functional TNFAIP3 (WT) in TNFAIP3-null DLBCLs as
the reconstitution causes cellular apoptosis and growth arrest (Honma et al., 2009;
Schmitz et al., 2009). Interestingly, KLHL6 BTB-mutations and TNFAIP3 biallelic
deletion or mutations do not co-occur in DLBCL patients, suggesting that these two
genes might have similar downstream NF-κB effectors. The fact that there was a partial
overlap between KLHL6 BTB-mutations and TNFAIP3 monoallelic deletion further
supports a notion of possible synergy of these mutations towards increasing NF-κB
activity. On the other hand, neither Roquin2 amplification nor sequence mutation of
TNFAIP3 mRNA at the 3’ UTR of Roquin2 binding site has been observed in DLBCLs.
This suggests that KLHL6 could play a tumor suppressor role via other mechanisms
beyond de-regulatioin of Roquin2 proteolysis and TNFAIP3 mRNA decay. Furthermore,
additional genetic lesions that could cooperate with the loss of KLHL6 in promoting
tumorigenesis in B-cell cancers remain open questions.
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Fig 4.1 KLHL6 is a tumor suppressor in ABC-DLBCL subtype
(A) Loss of Roquin2 had no significant effects on cell proliferation in SUDHL10 cells.
Left panel shows cell number counts of SUDHL10 expressing shRNA control or shRNAs
targeting Roquin2 (#1 and #2) (mean± s.d., n=3 independent experiments). Whole cell
lysates were analyzed by immunoblotting for the indicated proteins (Right panel). (B)
Loss of Roquin2 had no significant effects on cell proliferation in VAL cells. Same as in
(a) except that VAL cells were used. (C) Loss of Roquin2 had no significant effects on
cell proliferation in BJAB cells. Same as in (a) except that BJAB KLHL6+/+ and KLHL6-/were used. (D) Gene ontology (GO) analysis of genes regulated by the non-degradable
Roquin2 (Y691F) mutant in BJAB cells. (E) Ablation of KLHL6 in all three ABCDLBCL cell lines resulted in an increase in cellular proliferation. Left panel shows cell
counts of U2932-, OCI-LY10- and TMD8-Cas9 cells expressing the indicated gRNAs
and carrying a puromycin cassette (mean±s.d., n=3 independent experiments, two-way
ANOVA, *P value≤0.05; **P value≤0.01; *** P value≤0.001; ****P value≤0.0001).
Cells were grown in media containing 1µg/ml (U2932 and OCI-LY10) or 4µg/ml
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(TMD8) of F(ab’)2-IgM. Whole cell lysates were analyzed by immunoblotting for the
indicated proteins (Right panel). (F) Ablation of KLHL6 in all three ABC-DLBCL cell
lines resulted in a decrease in cellular apoptosis. U2932-, OCI-LY10-, and TMD8-Cas9
cells expressing the indicated gRNAs and carrying a GFP marker were grown as in (b)
and analyzed for cell apoptosis rates. Apoptosis was quantified on GFP+ and Annexin V+
cells (mean±s.d., n=3 independent experiments, one-way ANOVA, **P value≤0.01; ***
P value≤0.001). (G) Ablation of KLHL6 in U2932 cells resulted in an increase in cell
numbers and large colonies in 3D cultures. U2932-Cas9 cells were infected with
lentiviruses encoding scrambled gRNA or gRNAs against KLHL6 exon 1 carrying a
puromycin cassette. Whole cell lysates were analyzed by immunoblotting for the
indicated proteins (left top panel). Left bottom panel shows representative image of
U2932 cell colonies expressing indicated gRNAs and plated into a matrigel. After 14
days, the matrigel was dissolved and recovered. Cells were counted and plotted as shown
on the right panel (mean±s.d., n=4 independent experiments, one-way ANOVA, ****P
value≤0.0001). Scale bar 150µm. (H) Ablation of KLHL6 in U2932 cells resulted in an
increase in cellular proliferation. U2932 cells were infected with lentiviruses encoding
the indicated shRNAs carrying a puromycin cassette. Whole cell lysates were analyzed
by immunoblotting for the indicated proteins (left panel). Right panel shows MTS assay
for U2932 cells infected with lentiviruses encoding the indicated shRNAs and grown in
media containing 1µg/ml of F(ab’)2-IgM. Values were normalized to the shCTRL cells at
time 0 hour and set as 100% (mean±s.d., n=3 independent experiments, two-way
ANOVA; *** P value≤0.001, ****P value≤0.0001). (I) Ablation of KLHL6 in OCI111

LY10 cells resulted in an increase in cellular growth and survival. OCI-LY10 cells were
infected with lentiviruses encoding indicated shRNAs carrying a puromycin cassette.
Whole cell lysates were analyzed by immunoblotting for the indicated proteins (left
panel). Middle panel shows representative image of OCI-LY10 cell colonies infected
with indicated shRNAs and plated into a matrigel. After 14 days, the matrigel was
dissolved and recovered. Cells were counted and plotted as shown on the right panel
(mean±s.d., n=4 independent experiments, one-way ANOVA, ****P value ≤0.0001).
Scale bar 150µm. (J) Expression of BTB-mutants phenocopies loss of KLHL6 in
promoting ABC-DLBCL cell proliferation in vitro. U2932 KLHL6-/- cells were infected
with retroviruses encoding an empty vector (EV) or KLHL6 WT or BTB-mutants (L65P,
S94I and F97L). Whole cell lysates were analyzed by immunoblotting for the indicated
proteins (left panel). Right panel shows cell growth as measured by counting the number
of cells over time. Error bars represent s.d., n=3. Asterisks indicate: ****P value ≤0.001
calculated with ANOVA. (K) Expression of KLHL6 BTB-mutants phenocopies loss of
KLHL6 in promoting ABC-DLBCL growth in xenograft models. U2932 KLHL6-/- cells
were infected with retroviruses encoding an empty vector (EV), KLHL6 (WT) or KLHL6
(S94I) prior to sub-cutaneous injection of NOD/SCID/IL2Rγ-/- (NSG) mice. Left panel
shows a picture of the tumors after the experimental endpoint. Middle panel shows tumor
volume calculated by caliper measurements. Right panel shows tumor weight calculated
by the weight of the excised tumors at the experimental endpoint. Error bars represent
s.d., n=5. Asterisks indicate: *P value ≤0.05, **P value ≤0.01, and n.s. indicates nonsignificant P value. Statistical analysis was performed using the t-test. (L) Low level of
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KLHL6 expression correlates with poor survival in ABC-DLBCL patients. Gene
expression microarray data (diffuse large B-cell lymphoma tumors) were obtained from
GSE10846, GSE34171 and GSE31312 (Lenz et al., 2008f; Monti et al., 2012; Visco et
al., 2012). Kaplan–Meier analyses of ABC-DLBCL patients based on KLHL6 expression
is shown (n=367, cases were dichotomized into being above or below the median
expression level of KLHL6 expression within each dataset to avoid confounding batch
effects). Statistical analysis was performed using the Log-rank (Mantel-Cox) test.
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Fig 4.2 Roquin2 stabilization promotes ABC-DLBCL growth and survival
(A) Stabilization of Roquin2 promotes ABC-DLBCL growth in xenograft models. U2932
cells were infected with retroviruses encoding HA-Roquin2 (WT) or HA-Roquin2
(Y691F) and 1 x 107 cells were sub-cutaneously injected in NSG mice. On the left panel,
tumor volume was calculated by caliper measurements. On the right panel, tumor weight
was determined on the excised tumors at the experimental endpoint. Error bars represent
s.d., n=3. Statistical analysis was performed using ANOVA and the t-test for tumor
volume and tumor weight, respectively. Asterisks indicate: *P value ≤0.05, **P value
≤0.01, *** P value ≤0.001, ****P value ≤0.001). (B) Roquin2 (Y691F) protein levels are
similar to endogenous Roquin2 protein levels in KLHL6-/- cells. Indicated amounts of
recombinant Roquin2 (set as the standard) along with whole cell lysates from U2932
KLHL6+/+ and KLHL6-/- cells (clone-derived) (left panel) or U2932 stably expressing HARoquin2 (WT) and HA-Roquin2 (Y691F) cells (middle panel) were analyzed for
immunoblotting. Right panel shows intensity of quantified Roquin2 bands compared to
the standard. A representative blot from one experiment is shown. (C) Loss of KLHL6
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promotes cell proliferation in a Roquin2-dependent manner in U2932 cells. Whole cell
lysates were analyzed by immunoblotting for the indicated proteins (left panel). Right
panel shows cell number counts of GFP-sorted U2932 KLHL6+/+ and KLHL6-/- (clonederived) cells infected with scramble shRNA (shCTRL) or shRNA targeting Roquin2
(ShRoquin2#1 or #2) carrying a GFP marker. GFP+ cells were grown in media containing
1µg/ml of F(ab’)2-IgM. (mean±s.d., n=3 independent experiments, two-way ANOVA,
****P value≤0.0001). A representative blot from two independent experiments is shown.
(D) Same as (c) except that OCI-LY10 KLHL6+/+ and KLHL6-/- cells were utilized. (E)
Loss of Roquin2 increased toxicity of KLHL6-/- cells. GFP+-live OCI-LY10 KLHL6+/+
and KLHL6-/-(clone-derived) cells were infected with lentiviruses encoding the indicated
shRNAs carrying a GFP marker and monitored over time by flow cytometry. Cells were
grown in media containing 2µg/ml of F(ab’)2-IgM and normalized to the shCTRL cells
set as 100% (mean±s.d., n=3 independent experiments, two-way ANOVA, **P
value≤0.01; ****P value≤0.0001).
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Figure 4.3 Stabilization of Roquin2 down-regulate BCR responsive genes
(A) Concomitant deletion of the ROQ domain abolished the proliferative effect of
Roquin2 (Y691F). U2932 cells were infected with retroviruses encoding HA-Roquin2
(WT), HA-Roquin2 (Y691F) or HA-Roquin2 (Y691FΔROQ). Whole cell lysates were
analyzed by immunoblotting for the indicated proteins (left panel). Middle panel shows a
representative image of cell colonies. Cells were plated into a matrigel matrix and were
allowed to grow for 14 days. After 14 days, the matrigel matrix was dissolved with
dispase to recover the cells, which were counted and plotted on the right panel. Error bars
represent s.d., n=4. Scale bar 150µm. (B) Identification of mRNA targets affected by
stabilization of Roquin2 and BCR stimulation. The volcano plot (left panel) shows the
mRNAs (blue) down-regulated in U2932 cells stably expressing Roquin2 (Y691F) as
compared to Roquin2 (WT) after 12 hours of treatment with 10 µg/ml of F(ab’)2-IgM
(log2(fold-change) < –0.9; P value<0.001; n=3). Down-regulated mRNAs were further
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plotted in an MA (log ratio, mean average)-plot (right panel) to identify mRNAs (red) upregulated upon treatment with F(ab’)2-IgM in cells expressing Roquin (WT) (log2(foldchange)>1;P value<0.001). (C) 64 genes are BCR responsive transcripts controlled by
Roquin2 degradation. A venn diagram shows the overlap between genes down-regulated
by expression of non-degradable Roquin2 (Y691F) mutant and BCR responsive genes.
(D) Gene ontology (GO) analysis was performed on genes regulated by the nondegradable Roquin2 (Y691F) mutant. Bar plot shows the −log10 of the P value of the top
10 enriched GO terms of genes regulated by Roquin2 (Y691F) as determined by the
hypergeometric distribution. -reg., negative regulation; + reg., positive regulation. (E)
The list of Roquin2-regulated genes ranked by the percentage of genetic
alteration/mutation in human DLBCLs from the TCGA database and the base mean
expression from the RNA-seq analysis. The cut-off was set at 6% for genetic mutation
frequency. “Yes” indicates down-regulation of transcript is dependent on the ROQ
domain of Roquin2 and rescued at least 70%; “No” indicates down-regulation of
transcript is not dependent and not rescued. (F) Secondary q-PCR screening for mRNAs
levels of U2932 cells stably expressing HA-Roquin2 (WT), HA-Roquin2 (Y691F) or
HA-Roquin2 (Y691FΔROQ). The cells were treated with 10µg/ml of F(ab’)2-IgM for 12
hours and the value for each PCR product present in HA-Roquin2 (WT) cells was set as
100%. Rescued transcripts are considered as the ones whose mRNA levels reach at least
70% of the Roquin2 (WT) control (dashed line in the graph=70% rescue) (mean±s.d.,
n=3 independent experiments). (G) TNFAIP3 mRNA levels are regulated by Roquin2
degradation and mRNA decay activity. U2932 cells stably expressing encoding HA120

Roquin2 (WT), HA-Roquin2 (Y691F) or HA-Roquin2 (Y691FΔROQ) were treated with
10 µg/ml of F(ab’)2-IgM for indicated times. Levels of the indicated mRNAs were
analyzed by real time PCR. A representative experiment from two biological replicates is
shown. Value for PCR product present at time 0 hour was arbitrarily set as 1 for each
condition. (H) Ablation of KLHL6 shortened the half-life of TNFAIP3. U2932 cells were
electroporated with indicated siRNAs (left panel) and treated with actinomycinD for the
indicated times for qPCR analysis of TNFAIP3 mRNA. The value for PCR product
present at time 0 hour was arbitrarily set as 100% (mean±s.d., n=3 independent
experiments, two-way ANOVA, **P value ≤0.01, ****P value≤0.0001, n.s, not
significant). (I) Overexpression of KLHL6 increases the half-life of TNFAIP3. Same
analysis was performed in VAL cells expressing KLHL6 under a DOX-inducible
promoter. Cells were pre-treated with DOX for 12 hours and actinomycinD for the
indicated times (mean±s.d., n=3 independent experiments, two-way ANOVA, *P value
≤0.05; *** P value≤0.001).
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Figure 4.4 KLHL6-Roquin2 axis controls NF-κB activation via TNAFIP3
(A) Roquin2 stabilization induces a decrease in TNFAIP3 protein levels. U2932 cells
stably expressing HA-Roquin2 (WT) or HA-Roquin2 (Y691F) were treated with 10µg/ml
of F(ab’)2-IgM for the indicated times. Whole cell lysates were analyzed by
immunoblotting for the indicated proteins. (B) ChIP-seq peaks were analyzed and
visualized by using University of California Santa Cruz (UCSD) Genome browser (GEO
Series accession GSE55105). RPM, reads per million mapped. (C) KLHL6 is a bona fide
NF-κB target gene. Left panel shows analysis of level of KLHL6 mRNA by qPCR in
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U2932 cells treated with DMSO, 10µM of IKK inhibitor (IKK-16) or 5µM of BTK
inhibitor (ibrutinib) for 6 hours. The value for PCR product present without treatment
(DMSO) was set as 100% (mean±s.d., n=3 independent experiments, one-way ANOVA,
*** P value≤0.001; ****P value≤0.0001). Whole cell lysates were analyzed by
immunoblotting for the indicated proteins (Right panel). (D) KLHL6-/- cells are less
sensitive to ibrutinib. U2932 cells KLHL6+/+ and KLHL6-/- treated with increasing
amounts of ibrutinib for 48 hours, and cell proliferation was analyzed by MTS assay.
Values were normalized to the non-treated cells and set as 100% (mean±s.d., n=3
independent experiments, two-way ANOVA; *P value≤0.05, **P value≤0.01, *** P
value≤0.001, ****P value≤0.0001). (E) Loss of KLHL6 induces a decrease in TNFAIP3
protein levels. U2932 cells KLHL6+/+ or KLHL6-/- were treated with 10µg/ml of F(ab’)2IgM for the indicated times. Whole cell lysates were analyzed by immunoblotting for the
indicated proteins. (F) Knockdown of Roquin2 in U2932 KLHL6-/- cells rescues
TNFAIP3 levels. GFP-sorted U2932 KLHL6+/+, KLHL6-/- or KLHL6-/- cells were infected
with lentiviruses encoding the indicated shRNAs carrying a GFP marker and treated with
10 µg/ml of F(ab’)2-IgM for 6 hours. The whole cell lysates were analyzed by
immunoblotting for the indicated proteins. (G) Knockdown of Roquin2 increases
TNFAIP3 levels in HBL1 cells. HBL1 cells were electroporated with indicated siRNAs
and treated as in (E) for the indicated times. The whole cell lysates were analyzed by
immunoblotting for the indicated proteins. (H) Re-expression of KLHL6 (WT) in U2932
KLHL6-/- cells rescues TNFAIP3 levels. GFP-sorted U2932 KLHL6-/- (clone-derived)
cells were infected with retroviruses encoding empty vector (EV) or KLHL6 (WT)
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carrying a GFP marker and treated with 10µg/ml of F(ab’)2-IgM for 6 hours. The whole
cell lysates were analyzed by immunoblotting for the indicated proteins. (I) Loss of
KLHL6 enhances phosphorylation of IκBα. U2932 cells KLHL6+/+ or KLHL6-/- were
treated with 10µg/ml of F(ab’)2-IgM for the indicated times. Whole cell lysates were
analyzed by immunoblotting for the indicated proteins. (J) Re-expression of KLHL6
(WT) in U2932 KLHL6-/- cells mitigates IκBα phosphorylation. Same as in (h) except
that cells were treated with 10µg/ml F(ab’)2-IgM for the indicated times (min). (K) Loss
of KLHL6 promotes nuclear translocation of NF-κB transcription factors. U2932 cells
KLHL6+/+ or KLHL6-/- were fractionated into cytoplasmic and nuclear extracts. The
indicated cell lysates were analyzed by immunoblotting for the indicated proteins. (L)
Concomitant knockdown of Roquin2 in KLHL6-/- cells mitigated nuclear translocation of
NF-κB transcription factors. GFP-sorted U2932 KLHL6+/+, KLHL6-/- or KLHL6-/- cells
infected with lentiviruses encoding the indicated shRNAs carrying a GFP marker were
fractionated into cytoplasmic and nuclear extracts and analyzed by immunoblotting for
the indicated proteins. (M) Loss of KLHL6 increases RelA DNA-binding at the NFKBIA
promoter. U2932 KLHL6+/+, KLHL6-/- or KLHL6-/- cells were infected with indicated
shRNAs and analyzed for RelA binding degrees to its target NFBKIA promoter by
chromatin immunoprecipitaiton followed by qPCR. Data are displayed as fold
enrichment relative to IgG control. A representative graph from two independent
experiments is shown.
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Figure 4.5 KLHL6 BTB-domain mutations and TNFAIP3 mutations are mutually
exclusive in DLBCL patients
(A) BTB-associated mutations of KLHL6 with TNFAIP3 alterations do not overlap in
DLBCLs. Top panel shows tumors sequenced at UNMC (Idoia et al., 2016) and DCI
(Reddy et al., 2017) (n=1175) with deleterious mutations of KLHL6 in the BTB-domain
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and TNFAIP3 mutations. Bottom panel shows the TNFAIP3 subset with biallelic and
monoallelic deletions. (B) Some overlaps occur between deleterious BTB-domain
mutations of KLHL6 and monoallelic deletion of TNFAIP3. A heat map shows the
presence of biallelic deletion (dark blue), monoallelic deletion (light blue) and
monoallelic mutation (green) of TNFAIP3 in DLBCL tumors sequenced at UNMC (Idoia
et al., 2016) and DCI (Reddy et al., 2017) (n=1175). Deleterious mutations of KLHL6
BTB-domain are shown in these same cases. (C) The DLBCL patients with KLHL6
mutations exhibit higher NF-κB signatures. A heat map shows the tumor gene alterations
matched with gene expression profiling data available at UNMC. Single sample gene set
enrichment analysis (GSEA) was utilized to infer NF-κB activity using expression of
target gene sets from the molecular signatures database (NFκB_Q and NFκB_C) (Green
et al., 2014; Lenz et al., 2008f). The enrichment score is displayed as a row-normalized
heat map. (D) Tumor suppressor role of KLHL6 is abolished in TNFAIP3-null ABCDLBCLs. GFP-sorted RCK8 cells expressing Cas9, the indicated gRNAs and a GFP
marker, were grown in media containing 1µg/ml of F(ab’)2-IgM and cell numbers were
counted and graphed (right panel) (mean±s.d., n=3 independent experiments, two-way
ANOVA, n.s, not significant). Whole cell lysates were analyzed by immunoblotting for
the indicated proteins (Left panel). (E) Tumor suppressor role of KLHL6 is reduced in
TNFAIP3-null ABC-DLBCLs. Cells from (d) were analyzed for cell apoptosis rates
(mean±s.d., n=3 independent experiments, one-way ANOVA, n.s, not significant). (F)
Elevated apoptosis by knockdown of Roquin2 is only observed in cells harboring a
functional TNFAIP3 gene. GFP+ and AnnexinV+ HBL1 and HLY-1 cells expressing the
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indicated shRNAs were for cell apoptosis rates (mean±s.d., n=3 independent
experiments, one-way ANOVA, *P value≤0.05; *** P value≤0.001, n.s, not significant).
(G) KLHL6 is a tumor suppressor in ABC-DLBCLs. In ABC-DLBCL cells, active BCR
signaling sustains the NF-κB pathway. KLHL6 is a target of NF-κB and promotes
degradation of Roquin2 and TNFAIP3 mRNA stabilization, establishing a negative
feedback loop on NF-κB activity (left panel). Loss of KLHL6 disengages this negative
feedback by promoting Roquin2 stabilization, TNFAIP3 mRNA decay and higher IKK
activity, which further enhances the NF-κB activity (right panel).
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Data set

Cell type

# Reliplicates

RNA-seq

U2932 cells
expressing Roquin2
(WT) and Roquin2
(Y691F) with 0h
and 12h of 10µg/ml
of anti-IgM
treatment

3

Accession
number
GSE93675

Table 4.1 RNA-seq data sets generated in this dissertation
The table lists the mRNA fold changes in U2932 cells expressing Roquin2 (Y691F) vs
Roquin2 (WT) upon 12 hours treatment with 10 µg/ml of F(ab’)2-IgM. Quantification
analysis of RNA reads was performed using of R packages DEseq2 (n= 3 independent
experiments) (Love et al., 2014).
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GO ID

GO class

GO:0006954
GO:0046718
GO:0090084
GO:0042026
GO:0032757
GO:0050830
GO:0006986
GO:0032755
GO:0070370
GO:0034605
GO:0031295
GO:0045080
GO:0007267
GO:0006955
GO:0070374
GO:0042110
GO:0032496
GO:0050731
GO:0043536
GO:0051092
GO:0050829
GO:0001666
GO:0008284

BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP

GO:2001240
GO:0071222
GO:0042594
GO:0031663
GO:0032729
GO:0043406
GO:0045785

BP
BP
BP
BP
BP
BP
BP

GO:0002925 BP
GO:0048566 BP
GO:0002876 BP
GO:1902380 BP
GO:1904722
GO:0071230
GO:0006959
GO:0043410
GO:0030890
GO:0048661

BP
BP
BP
BP
BP
BP

GO:0038033 BP
GO:0070434
GO:0031397
GO:0033209
GO:0046641
GO:0010038
GO:0007568
GO:0030968
GO:0019221
GO:0045766
GO:0045732
GO:0050869

BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP

GO:1901029
GO:1903265
GO:0010460
GO:0043433

BP
BP
BP
BP

GO term
Background: genes with average expression > 1 RPKM
inflammatory response
viral entry into host cell
negative regulation of inclusion body assembly
protein refolding
positive regulation of interleukin-8 production
defense response to Gram-positive bacterium
response to unfolded protein
positive regulation of interleukin-6 production
cellular heat acclimation
cellular response to heat
T cell costimulation
positive regulation of chemokine biosynthetic process
cell-cell signaling
immune response
positive regulation of ERK1 and ERK2 cascade
T cell activation
response to lipopolysaccharide
positive regulation of peptidyl-tyrosine phosphorylation
positive regulation of blood vessel endothelial cell migration
positive regulation of NF-kappaB transcription factor activity
defense response to Gram-negative bacterium
response to hypoxia
positive regulation of cell proliferation
negative regulation of extrinsic apoptotic signaling pathway
in absence of ligand
cellular response to lipopolysaccharide
response to starvation
lipopolysaccharide-mediated signaling pathway
positive regulation of interferon-gamma production
positive regulation of MAP kinase activity
positive regulation of cell adhesion
positive regulation of humoral immune response
mediated by circulating immunoglobulin
embryonic digestive tract development
positive regulation of chronic inflammatory response
to antigenic stimulus
positive regulation of endoribonuclease activity
positive regulation of mRNA endonucleolytic cleavage
involved in unfolded protein response
cellular response to amino acid stimulus
humoral immune response
positive regulation of MAPK cascade
positive regulation of B cell proliferation
positive regulation of smooth muscle cell proliferation
positive regulation of endothelial cell chemotaxis by
VEGF-activated vascular endothelial growth factor receptor signaling pathway
positive regulation of nucleotide-binding oligomerization domain
containing 2 signaling pathway
negative regulation of protein ubiquitination
tumor necrosis factor-mediated signaling pathway
positive regulation of alpha-beta T cell proliferation
response to metal ion
aging
endoplasmic reticulum unfolded protein response
cytokine-mediated signaling pathway
positive regulation of angiogenesis
positive regulation of protein catabolic process
negative regulation of B cell activation
negative regulation of mitochondrial outer membrane permeabilization
involved in apoptotic signaling pathway
positive regulation of tumor necrosis factor-mediated signaling pathway
positive regulation of heart rate
negative regulation of sequence-specific DNA binding transcription factor activity
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P-value Enrichment FDR (%)
2.29E-05
2.65E-05
3.03E-05
6.42E-05
1.16E-04
1.19E-04
1.71E-04
2.36E-04
4.08E-04
4.92E-04
5.60E-04
6.77E-04
9.61E-04
9.89E-04
0.0017
0.0017
0.0035
0.0035
0.0036
0.0054
0.0059
0.0064
0.0068

7.43
16.47
59.03
47.23
39.36
19.04
17.36
31.49
88.55
24.86
12.83
70.84
11.14
5.99
9.52
16.29
7.87
12.76
32.20
6.95
25.30
6.63
4.07

0.03528
0.04078
0.04668
0.09881
0.17893
0.18228
0.26353
0.36314
0.62632
0.75366
0.85748
1.03623
1.46831
1.51131
2.62922
2.653
5.21571
5.31
5.40275
8.04951
8.65474
9.40337
9.96367

0.0086
0.0107
0.0119
0.0143
0.0155
0.0155
0.0155

20.84
8.59
17.71
16.10
15.40
15.40
15.40

12.4802
15.3085
16.7694
19.8324
21.413
21.413
21.413

0.0166
0.0166

118.07
118.07

22.7502
22.7502

0.0166
0.0166

118.07
118.07

22.7502
22.7502

0.0166
0.0169
0.0182
0.0226
0.0226
0.0241

118.07
14.76
14.17
12.65
12.65
12.21

22.7502
23.0212
24.6533
29.656
29.656
31.3475

0.0249

78.71

32.1053

0.0249
0.0274
0.0329
0.0330
0.0330
0.0339
0.0380
0.0380
0.0399
0.0399
0.0411

78.71
11.43
5.62
59.03
59.03
5.56
9.57
9.57
9.32
9.32
47.23

32.1053
34.747
40.2216
40.3284
40.3284
41.1695
44.8682
44.8682
46.517
46.517
47.5563

0.0411
0.0411
0.0411
0.0438

47.23
47.23
47.23
8.86

47.5563
47.5563
47.5563
49.7626

GO:0070936
GO:0033138
GO:0006972
GO:0097190
GO:0050862
GO:0043123
GO:0000122
GO:0032722
GO:0010941
GO:0044130
GO:0048010
GO:0006928
GO:0007165
GO:0060333
GO:0002548
GO:0043122
GO:0003009
GO:0007193
GO:0045662
GO:0042787
GO:0001819
GO:0006970
GO:0042981
GO:0007275
GO:0035924
GO:0010628

BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP

protein K48-linked ubiquitination
positive regulation of peptidyl-serine phosphorylation
hyperosmotic response
apoptotic signaling pathway
positive regulation of T cell receptor signaling pathway
positive regulation of I-kappaB kinase/NF-kappaB signaling
negative regulation of transcription from RNA polymerase II promoter
positive regulation of chemokine production
regulation of cell death
negative regulation of growth of symbiont in host
vascular endothelial growth factor receptor signaling pathway
movement of cell or subcellular component
signal transduction
interferon-gamma-mediated signaling pathway
monocyte chemotaxis
regulation of I-kappaB kinase/NF-kappaB signaling
skeletal muscle contraction
adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway
negative regulation of myoblast differentiation
protein ubiquitination involved in ubiquitin-dependent protein catabolic process
positive regulation of cytokine production
response to osmotic stress
regulation of apoptotic process
multicellular organism development
cellular response to vascular endothelial growth factor stimulus
positive regulation of gene expression

0.0478
0.0478
0.0491
0.0520
0.0570
0.0613
0.0621
0.0649
0.0649
0.0649
0.0698
0.0698
0.0714
0.0722
0.0727
0.0727
0.0805
0.0805
0.0805
0.0864
0.0882
0.0882
0.0929
0.0931
0.0958
0.0962

8.43
8.43
39.36
8.05
33.73
4.37
2.23
29.52
29.52
29.52
6.81
6.81
2.02
6.68
26.24
26.24
23.61
23.61
23.61
3.78
21.47
21.47
3.66
2.87
19.68
3.61

52.9269
52.9269
53.9094
55.9972
59.4935
62.1967
62.7059
64.4016
64.4016
64.4016
67.161
67.161
68.0057
68.4184
68.7155
68.7155
72.5071
72.5071
72.5071
75.1133
75.8394
75.8394
77.6925
77.7523
78.7682
78.9129

Table 4.2 GO enrichments of Roquin2 regulated genes
U2932 cells expressing Roquin2 (Y691F) vs Roquin2 (WT) were treated with 10 µg/ml
of F(ab’)2-IgM for 12 hrs (n= 3 independent experiments). GO analyses were performed
using version 6.8 of the DAVID web server (Huang et al., 2009a, c). Exact P values are
shown.
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#Gene set
WRE (Saddlepoint) P-value
KLHL6, TP53
0.007296593
KLHL6, MLL2
0.009864889
ARID1B, KLHL6
0.013723417
INO80, KLHL6
0.071010277
KLHL6, TNFAIP3
0.085828689
BCL6, KLHL6
0.085828689
BTG1, KLHL6
0.116142985
CHD1, KLHL6
0.127426758
KLHL6, SPEN
0.142065165
KLHL6, TAF1
0.146780171
CCND3, KLHL6
0.154272416
KLHL6, NF1
0.154272416
KLHL6, PRDM1
0.161910743
ARID5B, KLHL6
0.161910743
DDX3X, KLHL6
0.161910743
KLHL6, SETD5
0.170053834
KLHL6, TET2
0.185069315
KLHL6, MCL1
0.186363405
CDKN2A, KLHL6
0.186363405
BTK, KLHL6
0.197108625
CBLB, KLHL6
0.217375064
KLHL6, UBR5
0.228611023
DDX10, KLHL6
0.228611023
KLHL6, MLL3
0.230162112
KLHL6, MEF2B
0.236302759
KLHL6, MEF2BNB-MEF2B
0.236302759
KLHL6, PTPN6
0.25167532
IKBKB, KLHL6
0.25167532
KLHL6, TMSB4X
0.264893745
KLHL6, TOX
0.264893745
KLHL6, ZFAT
0.264893745
KLHL6, MAGT1
0.264893745
CD58, KLHL6
0.264893745
DICER1, KLHL6
0.264893745
GNAI2, KLHL6
0.264893745
KLHL6, TNFRSF14
0.271707356
KLHL6, WAC
0.276026659
CHD8, KLHL6
0.283441479
KLHL6, MYB
0.291571234
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#Gene set
WRE (Saddlepoint) P-value
HRAS, KLHL6
0.291571234
CD22, KLHL6
0.291571234
KLHL6, RARA
0.306825911
BRAF, KLHL6
0.306825911
HIST1H2BC, KLHL6
0.306825911
CD79B, KLHL6
0.313455867
DNMT3A, KLHL6
0.313455867
KLHL6, STAT5B
0.321352706
BCL7A, KLHL6
0.331514193
KLHL6, RUNX1
0.339731515
KLHL6, MAP2K1
0.358658894
KLHL6, ZNF608
0.366771011
KLHL6, LIN54
0.398063455
CXCR4, KLHL6
0.398063455
CREBBP, KLHL6
0.405364718
IRF8, KLHL6
0.408385843
ACTB, KLHL6
0.415044201
ATR, KLHL6
0.431749456
KCMF1, KLHL6
0.439622268
KLHL6, PTEN
0.439622268
KLHL6, TGFBR2
0.439622268
EZH2, KLHL6
0.442419554
ETS1, KLHL6
0.459153037
KLHL6, STAT3
0.472592121
KLHL6, ZBTB7A
0.472592121
EP300, KLHL6
0.483090559
KLHL6, MAP4K4
0.487558531
KLHL6, UBE2A
0.487558531
CASP8, KLHL6
0.493686666
CD70, KLHL6
0.496622919
B2M, KLHL6
0.496622919
IL16, KLHL6
0.502377438
DCAF6, KLHL6
0.502377438
JAK1, KLHL6
0.51773029
KLHL6, PTPRK
0.51773029
JUNB, KLHL6
0.51773029
CDC73, KLHL6
0.518526498
KLHL6, SGK1
0.530599488
KLHL6, SMARCA4
0.530599488
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#Gene set
WRE (Saddlepoint) P-value
KLHL6, MGA
0.530599488
KLHL6, NFKBIA
0.532770403
KLHL6, RHOA
0.532770403
GOLGA5, KLHL6
0.532770403
GNAS, KLHL6
0.540277952
KLHL6, PIM2
0.565577169
BCL10, KLHL6
0.565577169
ATM, KLHL6
0.57551293
KLHL6, RB1
0.587675935
IKZF3, KLHL6
0.598550468
KLHL6, MECOM
0.598550468
FOXO1, KLHL6
0.604824556
HNRNPU, KLHL6
0.615881531
CARD11, KLHL6
0.624780346
KLHL6, MYC
0.625882038
KLHL6, RRAGC
0.649495031
JAK3, KLHL6
0.650624883
BIRC6, KLHL6
0.655684962
FAM5C, KLHL6
0.661914103
KLHL6, PIK3CD
0.663416907
KLHL6, PHF6
0.667627082
KLHL6, POU2F2
0.667627082
EBF1, KLHL6
0.679660224
KLHL6, TMEM30A
0.688893946
KLHL6, MYD88
0.70470071
KLHL6, ZNF292
0.706970359
KLHL6, MSH2
0.715851297
KLHL6, NCOR1
0.715851297
ETV6, KLHL6
0.715851297
FOXP1, KLHL6
0.72033584
KLHL6, S1PR2
0.72033584
KLHL6, ZEB2
0.729192934
FUBP1, KLHL6
0.737060758
ARID1A, KLHL6
0.750943182
FAS, KLHL6
0.757016267
KLHL6, STAT6
0.763453997
KLHL6, TBL1XR1
0.763453997
KLHL6, NOTCH2
0.763849993
CD83, KLHL6
0.765570173
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#Gene set
WRE (Saddlepoint) P-value
KLHL14, KLHL6
0.774720583
FBXW7, KLHL6
0.776384508
KLHL6, TCL1A
0.776384508
BTBD3, KLHL6
0.792343414
HNRNPD, KLHL6
0.792343414
CIITA, KLHL6
0.792343414
KLHL6, ZFX
0.792343414
KLHL6, MSH6
0.813216926
KLHL6, PIK3R1
0.813216926
HIST1H1E, KLHL6
0.831918553
KLHL6, MTOR
0.836996935
KLHL6, SETD1B
0.839606965
GNA13, KLHL6
0.839606965
KLHL6, TIPARP
0.847348818
KLHL6, SYK
0.847348818
KLHL6, SETD2
0.850989763
KLHL6, MARK1
0.859572181
KLHL6, SF3B1
0.870536694
ANKRD17, KLHL6
0.873998924
DUSP2, KLHL6
0.880002839
IRF4, KLHL6
0.895653425
KLHL6, MET
0.900090752
KLHL6, NFKB2
0.90060563
KLHL6, NFKBIE
0.903203366
KLHL6, XPO1
0.908495003
KLHL6, PAX5
0.908495003
KLHL6, YY1
0.927248212
CHST2, KLHL6
0.945672185
BCL2, KLHL6
0.96295551
KLHL6, SOCS1
0.986246166
BTG2, KLHL6
0.986948128
KLHL6, PIM1
0.987391459
KLHL6, KRAS
0.990970456

Table 4.3 Mutual exclusive analyses of KLHL6 BTB-mutations in DLBCL
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The Weighted Exclusivity Test (WExT, http://compbio.cs.brown.edu/software/)
(Leiserson et al., 2016) was utilized to calculate the mutual exclusivity significance of
deleterious BTB-domain mutations of KLHL6 with the 150 genetic drivers of DLBCL
described in the DCI datasets (n=1001) (Reddy et al., 2017). Exact P values are shown.
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CHAPTER 5 : TYROSINE PHOSPHATASE PTPN14 REGULATES ROQUIN2
PROTEIN STABILITY

Chapter summary
Research described in this chapter was performed in collaboration with the
laboratories of Dr. Michael Washburn. Mass Spectrometry (MS) sample preparations
were carried out in our laboratory, and Anita Saraf and Laurance Florens performed MS
analysis in Dr. Michael Washburn laboratory (Stowers Institute).
The work described in this chapter is all unpublished and forms the body of
manuscript that I am currently planning to submit in a small journal. This chapter is
focused on elucidating regulation for Roquin2 protein stability by studying posttranslational modification of tyrosine 691 residue of Roquin2.

Jaewoo Choi, Anita Saraf, Laurence Florens, Michael P. Washburn, Luca Busino.
Tyrosine phosphatase PTPN14 regulates Roquin2 protein stability
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Introduction
Protein post-translational modifications (PTMs) regulate a variety of biological
processes such as switching protein activity, intracellular trafficking of transporters,
signal transduction, and other fundamental cellular mechanisms (Hunter, 2007; Moeller
et al., 2010; Nguyen et al., 2011). Phosphorylation and ubiquitylation are most
predominant and ubiquitous PTMs in eukaryotic proteaomes. Crosstalk between
phosphorylation and ubiquitylation can take many different forms. For example,
phosphorylation can activate E3 ligase activity or be a priming event to promote the
subsequent ubiquitylation and degradation of the substrates (Fuchs et al., 1996; Khosravi
et al., 1999; Sehat et al., 2007). Alternatively, ubiquitylation can influence protein
phosphorylation by regulating kinase activity (Hunter, 2007), suggesting that multiple
PTMs can work in a cis-regulatory manner to fine tune a plethora of complex cellular
processes. Phosphorylation is a direct and single step of addition of the phosphate group
by protein kinases. However, ubiquitylation is catalyzed in a stepwise manner through an
enzymatic cascade requiring an E1 ubiquitin activating-enzyme, an E2 ubiquitinconjugating enzyme, and an E3 ubiquitin-ligating enzymes (Deshaies and Joazeiro,
2009). Both phosphorylation and ubiquitylation are reversible by protein phosphatases
and deubiquitylation enzymes (DUBs), respectively (Alonso et al., 2004; Hershko and
Ciechanover, 1998).
Protein tyrosine phosphatases (PTPs) can contribute to the dynamic signal
transduction and protein regulation. Increasing evidence has suggested that PTPs have
essential roles in tumorigenesis and are primarily considered as tumor suppressors (Julien
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et al., 2011). For example, many studies have shown protein tyrosine phosphatase nonreceptor type 14 (PTPN14) is mutated in multiple types of cancers including colorectal,
breast, ovarian, liver cancers (Sjoblom et al., 2006; Wang et al., 2012; Wang et al., 2004;
Zhang et al., 2013). The most well known function of PTPN14 is to inhibit the oncogenic
function of yes-associated protein 1 (YAP1), a protein involved in the hippo-signaling
pathway (Liu et al., 2013; Wang et al., 2012). Recently, the p53-PTPN14-YAP1 pathway
has shown to suppress pancreatic cancer progression and PTPN14 also suppresses
metastasis by limiting protein trafficking in breast cancer (Belle et al., 2015; Mello et al.,
2017). PTPN14 (also known as PTPD2 or PEZ) has an N-terminal FERM domain and a
C-terminal phosphatase domain and plays critical roles in cellular proliferation and
growth, cell-cell adhesion and cell migration (Smith et al., 1995; Wadham et al., 2000,
2003) Only three substrates (YAP1, B-catenin, and p130Cas) have been identified so far,
and the other biological function of PTPN14 in different genetic and cellular context still
remains to be determined (Liu et al., 2013; Wadham et al., 2003; Zhang et al., 2013).
The Roquin family of proteins consists of Roquin1 (Rc3h1) and Roquin2
(Rc3h2). The N-terminal region of Roquin proteins comprises a RING finger, a
conserved ROQ domain, and a CCCH-type zinc finger. Mechanistically, mRNAs that
contain a constitutive-decay element (CDE) in a 3’ UTR sequence are recognized by the
ROQ domain of Roquin1 and 2 and undergo mRNA deadenylation and ultimately
degradation (Leppek et al., 2013; Schlundt et al., 2014; Tan et al., 2014). Most of Roquin
mRNA targets identified by the genome-wide crosslinked-immunoprecipitation (CLIP)Seq are involved in immunity, inflammation, and development. The recent study on the
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paracaspase MALT1 has revealed a regulatory control of Roquin proteins in T cells.
When CD4+ T cells are stimulated with pharmacological agents PMA and ionomycin,
Roquin proteins are cleaved by MALT1 and the specific MALT1 inhibitor, z-VPR-fmk,
blocks this cleavage (Jeltsch et al., 2014). Moreover, our study in the chapter 3 shows
that Roquin2 protein is targeted by CULLIN3-KLHL6 complex for proteasomal
degradation. Whether there are any other regulation components for Roquin2 protein
stability remain open questions.
Here, we show that tyrosine 691 of Roquin2 is directly phosphorylated in cells
and this phosphorylation disrupts interaction between Roquin2 and KLHL6. We also
present evidence that PTPN14 forms a trimeric complex with Roquin2 and KLHL6 and
enhances the KLHL6-Roquin2 interaction. Specifically, PTPN14 binds to the end of Cterminus domain of Roquin2 via its phosphatase domain. Overexpression of the wild-type
PTPN14 in B-cell lymphomas decreases the Roquin2 protein abundance compared to that
of trapping mutant PTPN14. These finding reveal PTPN14 as a novel regulator for
Roquin2 protein stability and add another layer of regulation on KLHL6-mediated
Roquin2 protein degradation.

Results
Tyrosine 691 in Roquin2 is phosphorylated in vivo
Our previous data in the chapter 3 shows that the integrity of tyrosine 691 residue
(Y691) in Roquin2 is critical for KLHL6 interaction as mutation to alanine and
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phenylalanine increases the protein stability. Since the tyrosine residue is often modified
post-translationally by phosphorylation (Hunter, 2007), we generated a phospho-specific
antibody against Y691 residue to test this hypothesis. HEK293T cells were transfected
with FLAG-STREP-tagged wild-type (WT) or FLAG-STREP-tagged Roquin2 (Y691F)
mutant, a non-phosphorylatable form of tyrosine. To increase the level of cellular
tyrosine phosphorylation, we treated the transfected cells with or without pervanadate, a
complex from vanadate and hydrogen peroxide, (Heffetz et al., 1990; Secrist et al., 1993)
for 15 min before SDS-lysis and affinity purification by streptavidin beads. After the
purification, the beads were treated with or without lamda (λ)-phosphosphotase (Fig
5.1A). Pre-treatment of cells with pervanadate induced a strong phosphorylation of
proteins in tyrosine as detected by analysis of whole cell lysates with a phospho-tyrosine
antibody (Fig. 5.1B). Under pervanadate treatment conditions, our phospho-antibody
specifically recognized Roquin2 (WT), but not the Roquin2 (Y691F) mutant (Fig. 5.1C).
To further assess the phospho-specificity of our antibody, we de-phosphorylated Roquin2
(WT) with λ-phosphatase (Fig 5.1A and 5.1C). This treatment abrogated the ability of
our antibody to recognize Roquin2 (WT) isolated from pervanadate treated cells,
suggesting that the antibody, indeed, recognizes a phosphorylated moiety in position 691.
Notably, the antibody could not detect the phosphorylation of tyrosine 691 at the steady
state. This could mean that the basal level of Roquin2 phosphorylation is very low or that
our antibody is not sensitive enough to detect the basal phosphorylation.
All together, our data suggest that the tyrosine in position 691 of Roquin2 is
phosphorylated in cells.
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Tyrosine 691 phosphorylation in Roquin2 is inhibitory for KLHL6 interaction
Most PTMs function is a creation of binding sites to promote recognition domains
for the protein interaction (Seet et al., 2006). Given that tyrosine 691 is critical for
interaction between KLHL6 and Roquin2 (chapter 3), we, next, investigated to assess the
effect of tyrosine 691 phosphorylation on the KLHL6-Roquin2 interaction. Since we
have found that tyrosine 691 is phosphorylated upon the pervanadate treatment (Fig 5.1B
and 5.1C), we examined the interaction between Roquin2 and KLHL6 in the same
condition. Interestingly, the pervanadate treatment disrupted the binding between
Roquin2 and KLHL6, suggesting that tyrosine phosphorylation negatively regulates the
interaction of the two proteins (Fig 5.2A). Next, to directly assess whether tyrosine
phosphorylation is inhibitory for the KLHL6-Roquin2 interaction, we synthesized an
unphospho- and phospho-peptide in tyrosine 691 (Fig 5.2B). Utilizing these peptides, we
performed in vitro binding assays and demonstrated that phosphorylation of tyrosine 691
impaired the ability to Roquin2 to associate with KLHL6 (Fig 5.2B). We also confirmed
that the peptide without the phosphorylation efficiently interacted with in vitro-translated
recombinant KLHL6 protein.
Collectively, these data show that phosphorylation at tyrosine 691 in Roquin2
negatively regulates the KLHL6-Roquin2 interaction.

PTPN14 specifically interacts with Roquin2
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Since Roquin2, but not its paralog Roquin1, specifically interacts with KLHL6,
we hypothesized that tyrosine 691 could be modified by a kinase or phosphatase specific
to Roquin2. To gain insight into the regulation components of tyrosine 691
phosphorylation in Roquin2, we compared the protein interactome of Roquin1 (WT) to
that of Roquin2 (WT) in HEK293T cells. FLAG-Roquin1 or FLAG-Roquin2 complexes
were biochemically immunopurified and the tryptic digestion of each protein eluate was
analyzed by mass spectrometry (Fig 5.3A and Supplementary table 5.1). It has been
established that Roquin proteins recruit the CCR4-NOT complex through C-terminal
region of the proteins (Leppek et al., 2013; Sgromo et al., 2017). Our proteaomic analysis
validated that Roquin1 and Roquin2 function by recruiting deadenylation factors such as
CNOT1, CNOT2, CNOT3, CNOT7, CNOT10, and CNOT11 (Figure 5.3B).
Additionally, we also identified a variety of ribosomal protein genes that are essential for
eurkaryotic ribosome assembly such as RPS or RPL genes (Provost et al., 2013; Warner,
1999). More importantly, we identified PTPN14 as a specific binding partner of Roquin2
immunoprecipitates as opposed to Roquin1 immunoprecipitates, suggesting that PTPN14
is a novel interactor of Roquin2 (Fig 5.3B). PTPN14 is a non-receptor type of tyrosine
phosphatase (Smith et al., 1995). To validate the mass spectrometric analysis, we
expressed and immunoprecipitated FLAG-tagged Roquin1 or Roquin2 from HEK293T
cells and confirmed interaction of endogenous PTPN14 with Roquin2 specifically.
Roquin1, although expressed at a higher level than Roquin2, is incapable of binding with
PTPN14 (Fig 5.3C).
Altogether, we identified PTPN14 as a specific binding partner of Roquin2.
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PTPN14 binds the C-terminal region of the Roquin2 protein through its phosphatase
domain
To determine the regions of Roquin2 that contribute to the interaction with
PTPN14, we generated a set of refined C-terminal deletion mutants in Roquin2 by sitedirected mutagenesis. Given that Roquin1 and Roquin2 have a high sequence similarity
including the RING, ROQ, and zinc finger domains (Pratama et al., 2013) and that
PTPN14 specifically interacts with Roquin2, we predicted that the binding region should
be confined in the C-terminal region of Roquin2. Consistent with our hypothesis, all Cterminal deletions eliminated the ability of Roquin2 to bind to PTPN14 upto the mutant
lacking the very C-terminal 50 amino acids (Fig 5.4A) (Pratama et al., 2013).
Interestingly, Roquin1 differs from Roquin2 in its C-terminal region as Roquin1 contains
a coiled-coil domain instead of a hydrophobic rich region domain that might be
responsible for binding to PTPN14.
Next, we utilized a panel of PTPN14 deletion mutants described from the
previous study (Szalmas et al., 2017). These mutants include deletions of FERM domain
(important for cell adhesion and cytoskeletal function), the linker 1 region, the linker 2
region (required for YAP1 interaction), the linker 3 region, and the phosphatase (PTP)
domain (Ogata et al., 1999; Wang et al., 2012). We co-transfected HEK293T cells with
N-terminal V5 tagged-PTPN14 wild-type and mutants with FLAG-tagged Roquin2, and
FLAG immunoprecipitates were probed with V5 and FLAG antibodies. FLAG-Roquin2
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efficiently co-precipitated wild-type and deletion mutants of PTPN14, except for the
mutant lacking the PTP domain (Fig 5.4B).
Thus, we concluded that the PTP phosphatase domain of PTPN14 is required to
bind the C-terminus of Roquin2.

PTPN14 enhances interaction between KLHL6 and Roquin2
Next, we investigated whether PTPN14 affects the interaction between KLHL6
and Roquin2. KLHL6 is an E3 ligase that specifically binds, ubiquitylates and degrades
Roquin2 as shown in the chapter 3. We transfected HEK293T cells stably expressing
HA-KLHL6 with FLAG-tagged Roquin2 and V5-tagged PTPN14. Cell lysates were
immunoprecipitated with anti-FLAG, and the precipitates were probed with FLAG,
KLHL6, or V5 antibodies. As expected, FLAG-Roquin2 co-immunopurified both V5tagged PTPN14 and HA-tagged KLHL6, indicating that Roquin2, KLHL6 and PTPN14
form a trimeric complex (Fig 5.5A). Furthermore, expression of PTPN14 increased the
binding of KLHL6 and Roquin2. These results suggest that PTPN14 might play a role in
promoting KLHL6 and Roquin2 interaction for the efficient degradation of Roquin2.
Given that phosphorylation at tyrosine 691 of Roquin2 is inhibitory for KLHL6 binding,
we expected that PTPN14 might regulate tyrosine 691 directly to bring KLHL6 and
Roquin2 together.
Thus, we propose a model where PTPN14 binds at the hydrophobic rich region of
Roquin2 and dephosphorylates tyrosine 691 phosphorylation to enhance KLHL6Roquin2 interaction (Fig 5.5B).
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PTPN14 regulates Roquin2 protein stability
Having established that PTPN14 forms a trimeric complex with Roquin2 and
KLHL6, we, then, investigated whether PTPN14 promotes degradation of Roquin2 via
KLHL6. We transfected HA-tagged Roquin2, V5-tagged PTPN14, Flag-tagged KLHL6
in HEK293T cells in different combinations and see whether PTPN14 has any effects on
Roquin2 protein levels. As shown in Figure 5.6A, expression of KLHL6 induced
degradation of Roquin2 and, more importantly, the degradation was enhanced when
Roquin2 was co-expressed with PTPN14. This suggests that PTPN14 promotes Roquin2
degradation dependent on KLHL6.
We next examined the kinetics of Roquin2 degradation by expressing PTPN14
using a doxycycline-dependent promoter in OCI-LY10, a human DLBCL cell line
expressing both endogenous KLHL6 and Roquin2. We generated two different cell lines:
one expressing PTPN14 (WT) and the other expressing PTPN14 (D1079A) mutant. This
mutant traps the phosho-substrates by keeping them from being dephosphorylated
(Blanchetot et al., 2005) (Zhang et al., 2013). We stimulated these cells with the fragment
affinity-purified antibody F(ab’)2-IgM to activate B-cell receptor (BCR) signaling
pathway after pre-treatment with the doxycycline for 12 hours. We have shown that BCR
crosslinking induces degradation of Roquin2 in a KLHL6-dependent manner in ABCDLBCLs in chapter 3. As shown in Figure 5.6B, Roquin2 was degraded upon BCR
stimulation in cells expressing PTPN14 (WT) while this degradation was diminished in
cells expressing PTPN14 (D1079A) mutant. This suggests that the trapping mutant might
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potentially enrich phosphorylated Roquin2, which might be insensitive to KLHL6mediated degradation, thus leading to accumulation of Roquin2 substrate.
All together, we conclude that PTPN14 functions in promoting Roquin2
degradation.

Discussion
By generating a phospho-specific antibody against tyrosine 691 in Roquin2, we
have demonstrated that Roquin2 is phosphorylated in vivo. Upon phosphorylation,
KLHL6 dissociates from Roquin2, so phosphorylation directly inhibits the KLHL6mediated protein degradation. Using a proteomic analysis to analyze co-associated
proteins to Roquin2, we have identified the tyrosine phosphatase PTPN14. PTPN14
interacts with Roquin2 and regulates Roquin2 protein stability, as the trapping mutant is
able to inhibit BCR-mediated degradation of Roquin2.
Furthermore, we have shown that the integrity of tyrosine 691 residue in Roquin2
is critical for KLHL6 and Roquin2 interaction as both mutation of tyrosine to alanine or
phenylalanine can disrupt interaction of two proteins in chapter 3. Now, we have the
evidence that phosphorylation at this site inhibits its binding to KLHL6. Consistent with
this data, we show that phosphorylated Roquin2 peptide abrogated the ability to Roquin2
to co-immunoprecipitate with KLHL6, suggesting phosphorylation-dependent substrate
stabilization. Several other studies have shown that phosphorylation disrupts interaction
between E3 ligases and substrates. Although most of substrates of SCF ubiquitin ligases
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are recognized in a phosphorylation-dependent manner, phosphorylation of p85β at
tyrosine residue has been shown to inhibit the interaction with its ligase FBXL2 (Kuchay
et al., 2013). Furthermore, Aurora A is phosphorylated in serine residue within “A-box”
that inhibits APC/C (the ubiquitin ligase anaphase-promoting complex)-dependent
degradation (Song and Rape, 2011).
The role of tyrosine 691 phosphorylation prompts us to search for tyrosine kinases
or phosphatases, and we are able to identify PTPN14 as a binding partner for Roquin2 by
mass spectrometry analysis. Since Roquin2 can form a trimeric complex with PTPN14
and KLHL6, it is conceivable that PTPN14 can bring Roquin2 and KLHL6 together to
ensure de-phosphorylation and efficient degradation of Roquin2. In further support of this
idea, expression of PTPN14 makes Roquin2 interact with KLHL6 more strongly,
suggesting that tyrosine phosphorylation can play a role in protein-protein interaction.
Our mapping experiments show that PTPN14 binds at the C-terminus of Roquin2
through its PTP domain. This is in line with the fact that PTPN14 binds only Roquin2,
but not Roquin1. The sequence of RING, ROQ, and CCCH (C3H) domain in Roquin1
and Roquin2 has similarity of 82%, 99%, 81%, respectively (Pratama et al., 2013), so it is
likely that PTPN14 binds the C-terminus of Roquin2 where sequence similarity with
Roquin1 is only about 45%. Although we have not determined the structure of this
trimeric complex, it would be interesting to investigate where this tyrosine
phosphorylation is located within the complex and how conformational change occurs
upon binding of PTPN14 to KLHL6-Roquin2 complexes.
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The fact that tyrosine 691 can be phosphorylated in cells suggests that there might
be potential tyrosine kinases involved in this process. In agreement with this hypothesis,
we are able to see the effects of overexpression of PTPN14 in both HEK293T cells and
human DLBCL cell line in terms of Roquin2 down-regulation, suggesting there might be
a basal level of tyrosine 691 phosphorylation in cells. Recent study shows that Roquin1
can specifically interact with the α1 subunit of AMPK kinase and negatively regulate
AMPK kinase activity in follicular helper T cells (Ramiscal et al., 2015). Furthermore,
Roquin2 can interact and promote ubiquitylation and proteasomal degradation of ASK1
kinase upon the oxidative stress to inhibit reactive oxygen species (ROS)-induced cell
death (Maruyama et al., 2014). Although, to date, there are no tyrosine kinases identified
that associate with Roquin2 proteins, it is possible that PTM crosstalk between potential
tyrosine kinase and PTPN14 phosphotase exists to fine-tune regulation of Roquin2
stability. Furthermore, in chapter 3, we have found that BCR signaling induces
degradation of Roquin2 in a KLHL6-dependent manner. It is conceivable that dephosphorylation at tyrosine 691 of Roquin2 might happen in this specific context to
promote degradation. Moreover, it would be also interesting to examine whether Roquin2
is constitutively phosphorylated by unknown tyrosine kinases in ABC-DLBCL cell lines
that exhibit chronic active BCR signaling.
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Figure 5.1 Tyrosine 691 in roquin2 is phosphorylated in vivo
(A) A schematic model of validation for phospho-antibody again tyrosine 691
residue in Roquin2. (B) HEK293T cells were transfected with cDNAs encoding FLAGSTREP-tagged Roquin2 (WT), Roquin2 (Y691F) or empty vector (EV). The transfected
cells were treated with 100µM of pervanadate for 15 min and lysed in a denatured
condition (1% SDS-lysis). Cell lysis was diluted with NP-40 buffer (0.1% SDS final
concentration) and whole cell lysates were used for immunoblot analysis. (C) Exogenous
proteins were affinity-purified (AP) from cell extracts of (b) with an anti-streptavidin
resin. The purified complexes were, then, treated with lamda (λ)-phosphotase and probed
with antibodies to the indicated proteins.
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Figure 5.2 Tyrosine 691 phosphorylation in Roquin2 is inhibitory for KLHL6
interaction
(A) HEK293T cells stably expressing HA-tagged KLHL6 were transfected with cDNAs
encoding FLAG-tagged Roquin2. The transfected cells were treated with 100µM of
pervanadate for 15 min and exogenous proteins were immunopurified from cell extracts
with an anti-FLAG resin. Immunocomplexes were probed with antibodies to the
indicated proteins. Bottom panel shows whole cell lysates (WCL). (B) Top panel shows a
schematic representation of the sequence of the biotinylated unphosphosphorylatedRoquin2 peptides or phosphorylated-Roquin2 peptides. Bottom panel shows a
streptavidin pull-down assay using the indicated amount of biotinylated Roquin2 peptides
incubated with FLAG-tagged in-vitro translated KLHL6 protein. Affinity Purification,
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AP. Immunoblot analysis for the indicated proteins was performed using KLHL6
antibody.
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Figure 5.3 PTPN14 specifically interacts with Roquin2
(A) Biochemical purification of Roquin1 or Roquin2 protein complexes. HEK293T cells
were transfected with cDNAs encoding FLAG-Roquin1 (WT) or FLAG-Roquin2 (WT).
Proteins were immunoprecipitated (IP) with an anti-FLAG resin, eluted with a FLAG
peptide. 1% of samples were resolved by SDS-PAGE. The gel was stained with silver
staining for protein visualization. (B) Mass spectrometry analysis of Roquin1 (WT) and
Roquin2 (WT). Normalized Spectral Abundance Factors (NSAFs) were calculated for
each detected protein and plotted on a log scale. X-axis represents NSAF scores
distribution of all proteins detected from Roquin2 protein complexes while Y-axis
represents NSAF scores distribution of all proteins detected from Roquin1 protein
complexes. Red dots represent NSAF scores for the baits such as Roquin1 and Roqui2.
The green dot represents the NSAF score for PTPN14. The orange and cyan dots and
circles represent common interactors between Roquin1 and Roquin2. (C) HEK293T cells
were transfected with cDNAs encoding empty vector (EV), FLAG-tagged Roquin1 or
FLAG-tagged Roquin2. Exogenous proteins were immunopurified from cell extracts with
an anti-FLAG resin and immunocomplexes were probed with antibodies to the indicated
proteins. Bottom panel shows whole cell lysates (WCL).
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Figure 5.4 PTPN14 binds the C-terminal region of the Roquin2 protein through its
phosphatase domain
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(A) HEK293T cells were transfected with constructs encoding an empty vector (EV),
FLAG-tagged Roquin2 (WT) or FLAG-tagged Roquin2 deletion mutants as indicated.
Top panel shows a schematic representation of Roquin2 (WT) or Roquin2 deletion
mutants. Roquin2 mutants that interact (+) or do not interact (-) with endogenous
PTPN14 are shown. Bottom panel shows immunoblot analysis of FLAG-Roquin2
immunoprecipitation (IP). Immunocomplexes were probed with antibodies to the
indicated proteins. (B) HEK293T cells were co-transfected with constructs encoding an
empty vector (EV), V5-tagged PTPN14 (WT) or V5-tagged PTPN14 deletion mutants
and FLAG-tagged Roquin2 as indicated. Top panel shows a schematic representation of
PTPN14 (WT) or PTPN14 internal deletion mutants. PTPN14 mutants that interact (+) or
do not interact (-) with exogenous Roquin2 are shown. Bottom panel shows immunoblot
analysis of FLAG-Roquin2 immunoprecipitation (IP). Immunocomplexes were probed
with antibodies to the indicated proteins.
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Figure 5.5 PTPN14 enhances interaction between KLHL6 and Roquin2
(A) HEK293T cells stably expressing HA-tagged KLHL6 were co-transfected with
cDNAs encoding FLAG-tagged Roquin2 and V5-tagged PTPN14. Exogenous Roquin2
proteins were immunopurified from cell extracts with an anti-FLAG resin and
immunocomplexes were probed with antibodies to the indicated proteins. Bottom panel
shows whole cell lysates (WCL). (B) A schematic model of trimeric complex composed
of Roquin2, KLHL6 and PTPN14. PTPN14 binds Roquin2 through its PTP domain and
KLHL6 binds Roquin2 at tyrosine 691 residue. PTPN14 might regulate Roquin2 and
KLHL6 interaction by direct de-phosphorylation of tyrosine 691 in Roquin2.
Phosphorylation, P.
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Figure 5.6 PTPN14 regulates Roquin2 protein stability
(A) HEK293T cells were co-transfected with cDNAs encoding FLAG-HA-tagged
Roquin2 (WT), FLAG-tagged KLHL6, and increasing amounts of V5-tagged PTPN14 in
different combinations. Whole cell lysates were probed with antibodies to the indicated
proteins. (B) OCI-LY10 cells were lenti-virally transduced to express doxycycline
(DOX) controllable HA-tagged PTPN14 (WT) or PTPN14 (D1079A) mutant. DOX was
pre-added for 12 hours and, then, cells were stimulated with anti-IgM (10µg/ml) with
indicated time points. Whole cell lysates were probed with antibodies to the indicated
proteins.
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Data set

Cell Type

Condition

# Replicates

Mass
Spectrometry

HEK293T cells

Empty Vector,
Roquin1 (WT),
Roquin2 (WT)

1

Accession
Code
PXD009312

Table 5.1 Proteomic analyses of Roquin1 and Roquin2 complexes generated in this
dissertation
List of Roquin1 and Roquin2 interacting proteins identified by proteomic analysis of
Roquin1 and Roquin2 complexes purified from HEK293T cells.
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CHAPTER 6 : CONCLUSIONS AND FUTURE DIRECTIONS

KLHL6 as a tumor suppressor in DLBCL
Here, we find that KLHL6 is a novel CULLIN3-based E3 ligase and reveal that
KLHL6 cancer-associated mutations are loss of function. We also demonstrate that loss
of KLHL6 (WT) promotes cancer cell proliferation and survival with anti-apoptotic
effects while re-expression of KLHL6 (WT) in KLHL6-null cells has an opposite effect.
Although these data suggest that KLHL6, at least, is a tumor suppressor in terms of tumor
maintenance in cancer cells, we do not have any evidence whether loss of KLHL6 plays a
significant role in DLBCL tumor initiation or maintenance in genetic mouse models.
Our laboratory has generated Klhl6-null animals using heterozygous embryos
from the EMMA consortium. Consistent with the fact that KLHL6 is specifically
expressed in lymphoid tissues, Klhl6-null mice show several defects in B-cell
development. The population of immature B-cells is increased while the frequency of
mature B-cells is decreased two- to three-fold in the Klhl6-null mice. We also found that
the frequencies of progenitor B (pro-B) and precursor B (pre-B) cells in bone marrow of
Klhl6−/− mice are normal with no defects in hematopoietic stem cells and thymic T-cells,
suggesting that there is a specific block in B-cell differentiation from the immature to
mature transition. All of results above are indeed in agreement with previous
observations that Klhl6 is not required for the early stages of B-cell development (Kroll et
al., 2005). In addition to the B-cell defect in the bone marrow, Klhl6-null animals show a
cell-intrinsic defect in GC-cell expansion upon immunization (Kroll et al., 2005). More
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importantly, aging these Klhl6−/− mice did not show any symptoms of lymphoma and we
thus concluded that loss of KLHL6 is not sufficient to induce cellular transformation and
there likely needs to be other genetic alterations to contribute to lymphomagenesis.
Genome analysis of DLBCL revealed co-occurrence of KLHL6 mutations with
translocation of BCL6 under the IgH promoter (Morin et al., 2011), thus we expect that
loss of KLHL6 is required for germinal center tumorigenesis induced by BCL6. The
EµHA-Bcl6 mice mimicking a chromosomal translocation detected in human DLBCL
patients develop lympho-proliferative diseases with increased germinal center formation
and dysregulated post-germinal center differentiation. Starting at the age of 13 months,
EµHA-Bcl6 show increased mortality, with tumors displaying morphological and
immunophetypic features reminiscent of the human DLBCL (Cattoretti et al., 2005).
We thus generated EµHA-Bcl6/Klhl6-/- mice by breeding our Klhl6-null mice with
EµHA-Bcl6 mice (Cattoretti et al., 2005) and have now three cohorts of EµHABcl6/Klhl6-/-, EµHA-Bcl6/Klhl6-/+, EµHA-Bcl6/Klhl6+/+ mice for ongoing projects in our
laboratory. We are monitoring these mice for any signs of lymphoma progression and
will consider morbidity of mice at the end-point of the experiment to calculate the median
survival and construct a Kaplan-Meier curve. We expect that the onset and penetrance of
Eµ-HA-Bcl6-induced tumors will be accelerated in Klhl6-null mice. Moreover, since loss
of KLHL6 promotes the survival of cancer cells, we expect that Klhl6-null mice have a
survival advantage in producing secondary tumors. It will be also important to determine
whether KLHL6-negative lymphomas are addicted to or dependent on Roquin2 for the
growth and survival. We plan to perform a rescue experiment similar to in vitro system
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where we will isolate splenic tumors from EµHA-Bcl6/Klhl6-/- mice and utilize shRNA
against Roquin2 to knockdown before transplanting into syngeneic mice. Since loss of
Roquin2 induces cellular apoptosis in ABC-DLBCL, we expect the lower penetrance
and/or longer tumor latency in EµHA-Bcl6/Klhl6-/- mice with knockdown of Roquin2.
It would be also interesting to investigate whether deleting Klhl6 in the context of
B-cell lineage p53 deletion could uncover the tumor suppressive role of KLHL6. This
experiment can be carried out by crossing Klhl6-null mice with CD19-Cre p53flox/flox
mice. All of these in vivo investigations are required to shed light on how KLHL6
contributes to pathogenesis of mature B-cell tumors and some of these further studies are
ongoing in our laboratory. In the future, we will have direct evidence to state that KLHL6
is a tumor suppressor in DLBCL biology. It is also worth noting that KLHL6 mutations
are not observable at a high frequency in non-B-cell cancers, suggesting a possibly
differential role for KLHL6 in a different genetic and cellular context.

Roquin2 as an oncogene in DLBCL
We have demonstrated that deregulation of Roquin2 proteolysis or Roquin2
stabilization affects Roquin2 target mRNA stability, which is dependent on a ROQ
domain necessary for RNA recognition. More specifically, we show that KLHL6Roquin2 axis controls NF-κB activation in ABC-DLBCLs by controlling TNFAIP3/A20
mRNA decay. However, Roquin proteins bind and degrade other NF-κB inhibitors
mRNAs such as NFKBIZ and NFKBID (Leppek et al., 2013). NFKBID did not score in
our RNA-sequencing analysis whereas NFKBIZ did score in our primary screen as a
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gene that was down-regulated in non-degradable Roquin2 mutant (Y691F) but failed to
score as a BCR-dependent transcript. Moreover, we also found that another NF-κB
inhibitor, NFKBIE, scored in our primary RNA-sequencing screening, but was not
effectively rescued in the secondary q-PCR screening. Despite the fact that some of these
NF-κΒ pathway inhibitors might not be the direct targets of Roquin2, they are indirectly
down-regulated by Roquin2 and may contribute to increased NF-κB activation for the
survival of ABC-DLBCLs. We specifically chose to further study A20 and its
downstream effects on the NF-κB signaling pathway, as it is the most well known tumor
suppressor and negative regulator of NF-κB in ABC-DLBCL biology. However, we
cannot exclude the possibility that the growth advantages induced by stabilization of
Roquin2 could be due to combinatorial effects of multiple Roquin2 specific mRNA
targets. It would be interesting to see whether any other NF-κB pathway inhibitors are
affected by the KLHL6-Roquin2 axis in ABC-DLBCLs.
Additionally, we also found TNFRSF14 (the tumor necrosis factor receptor
superfamily member herpesvirus entry mediator, HVEM) as Roquin2 specific mRNA
targets that might play a role in GCB-DLBCLs since it is frequently mutated in GC
lymphomas, especially follicular lymphoma (Launay et al., 2012; Lohr et al., 2012).
TNFRSF14 regulates the immune response in T-cells by activation of inhibitory and
inflammatory responses. TNFRSF14 can act as a receptor by binding TNF-related ligands
such as lymphotoxin-α and LIGHT (lymphotoxin-like, exhibits inducible expression, and
competes with herpes simplex virus glycoprotein D for HVEM, a receptor expressed by T
lymphocytes). It also can act as a ligand by engaging with the immunoglobulin
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superfamily, B and T lymphocyte attenuator (BTLA) and CD160, and regulate diverse
signaling pathways for the immune responses (Murphy and Murphy, 2010). A recent
study reveals that TNFRSF14 loss increases production of TNF family of cytokines that
activate lymphoid stromal cells and recruitment of T follicular help (TFH) cells. This, in
turn, provides a tumor-supportive microenvironment via production of IL-4, IL-21 and
CD40L (Ame-Thomas and Tarte, 2014; Boice et al., 2016). Therefore, it is conceivable
that mutations of KLHL6 with Roquin2 stabilization might contribute to the pathogenesis
of follicular lymphoma by linking tumor microenvironment. In line with this, we cannot
exclude the fact that KLHL6 might have other substrates that are involved in different
biological processes such as cellular migration, adhesion or immune surveillance in
patients. We plan to study other unknown KLHL6 substrates or different Roquin2 mRNA
targets and further evaluate the functional impact of the KLHL6-Roquin2 axis in GCBDLBCLs. We have defined the interactome landscape of KLHL6 for putative substrates
and interactors, and we plan to validate these novel candidate substrates similarly to what
we have performed with Roquin2. The characterization of these novel substrates will
constitute the basis for new projects, and future studies will address another molecular
mechanisms controlled by KLHL6-mediated degradation in the context of B-cell cancers.
Although Roquin2 stabilization or deregulation of Roquin2 proteolysis promotes
cancer cell proliferation and survival and loss of Roquin2 causes cellular apoptosis in
ABC-DLBCLs, we do not have genetic mouse evidence to state that Roquin2 is an
oncogene. Several studies have shown that overexpression of Roquin1 in T-cell
lymphoma cell lines or Roquin1 transgenic mice in T-cells promotes production of
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inflammatory cytokines such as IL-2, TNF-α, IFN-γ and develop more severe collageninduced arthritis with autoimmune symptoms (Ji et al., 2012; Kim et al., 2012).
Moreover, T-lymphoma cell lines overexpressing Roquin were hyper-responsive to T-cell
receptor stimulation with anti-CD3/CD28 in vitro. This is in line with the fact that
Roquin proteins might play an oncogenic role by regulating inflammatory and immunerelated mRNA targets in T-cells. Although Roquin1 protein alterations or mutations are
not seen in angioimmunoblastic T-cell lymphoma (AITL), Roquin2 missense mutation at
tyrosine residue (Y691) was recently uncovered in thymic lymphoma from TCGA data
analysis. This suggests that Roquin1 and Roquin2 might play a non-redundant role in Tcell cancers. This is also in line with the fact that KLHL6 mutation only affects Roquin2
proteolysis in B-cell cancers and not Roquin1, implying that there is a specific function
of Roquin2 in the development of DLBCLs. Transgenic mice overexpressing Roquin2 or
the non-degradable Roquin2 mutant (Y691F) in the germinal center or in mature B-cells
might be helpful to model the oncogenic role of Roquin2 in DLBCL in vivo. Moreover,
our collaborators and we are currently breeding Roquin2 knockout mice with mouse
model of murine DLBCLs. We expect that knockout of Roquin2 will decrease the
oncogenic progression of DLBCL tumors with lower tumor penetrance and longer tumor
latency.

PTPN14 as a tumor suppressor in DLBCL
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We have demonstrated that Roquin2 protein stability is decreased by
overexpression tyrosine phosphatase, PTPN14. Moreover, Roquin2 is phosphorylated in
tyrosine 691 residue in cells and this phosphorylation disrupts KLHL6-Roquin2
interaction. Although we do not have direct evidence that PTPN14 dephosphorylates
tyrosine 691 of Roquin2 at this point, we are currently performing in vitro phosphatase
assay to link the mechanism of phosphorylation and protein degradation. PTPN14 has
been regarded as a tumor suppressor in a variety of cancers as mutation and deletion are
identified (Sjoblom et al., 2006; Wang et al., 2004; Zhang et al., 2013). Consistent with
this idea, PTPN14 negatively regulates the stability of Roquin2, which plays an
oncogenic role in ABC-DLBCL cell lines. In chapter 3, we have shown that stabilization
of Roquin2 by cancer-associated mutations of KLHL6 or loss of KLHL6 promotes
DLBCL growth and survival by regulation of mRNA decay of the tumor suppressor and
NF-κB pathway inhibitor, TNFAIP3. The role of protein tyrosine phosphatases in
lymphoma has not been extensively studied. However, there are some cases reported
where PTPN1 that is frequently mutated in Hodgkin lymphoma, and primary mediastinal
B cell lymphoma with loss of function mutations, suggesting a tumor suppressor role
(Gunawardana et al., 2014). Furthermore, inactivating mutations and epigenetic silencing
of PTPN13 have been reported in non-Hodgkin’s and Hodgkin’s lymphoma (Ying et al.,
2006).
Interestingly, we have noticed PTPN14 protein is also expressed at very low
levels and almost non-detectable in ABC-DLBCL cell lines (data not shown). As a future
direction, it would be interesting to determine whether there are unknown mechanism to
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down-regulate PTPN14 mRNA or protein in human B-lymphomas. Alternatively,
whether overexpression of PTPN14 in ABC-DLBCLs has any impacts on cancel cell
proliferation and whether it can regulate NF-κB pathway through Roquin2 degradation
remain open questions.

Concluding remarks
The studies presented in this dissertation focus on defining molecular mechanisms
by which the KLHL6-Roquin2 axis contributes to growth and survival of ABC-DLBCLs.
This work provides insight into the distinct role of KLHL6 as an E3 ligase for Roquin2
and how misregulation of this pathway impacts maintenance of mature B-cell cancers in
in vitro and in vivo xenograft experiments. The identification of KLHL6 as the E3 ligase
for Roquin2 provides essential information and tools to elucidate the molecular link
between the ubiquitin proteasome system and mRNA decay. Understanding whether
deregulation of Roquin2 proteolysis has any functional consequences in terms of mRNA
decay will allow us to understand its role in B-cell biology further. Additionally, the
studies here highlight the post-translational modifications that add another layer of
regulation on KLHL6-Roquin2 axis. As targeting specific ubiquitin ligases is
therapeutically feasible and relevant to human cancers, a deeper molecular understanding
of KLHL6-mediated proteolysis of Roquin2 in cancers can potentially broaden
therapeutic approaches for the treatment of B-cell malignancies.
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